The Role of N1-Src in Neuronal Development by Wetherill, Sarah Jane
 
 
1 
 
 
 
 
The Role of N1-Src in Neuronal 
Development 
 
 
 
 
 
Sarah Jane Wetherill 
 
 
PhD 
 
 
 
 
 
 
 
University of York 
Biology 
May 2016
 
 
2 
 
Abstract 
Protein phosphorylation by tyrosine kinases evolved in multicellular organisms to 
regulate intracellular signalling pathways associated with proliferation, differentiation and 
migration. In most tissues, basal protein tyrosine phosphorylation is maintained at low 
levels, but in the brain, basal tyrosine kinase activity is high and regulates key processes 
in the developing and mature brain and is dysregulated in neurological disorders. N1-Src 
is a neuronal splice variant of the ubiquitous proto-oncogene C-Src tyrosine kinase, 
which differs by a six amino acid insert in its SH3 domain. Since the SH3 domain confers 
substrate specificity, it is anticipated that both C- and N1-Src will have different 
substrates and functions. Specifically, N1-Src is highly active in the developing brain and 
has been implicated in neuronal differentiation. Studies also suggest a role for N1-Src in 
ion channel regulation, however, the mode of action of N1-Src remains poorly 
understood. The primary aim of this study was to further clarify the role of N1-Src in both 
the developing and adult brain. To achieve this, a multidisciplinary approach was 
adopted, which sought to 1) identify novel N1-Src substrates 2) determine the function 
of N1-Src in developing neurons and 3) dissect the signalling pathways downstream of 
N1-Src. 
Recombinant, active Src kinases were generated to undertake in vitro kinase assays 
with putative N1-Src substrates. Src-dependent phosphorylation of HCN1, a pacemaker 
channel identified as an N1-Src interactor in a yeast 2-hybird screen, could not be 
detected. This result was not conclusive as surprisingly, the assay did not detect Src or 
PKC phosphorylation of NR2A, an NMDA receptor subunit, previously characterised as 
a robust Src and PKC substrate. However, a screen of several putative N1-Src SH3 
binding peptides revealed some encouraging candidates to pursue as substrates. To 
address the function of N1-Src in neuronal development, N1-Src was overexpressed or 
knocked down in cultured hippocampal neurons. Both manipulations were detrimental to 
neurite outgrowth and neuronal polarization, suggesting that N1-Src activates 
cytoskeletal remodelling pathways and precise levels of N1-Src are required for normal 
cellular development in vitro. The molecular mechanism of this phenomenon was 
investigated in a fibroblast cell line, in which N1-Src overexpression induces neurite-like 
processes. Using this model, an investigation into the role of N1-Src in RhoA signalling 
implied that N1-Src does not drive process outgrowth via the inhibition of RhoA, however 
constitutive activation of RhoA, prevented N1-Src mediated process extension. 
Preliminary results suggested that N1-Src overexpression enhances RhoA activation, 
which could form part of a negative feedback loop. Taken together, I have implicated N1-
Src in neurite outgrowth, which provides a starting point for understanding the 
mechanistic role of N1-Src in pathways that dictate neuronal morphology. 
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Chapter 1. Introduction 
1.1 Protein Phosphorylation 
Protein phosphorylation is a post-translational modification (PTM), which alters protein 
function. The phenomenon of protein phosphorylation was first observed by Burnett and 
Kennedy in 1954, who demonstrated that casein was phosphorylated by the liver 
enzyme, casein kinase. Since this initial discovery, the field has expanded greatly with 
approximately 17,000 proteins known to be phosphorylated at one or more sites. Protein 
phosphorylation is therefore acknowledged as a key regulator of many cell biological 
mechanisms including proliferation, differentiation, migration, and trafficking, as well as 
many neuronal and immunological processes.  
Phosphorylation is a reversible covalent modification that involves the transfer of a 
phosphoryl group to a hydroxylated amino acid residue (serine (Ser), threonine (Thr) or 
tyrosine (Tyr)) on a protein substrate. In cells, the forward phosphorylation reaction is 
catalysed by enzymes called kinases, which use adenosine triphosphate (ATP) 
molecules as phosphoryl donors. Phosphatase enzymes catalyse the reverse, 
dephosphorylation reaction, which remove the phosphoryl group from the amino acid 
residue.  
As one of the largest gene families, the protein kinases make up 1.7 % of the human 
genome, with 518 members, most of which contain a conserved protein kinase catalytic 
domains that facilitate phosphoryl transfer (Manning et al., 2002). There are two main 
types of kinases; the Ser/Thr kinases and Tyr- kinases. Although, dual specificity kinases 
with both Ser/Thr and Tyr- kinase activity, also exist (e.g. (Roskoski, 2012)). The 
proportion of Ser, Thr, and Tyr phospho-sites within the phosphoproteome varies. Of the 
6,600 phosphorylation sites derived from 2,244 proteins in the phosphoproteome of 
HeLa cells, 86.4 % of the sites were phosho-serine residues, 11.8 % were 
phosphothreonine residues and 1.8 % were phosphotyrosine residues (Olsen et al., 
2006).  
A further class of kinase, termed the pseudokinases, has also been described (reviewed 
in (Zeqiraj and van Aalten, 2010). These kinases lack residues present in the active site 
of the conserved eukaryotic kinase domain that are critical for catalysis. For example, 
the psuedokinase STRAD, which forms part of a tumour suppressing complex with the 
adaptor protein MO25 and the kinase LKB1, serves to activate LKB1 via a 
phosphorylation independent mechanism. When bound as a psuedosubstrate in 
complex with LKB1, STRAD acts as an allosteric activator of the kinase (Zeqiraj et al., 
2009). The pseudokinase is thought to have lost its ability to catalyse substrate 
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phosphoyrlation throughout evolution (Zeqiraj and van Aalten, 2010). Further examples 
of pseudokinases, whose functions are mediated via the formation of protein-protein 
interactions, include ILK (Fukuda et al., 2009), HER3 (Jura et al., 2009) and VRK3 (Kang 
and Kim, 2008). Whilst all pseudokinases were widely considered in the field to be 
inactive, in the past decade studies have emerged that have demonstrated that several 
pseudokinases are in fact catalytically active (Taylor and Kornev, 2010), although they 
are still the subject of much controversy.  
Phosphorylation can exert its effects by modifying the activity, stability or localization of 
the target protein. In addition, protein phosphorylation can also facilitate or disrupt 
protein-protein interactions (Sopko and Andrews, 2008). This places both kinases and 
phosphatases at the centre of many diverse signalling networks, which regulate virtually 
all cellular processes. Given that protein phosphorylation is linked to such a broad range 
of functions in cell biology, it is unsurprising that the deregulation of both kinases and 
phosphatases can result in a variety of disease pathologies. For example multiple types 
of cancer (Mammoto et al., 2016), vascular diseases (Nakamura et al., 2016) and 
neurodegenerative diseases (Gatta et al., 2016) have been linked to aberrant protein 
phosphorylation.   
1.1.1 Tyrosine Phosphorylation  
Whilst tyrosine phosphorylation accounts for the lowest proportion of protein phospho-
sites in comparison to Ser/Thr, this does not make it any less important. The human 
kinome contains 90 tyrosine kinases, which can be categorised into to two families: 
receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs) (Manning 
et al., 2002).  
RTKs account for 58 of the 90 tyrosine kinases and are type 1 transmembrane proteins 
that contain three distinct domains: an N-terminal extracellular domain, a single 
transmembrane domain and a C-terminal cytoplasmic domain (Manning et al., 2002). 
Generally, RTKs are activated upon ligand binding to the extracellular domain, which 
results in receptor dimerization (or in some cases oligomerisation), triggering the 
transphosphorylation of tyrosines in their cytosolic C-terminal domain. This in turn, 
creates binding sites for proteins containing Src homology 2 (SH2) domains (discussed 
in Section 1.2.4) or phosphotyrosine binding (PTB) domains. The subsequent RTK 
phosphorylation of various docking proteins, such as Gab1, can also facilitate the 
recruitment of other signalling proteins that act in downstream signalling transduction 
pathways (Lemmon and Schlessinger, 2010). Therefore, in effect, the intracellular 
domains of activated RTKs act as junctions where multiple signalling pathways can be 
triggered (Lemmon and Schlessinger, 2010).  
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Two of the major downstream signalling pathways that are triggered downstream of RTK 
activation include the Ras/Map kinase (MAPK) and the PI-3K/Akt pathways. Both of 
these pathways are initiated through the recruitment of the adaptor protein Grb2, which 
binds to the phosphorylated C-terminal tail of RTKs (Lemmon and Schlessinger, 2010). 
To stimulate the Ras/MAPK pathway, the two SH3 domains of Grb2 bind to SOS, a 
guanine nucleotide exchange factor (GEF) that catalyses the activation of the GTPase 
Ras. Activated Ras recruits and activates RAF, which triggers a MAPK cascade involving 
the subsequent activation of MEK and ERK (English et al., 1999). To activate the PI-3K 
pathway, Grb2 recruits the docking protein Gab1, which becomes phosphorylated and 
binds to the p85 subunit of PI-3K, resulting in the activation of the kinase. PI-3K catalyses 
the production of the lipid, phosphoinositide-3,4,5-triphosphate (PIP3). PIP3 recruits Akt 
to the membrane via its pleckstrin-homology (PH) domain, where it is activated and 
phosphorylates downstream targets (Cantley, 2002). These pathways together with 
others, form an interconnected complex signalling network that regulate key cellular 
processes including cell proliferation, differentiation and survival (Lemmon and 
Schlessinger, 2010). 
Dissimilar to RTKs, nRTKs are mainly cytosolic intracellular proteins, although some are 
membrane localised since they contain an N-terminal lipid modification. Many act as 
additional subunits of cell surface receptors that do not have catalytic tyrosine kinase 
domains themselves (reviewed in Hunter, 2009) whilst some kinases, such as Src, are 
recruited to activated RTKs. Therefore, in response to receptor ligand binding, nRTKs 
are capable of triggering downstream signalling events (Neet and Hunter, 1996). Whilst 
there are nine families of nRTKs, the Src family of kinases will be the point of discussion 
in the remainder of this introduction.    
1.2 The Structure and Regulation of Src Family kinases (SFKs) 
Src family kinases (SFKs) are nRTKs, which comprise 11 known individual members 
(Manning et al., 2002). Eight of the family members, namely Blk, C-Src, Fgr, Fyn, Hck, 
Lck, Lyn and Yes, have been the most comprehensively studied and over the years, 
structural studies have revealed that SFKs share the same conserved modular structure, 
differing only by the N-terminal regions of the protein (Figure 1.1). The modular domains, 
termed Src homology (SH) domains, have since been described to occur in many other 
types of protein. The SFKs each comprise the following six domains: the SH4, unique, 
SH3, SH2, SH1 (or kinase domain) and the C-terminal domains (Figure 1.1; reviewed in 
Engen et al., 2008). The role of each of these domains in both the function and regulation 
of the kinase is discussed below.   
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Figure 1.1: Schematic Diagram Illustrating the Modular Structure of SFKs. 
The structure of each family member contains an N-terminal SH4 domain, followed by 
the unique, SH3, SH2 and catalytic kinase domains. The SH4 domain contains a lipid 
modification, which facilitates membrane tethering. Both the SH3 and SH2 domains 
confer substrate specificity by binding PXXP or phosphotyrosine motifs respectively, 
whereas the kinase domain catalyses the phosphorylation of bound substrates. The 
phosphorylation of Y-416 in the kinase domain promotes catalytic activity. Adjacent to 
the kinase domain is the C-terminal tail, which contains the highly conserved Y-527 and 
regulates the autoinhibition of SFKs upon phosphorylation.  
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1.2.1 The SH4 Domain  
The N-terminal region of SFKs, comprising the SH4 and unique domains, is the least 
conserved area of the protein and its structure is intrinsically disordered. Lipid 
modification of the SH4 domain facilitates tethering to the plasma membrane, as well as 
other intracellular membrane compartments and is required for SFK function in vivo 
(Resh, 1994). All SFKs are myristoylated and many undergo additional palmitoylation 
(Resh, 1994, Koegl et al., 1994). Indeed, the myristoylation and palmitoylation sites, Gly-
2 and Cys-3 (except in C-Src and Blk) respectively, are two of just a few conserved 
residues at the N-terminus (Koegl et al., 1994).  
The sole irreversible myrystoylation of SFKs occurs promptly after translation, whereas 
palmitoylation is a more dynamic, reversible modification that is dependent upon 
myristoylation and can occur at multiple sites in some SFKs (e.g. Lck and Fyn; (Buss et 
al., 1984, Paige et al., 1993, Koegl et al., 1994). Whilst this secondary modification 
strengthens membrane binding, palmitoylation has also been reported to localise SFKs 
to caveolae in the plasma membrane and to regulate the trafficking of SFKs (Shenoy-
Scaria et al., 1994, Sato et al., 2009). The basic residues that flank the lipid modification 
sites also promote the kinases’ interaction with the negatively charged plasma 
membrane (Silverman et al., 1993). Localisation of SFKs to the membrane enables the 
kinases to interact with and phosphorylate other membrane-localised proteins, as well 
as cytoplasmic components. Therefore, this modification is intrinsic to the function of 
SFKs, which are key components of many different signalling pathways and regulate 
many cellular processes. 
1.2.2 The Unique Domain 
The unique domain is the intrinsically disordered region (IDR) situated between the SH4 
and SH3 domains of SFKs, which typically consist of 50-80 residues. Whilst the unique 
domains are not conserved between the different SFK members, the domain of each 
individual kinase is conserved between species (Amata et al., 2014). This indicates a 
specific role of the unique domain in the regulation and function of each kinase. In 
support, the swapping of the unique domains of C-Src and Yes, effectively switches the 
functional properties of the kinases (Summy et al., 2003, Hoey et al., 2000).  
Post-translational modification of the unique domain via phosphorylation has proved to 
be an important regulator of SFK function (Amata et al., 2014). In the literature there are 
many examples that demonstrate the divergent roles of the multiple phosphorylation 
events within the unique domains of SFKs (reviewed in Amata et al., 2014). For example, 
phosphorylation of C-Src by PKA at Ser-17 has been implicated in the translocation of 
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the kinase to the cytosol in response to platelet-derived growth factor (PDGF) and the 
cAMP dependent activation of the small GTPase Rap1 (Walker et al., 1993, Obara et al., 
2004). Whereas, Thr-37, Thr-46 and Ser-75 phosphorylation by cyclin-dependent kinase 
1 (cdk1) promotes the activation of Src during mitosis, by disrupting regulatory 
intramolecular interactions (Shenoy et al., 1992).  
In recent years, a novel regulatory mechanism involving unique-lipid interactions in C-
Src has emerged. Whilst the unique domain has been defined as an IDR, NMR 
spectroscopy revealed the presence of two partially structured regions between residues 
60-74 (Pérez et al., 2009). Perez and colleagues demonstrated using NMR that this 
region comprises an additional lipid binding site, which promotes intermolecular 
interactions with acidic lipids. Further experiments established that lipid binding by the 
unique domain could be regulated by the phosphorylation of Ser-37 and Thr-75, which 
largely diminished unique-lipid binding, with little effect observed on SH4-lipid 
interactions (Perez et al., 2013). In the same study, the unique domain was found to 
interact with the SH3 domain, which also displayed a degree of lipid binding. The binding 
of the SH3 domain to positively charged lipids and the unique domain occurred away 
from the substrate docking site, and interaction of the SH3 domain with a high affinity 
proline rich peptide resulted in the abolition of unique-SH3 contacts. In addition to this, 
the unique-SH3 interaction was perturbed by the binding of calcium-loaded calmodulin 
to the unique domain, which prevented unique-lipid interactions, suggesting this 
interaction is regulated by calcium signalling (Perez et al., 2013). It is now thought that 
the SH3 domain acts as a scaffold for the unique domain, which forms a disordered loop 
between the SH4 and SH3 domains (Maffei et al., 2015).   
Together these data present a novel regulatory role for the unique domain, although thus 
far, these interactions have only been described in vitro. Nevertheless, the observation 
that C-Src mutants, defective in unique-lipid binding, negatively affected Xenopus laevis 
oocyte maturation, a process that is usually promoted by wild type (WT) C-Src, suggests 
unique-lipid interactions are required for C-Src function, and could be relevant to other 
SFKs.   
1.2.3  The SH3 Domain 
The SH3 domain, which consists of approximately 60 amino acid residues, is widely 
recognised throughout cell biology as a facilitator of protein-protein interactions. Whilst it 
was first described as one of the six modular domains of C-Src, almost 300 SH3-
containing proteins have since been identified in humans (Kärkkäinen et al., 2006). In 
addition to their presence in eukaryotes, SH3 containing proteins also occur in 
prokaryotes and viruses (Whisstock and Lesk, 1999). Therefore, it is unsurprising that 
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SH3 domains are key players in many signal transduction pathways. Some of their main 
functions include promoting multiprotein complex formation, substrate recognition, and 
enzymatic regulation, as well as enhancing localised protein concentration (Mayer, 
2001). 
In SFKs, SH3 domains play multiple key roles. Primarily, the SH3 facilitates substrate 
docking and has an important role in the regulation of kinase activity via the formation of 
intramolecular interactions (discussed in Section 1.2.7). More recently, the SH3 was 
shown to act as a scaffold for the intrinsically disordered unique domain and is thought 
to interact with the lipid membrane (discussed in Section 1.2.2, (Perez et al., 2013)).  
When the structure of the C-Src SH3 domain was solved in 1992, it was revealed that 
the protein consisted of two short three-stranded anti-parallel β-pleated sheets that were 
positioned at approximately right angles to each other (Figure 1.2, (Yu et al., 1992). A 
hydrophobic core was identified at the interface between the two β-pleated sheets, which 
was flanked by connecting n-Src and RT loops (Feng et al., 1995, Yu et al., 1992, Noble 
et al., 1993, Xu et al., 1997). This conserved hydrophobic region, a flat surface populated 
mostly by aromatic residues, contains three shallow binding pockets and is the site of 
substrate recognition (Noble et al., 1993, Musacchio et al., 1994).  
SH3 domains interact with substrate regions that contain short amino acid sequences, 
rich in proline residues, called PXXP motifs (where X is any amino acid residue). The 
motifs adopt the conformation of a left handed polyproline helix type 2 (PPII, (Musacchio 
et al., 1994)). Since all SH3 domains recognise a consensus centred around a PXXP 
motif, it is the flanking residues that confer specificity to individual proteins, ensuring that 
all SH3 domains do not recognise the same subsets of proteins. Whilst the third binding 
pocket, dubbed the ‘specificity pocket’, facilitates the binding of the flanking residues, 
further interactions with the n-Src and RT loops (the main sources of variation in SH3 
domains) outside of the hydrophobic core, have also been described (Alexandropoulos 
et al., 1995, Ren et al., 1993, Weng et al., 1995, Rickles et al., 1995, Feng et al., 1995). 
C-Src is capable of binding two types of sequence; the class I R/KΦPXΦP and class II 
PΦXPΦR/K motifs (where Φ and X represent a hydrophobic or any amino acid residue 
respectively; (Zarrinpar et al., 2003, Mayer, 2001). These motif sequences reflect the 
ability of the SH3 hydrophobic core to bind the PPII substrates in two opposing 
conformations (Feng et al., 1994). Whilst two of the shallow substrate pockets on the 
binding interface form contacts with the two ΦP dipeptides, the third pocket, formed by 
the n-Src and RT loops, is typically occupied with the side chain of a positively charged 
residue (R/K, Figure 1.2, (Feng et al., 1995, Kay et al., 2000, Mayer, 2001)). 
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A diagram of the crystal structure of the C-Src SH3 domain (purple) in complex with a 
class I ligand (grey, R/KΦPXΦP). The ligand forms contacts with three pockets on the 
binding interface. The two ΦP dipeptides interact with two shallow pockets, whereas the 
third pocket, occupied with the side chain of the positively charged residue flanking the 
PXΦP motif. The position of the n-Src loop, which form part of the specificity pocket, is 
indicated. The n-Src loop is also the region of the SH3 domain in which N1 and N2 mini-
exon inserts are incorporated, which gives rise to the neuronal splice variants of Src 
(discussed further in Section 1.5). The crystal structure was solved by Feng et al., (1995) 
and the image was created by Dr Gareth Evans (University of York). PDB code 1QWF. 
  
Figure 1.2: The Structure of the C-Src SH3 Domain in Complex with a Class I 
Ligand. 
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1.2.4 The SH2 Domain 
The approximately 100 amino acid SH2 domain resides C-terminal to the SH3 domain 
and also recognises a specific short peptide motif. SH2 domains were first described by 
Sadowski and colleagues (1986) as a non-catalytic conserved domain observed in SFKs 
and fps . They speculated that the domain may facilitate protein-protein interactions. It is 
now known that there are 110 proteins in the human proteome, that contain at least one 
SH2 domain, which effectively link tyrosine kinases to a diverse array of signalling 
pathways, since they specifically bind phosphotyrosine containing motifs (Liu et al., 
2006). In SFKs, the SH2 domain provides a site for substrate recognition but also plays 
a key role in their autoinhibition, by facilitating an intramolecular interaction with the C-
terminal tail. This interaction will be discussed further in Section 1.2.7.   
Pioneering studies established that SH2 domains, confer specificity for different binding 
partners, through the recognition of different phosphotyrosine containing consensus 
motifs (Zhou et al., 1993, Songyang et al., 1994). For example, the Abl SH2 domain 
recognises the motif pYENP (where p signifies a phosphorylated residue), whereas the 
Crk SH2 domain binds to pYDHP motifs (Songyang et al., 1994). Similar studies have 
also identified the SFK SH2 binding motif, pYEEI, which was determined from a 
phospho-peptide library screen, after it bound to the SH2 domain with high affinity (Zhou 
et al., 1993). Further studies confirmed that the phosphorylation of the tyrosine residue 
was critical for this high affinity interaction (Bradshaw et al., 1999). In addition to the 
canonical pYEEI binding motif, more comprehensive studies have highlighted the 
significance of other residues flanking the motif between residue positions -2 to +4, which 
may also confer binding specificity to SFKs (Bradshaw et al., 1999, Filippakopoulos et 
al., 2009). 
Waksman and colleagues (1993) determined the crystal structure of the V-Src SH2 
domain in complex with an 11-residue pYEEI peptide (Figure 1.3). The study likens the 
ligand to a ‘two-pronged plug’ that engages with the SH2 domain, which is described as 
the corresponding ‘two holed socket’. The protein is composed of two β-sheets linked by 
a single β-strand, which are flanked at either side by an α-helix (Figure 1.3). The largest 
β-sheet is central to the domain and separates the SH2 into two functionally distinct 
areas.   
The phosphotyrosine forms a series of interactions with a pocket at one side of the 
domain, consisting of one face of the central β-sheet, a loop and an α-helix. Whereas 
the distal Ile residue, occupies the hydrophobic pocket on the other side of the central β-
sheet, which effectively engulfs the side chain of the residue. The remaining two central 
Glu residues are positioned on the surface of the SH2 domain and form contacts with  
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A diagram of the crystal structure of the V-Src SH2 domain in complex with a 
phosphotyrosine ligand (green). The protein is composed of two β-sheets (orange) linked 
by a single β-strand, which are flanked at either side by an α-helix (blue). The SH2 is 
partitioned into two functionally distinct compartments by the largest β-sheet at the centre 
of the domain. The phosphotyrosine interacts with a binding pocket at one side of the 
domain, whereas the distal Ile residue forms contacts with the hydrophobic pocket on 
the other side of the central β-sheet. The two central Glu residues lie on the surface of 
the SH2 domain. The crystal structure was solved by Waksman et al. (1993). The image 
was generated in RCSB Protein Workshop, PDB code 1SHA. 
  
Figure 1.3: The Structure of the V-Src SH2 Domain. 
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basic residues (Waksman et al., 1993). These findings were further supported by a 
similar study in which the SH2 domain of a different SFK, Lck, was crystalised (Eck et 
al., 1993). 
1.2.5 The SH1 (Kinase) Domain 
The catalytic kinase domain is connected to the SH2 domain via a flexible regulatory 
linker, and houses the active site of the enzyme where substrate phosphorylation takes 
place. The crystal structures of dozens of catalytic domains obtained from different 
kinases have revealed that the domains are structurally similar (Nolen et al., 2004). In 
fact, Manning and colleagues (2002) were able to identify 478 kinases in the human 
genome on the basis that they shared structurally conserved features of a common 
catalytic domain. However, in a similar fashion to SH2 and SH3 domains, the kinase 
domain recognises a specific motif that also governs substrate binding. Songyang and 
colleagues (1995) demonstrated that whilst catalytic domains shared many conserved 
mechanistic properties, substrate recognition was dependent on differing sequence 
motifs for the kinases tested. Whilst both V- and C-Src recognised the sequence 
EEEIYGEF, the SFK Lck optimally bound to peptides containing the sequence 
XEXIYGVLF (where X is any amino acid, (Songyang et al., 1995)). This indicated that 
the kinase domain further contributes to the substrate specificity already conferred by 
SH2 and SH3 domains.  
The kinase domain consists of two distinct lobes that are connected by a short linker 
region. The composition of the smaller N-terminal (N) lobe includes five antiparallel β-
strands, as well as an α-helix and a glycine-rich loop. Whereas the larger C-terminal (C) 
lobe is comprised of seven α-helices, a four stranded β-sheet situated on the surface of 
a deep cleft that exists between the two lobes, and also a series of loops including a 
catalytic and an important regulatory activation loop. The cleft that occurs between the 
lobes facilitates nucleotide binding and substrate phosphorylation. Here, the terminal 
phosphoryl group of ATP is added to a tyrosine residue. Whilst the N-lobe is 
predominantly concerned with Mg-ATP binding at the base of the cleft which exposes a 
transferrable phosphate group, the C-lobe is associated with substrate recognition and 
catalysis (Knighton et al., 1991, Boggon and Eck, 2004).    
The N- and C- lobes work in synchrony during catalysis, facilitating ‘open’ and ‘closed’ 
conformations (Yamaguchi and Hendrickson, 1996). In the open conformation, which is 
promoted and stabilised by the phosphorylation of Tyr-416 (chicken C-Src nomenclature) 
on the C-lobe’s activation loop, ATP and substrate binding occurs (Breitenlechner et al., 
2005, Huse and Kuriyan, 2002, Roskoski, 2004). When the two lobes effectively ‘close’ 
together, the phosphorylation event occurs and ADP is released upon the ‘re-opening’ 
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of the complex (Roskoski, 2004). The phosphorylation at Tyr-416 can either occur as a 
result of auto- or trans-phosphorylation, the latter of which occurs between SFK 
molecules, indicating that Tyr-416 phosphorylation is a self-regulatory event amongst 
SFKs (Sugimoto et al., 1985, Imamoto and Soriano, 1993). This mechanism of regulation 
has also been observed for multiple other unrelated kinases, whereby phosphorylation 
of the activation loop propagates increased kinase activity (Huse and Kuriyan, 2002). 
1.2.6 The C-terminal Domain (CTD) 
The C-termini of SFKs contain between 15-17 residues, including the highly conserved 
Tyr-527 residue. The phosphorylation of Tyr-527 by the tyrosine kinases Csk or Chk, 
promotes an autoregulatory structural conformation that inhibits kinase activity 
(discussed further in Section 1.2.7). Importantly, phosphatases that facilitate the 
dephosphorylation of this residue, such as PTP1B, PTPα and SHP1/2, facilitate the 
activation of the kinase (Bjorge et al., 2000, Harder et al., 1998, Somani et al., 1997, 
Zhang et al., 2004).  
1.2.7 The Autoregulation of SFKs 
Whilst SFK activity can be regulated by myristoylation, palmitoylation and 
phosphorylation, which are outlined above, the autoinhibition of SFKs is probably the 
most studied and best characterised regulatory mechanism and is described below.  
Phosphorylation of Tyr-527 in the C-terminal region of SFKs generates an SH2 domain 
binding motif that facilitates an intramolecular interaction between the C-terminal tail and 
the SH2 domain of the kinase (Xu et al., 1997, Schindler et al., 1999, Sicheri et al., 1997, 
Williams et al., 1997). The importance of this interaction has been demonstrated on 
multiple occasions, including in a study on C-Src, whereby the substitution of Tyr-527 
with a Phe residue, resulted in the constitutive activation of C-Src and cellular 
transformation (Reynolds et al., 1987). Such studies indicated that the SH2:Y527 
interaction forms part of an autoinhibitory mechanism. Tyrosine phosphorylation at Tyr-
527 is coordinated by C-terminal Src kinase (Csk), whose major role in maintaining SFKs 
in the inactive conformation was highlighted by gene knock-out studies in mice. A large 
increase in the activity of C-Src, Fyn and Lyn was observed in Csk-/- mice, which was 
thought to contribute to the resultant embryonic lethal phenotype (Imamoto and Soriano, 
1993, Nada et al., 2003).  
In addition to the SH2:Y527 interaction, crystal structures of C-Src, Hck and Lck revealed 
that a second interaction occurs simultaneously between the SH3 domain and a PPII 
helix present in the linker region connecting the SH2 and kinase domains (Xu et al., 
1997, Schindler et al., 1999, Sicheri et al., 1997). The SH3:linker interaction is thought 
to stabilise the SH2:Y527 interaction. Mutations of critical proline residues in the PPII 
 
 
28 
 
helix of the linker responsible for SH3 binding in Hck, resulted in elevated kinase activity 
and increased transforming capabilities in mouse fibroblasts (Briggs and Smithgall, 
1999). This indicated the importance of this interaction in conjunction with SH2:Y527 
binding.  
The result of both the SH2:Y527 and SH3:linker interactions is the subsequent effects 
on the catalytic kinase domain. In this ‘closed’ inhibitory conformation (Figure 1.4), both 
the SH2 and SH3 domains apply pressure on the kinase domain, at the opposite side to 
the active site, which alters the orientation of both the N- and C-lobes. In the active site 
cleft, a catalytically important α-helix is displaced and the activation loop is forced into a 
partially helical conformation that is incompatible with substrate binding, and prevents 
autophosphorylation at Tyr-416 (Xu et al., 1997, Schindler et al., 1999, Sicheri et al., 
1997).  
The interaction formed between the C-terminal tail and the SH2, as well as those formed 
between the SH3 and the linker are relatively weak. This is because the SH2 and SH3 
binding motifs present in the linker and C-terminal tail respectively, do not conform 
exactly to the specific motifs described above (i.e. SH3: PXXP; SH2: YEEI). This means 
that higher affinity substrates are capable of displacing these interactions (Figure 1.4), 
The binding of an SH2 or SH3 containing substrate partially activates the kinase and 
promotes Tyr-416 phosphoryaltion, although whether the displacement of one of the 
intermolecular interactions results in the disruption of the second to promote the open 
active kinase conformation is still uncertain (Figure 1.4).  
The significance of this autoregulatory mechanism, which has been alluded to in the 
above paragraphs, lies in the ability of constitutively activated C-Src to transform ‘normal’ 
cells into ‘cancerous’ cells, in which cell proliferation and survival mechanisms are 
upregulated. For example, a strain of the closely related viral oncogene V-Src promotes 
cell transformation due to its high constitutive activity, which is attributed to the deletion 
of a portion of the C-terminus or the mutation of Tyr-527. The absence of the Tyr-527 
residue, is therefore thought to prevent the autoinhibition of the kinase, which promotes 
cellular phenotypes that would usually be tightly regulated. Examples demonstrating the 
critical nature of this mechanism in the context of typical SFKs are outlined above 
whereby the mutation of Tyr-527 or the critical proline in PPII helix linker resulted in cell 
transformation (Reynolds et al., 1987, Briggs and Smithgall, 1999).  
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Figure 1.4: A Schematic Illustrating SFK Activation. 
In the closed inactive complex, SH3: linker and 
SH2: Y257 interactions prevent catalytic activity. 
Since these interactions are low affinity, they can 
be displaced by higher affinity SH3 or SH2 
containing substrates, which facilitates the 
autophosphorylation of Tyr-416 at the active site 
of the kinase domain, resulting in partial activation. 
These SH2 and SH3 substrate bound 
conformations are thought to promote the open 
kinase conformation, resulting in full kinase 
activation.  
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1.3 Cellular Functions of C-Src 
The founding member of SFKs, C-Src, is a proto-oncogene that was first discovered after 
its viral counterpart V-Src, a retroviral oncogene accountable for sarcomas caused by 
the Rous sarcoma virus, was found to have been captured from its host genome 
(Stehelin et al., 1976, Shalloway et al., 1981, Takeya and Hanafusa, 1983). Since, its 
discovery, a large number of C-Src substrates have been identified and a diverse range 
of functions have since emerged for the kinase, including roles in cell proliferation, 
differentiation, motility and survival. In addition to this, C-Src has been implicated in the 
mechanisms governing learning and memory (Engen et al., 2008). Therefore, it is 
unsurprising that C-Src activity lies at the heart of a diverse range of signalling networks, 
due to its ability to phosphorylate and recognise a plethora of substrates.  
Upstream of C-Src, kinase activity has been shown to be upregulated in response to a 
range of cell surface receptor signals. For example, multiple mitogen activated growth 
factor receptors (e.g. epidermal growth factor receptors (EGFR) and PDGFRs), Integrins, 
G-protein coupled receptors (GPCRs e.g. β-adrenergic receptor) and receptor tyrosine 
phosphatases (e.g. PTPα) have all been linked to C-Src activation and subsequent 
signalling events (Gould and Hunter, 1988, Luttrell et al., 1999, Schaller et al., 1999, 
Zheng et al., 2000). These studies, amongst others, have shown or suggested that C-
Src is involved in the intracellular relay of cell-cell and cell-matrix signals; a phenomenon 
that is now widely acknowledged and has been investigated a great deal.  
Perhaps one of the most well-known roles of C-Src is its participation in focal adhesion 
signalling and cell spreading. In both C-Src-/- fibroblasts and osteoclasts, as well as 
epithelial cells treated with an SFK inhibitor, both integrin-dependent cell-matrix 
adhesion and cell spreading are reduced (Kaplan et al., 1995, Felsenfeld et al., 1999, 
Lakkakorpi et al., 2001, Jones et al., 2002). Active C-Src localises at focal adhesions at 
sites of integrin clustering on the cell membrane, which is triggered by ECM stimuli 
(Kaplan et al., 1994, Playford and Schaller, 2004). However, this localisation is abolished 
in the absence of the SH4 or SH3 domains of the kinase, which highlights the necessity 
of membrane association and the likely role of the SH3 domain in substrate recognition 
(Kaplan et al., 1994). At focal adhesions, C-Src is found in complex with multiple other 
proteins including Focal adhesion kinase (FAK), p130CAS and paxillin, which have also 
been shown to be phosphorylated by the kinase (Glenney and Zokas, 1989, Kanner et 
al., 1990).  
During cell spreading, integrin engagement results in the autophosphorylation of FAK at 
Tyr-397, which recruits C-Src by providing an SH2 binding site (Schaller et al., 1994). C-
Src phosphorylates FAK at multiple sites, enabling the recruitment of other focal 
 
 
31 
 
adhesion complex components (Calalb et al., 1995, Calalb et al., 1996). This triggers a 
series of signalling events that regulate Rho GTPase-mediated cytoskeletal dynamics. 
The recruitment and phosphorylation of the scaffolding protein p130CAS, paves the way 
for the further recruitment of Crk, DOCK180 and ELMO1. A complex between the latter 
two proteins activates Rac1 via guanine nucleotide exchange factor (GEF) activity 
(Chodniewicz and Klemke, 2004). In a parallel pathway, Rac1 activation is also promoted 
via the FAK/Src complex component Paxillin, whose phosphorylation recruits Paxillin 
kinase linker (PKL) and subsequently β-PIX, which is also a Rac1 GEF (ten Klooster et 
al., 2006). Simultaneously, the transient inactivation of RhoA is promoted via the FAK/Src 
complex, through the recruitment and phosphorylation of p190rhoGAP. The latter, is a 
GTPase activating protein (GAP) that renders RhoA inactive by stimulating GTP 
hydrolysis (Arthur et al., 2000, Ren et al., 2000). Whilst Rac1 activation promotes cell 
protrusion, RhoA inactivation suppresses contractility of the actin cytoskeleton. 
Therefore, through co-ordinating the activities of Rac1 and RhoA, the FAK/Src complex 
facilitates cell spreading (Huveneers and Danen, 2009).  
In conjunction with integrin-dependent FAK/Src signalling, considerable crosstalk with 
growth factor receptors and cell adhesion molecules also plays a role in the regulation 
of cell spreading. For example, the integrin-dependent Src-mediated phosphorylation of 
EGFR promotes cell spreading upon the stimulation PI3K signalling, which results in 
Vav1-mediated Rac1 activation (Moro et al., 2002, Marcoux and Vuori, 2003). Since C-
Src was first discovered, a clearer picture has emerged whereby a range interconnected 
networks involving different types of cell surface receptors, co-ordinate downstream Rho 
GTPase-mediated cytoskeletal dynamics, via a combination of intermediate signals in 
which C-Src is a key player. Together, such networks are capable of regulating cell-
matrix adhesion and cell-cell adhesion to coordinate processes that include cell 
migration, proliferation and survival (Huveneers and Danen, 2009).  
1.3.1 C-Src Functions in the Brain 
1.3.1.1 The Role of C-Src in the Developing Brain 
In the 1980’s, a body of work investigating the relative expression of C-Src in various 
organisms, indicated that in both frogs and fish, C-Src expression was at its highest in 
both the developing and mature brain (Schartl and Barnekow, 1984). Further studies 
demonstrated that in some areas of the rat brain including the cerebellum, hippocampus 
and striatum, maximal C-Src expression was between 6 to 20 times higher in comparison 
to the corresponding adult tissues. It was observed that these increases in C-Src activity 
largely correlated with peak times of neurogenesis and neuronal growth, suggesting a 
potential role for C-Src in neuronal development (Cartwright et al., 1988). Manness and 
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colleagues proposed that C-Src expression occurs in two phases during neuronal 
development (Maness et al., 1986, Fults et al., 1985). Firstly, C-Src expression becomes 
elevated in the neuroectoderm of gastrulating embryos, which coincides with the period 
when cells commit to a specific cell lineage (Maness et al., 1986). The second phase, 
described in cerebellar neuronal progenitor cells, occurs during neuronal differentiation 
(Fults et al., 1985). 
Since these observations were made, C-Src has been implicated in multiple roles during 
neuronal development. The enrichment of activated C-Src in neuronal growth cone 
membranes indicated a potential role for the kinase in axonal outgrowth and guidance, 
which was confirmed in later studies (Maness et al., 1989). Growth cones are the 
dynamic structures present at the tip of growing axons, which facilitate the directional 
outgrowth of axons in response to external stimuli including a variety of guidance cues, 
as well as cell adhesion molecules present on neighbouring cells. SFKs have been 
implicated downstream of multiple cell surface receptors including EphA, Trk, DCC and 
PlexinA, which are stimulated by the following guidance cues: ephrins, neurotrophins, 
netrin and semaphorins respectively to promote neurite outgrowth (Knoll and Drescher, 
2004, Liu et al., 2004, Falk et al., 2005). However, the specific mechanisms through 
which the kinases act are largely uncharacterised. Specifically, the recruitment of both 
C-Src and FAK to the activated netrin receptor DCC has been shown to be required for 
netrin mediated neurite outgrowth (Liu et al., 2004). Whilst the direct mechanism involved 
in unknown, netrin mediates neurite outgrowth via the modulation of PI3K, ERK and Rho 
GTPases; therefore, it is likely that Src/FAK signalling acts upstream of these signalling 
components (Liu et al., 2004).  
C-Src mediated neurite outgrowth can also be regulated by cell adhesion receptors, in 
particular L1-CAM. Ignelzi and colleagues (1994) demonstrated that neurite outgrowth 
was reduced in Src-/- cerebellar granule neurons (CGNs) that were cultured on, L1-CAM. 
Neurite outgrowth on the extracellular matrix component laminin, which stimulates 
integrin signalling, was unaffected (Ignelzi Jr et al., 1994). This pointed towards a specific 
role for C-Src in L1-CAM-mediated neurite outgrowth, since laminin failed to evoke a 
response. However, it is possible that the functional redundancy between SFKs could 
mask a potential role for C-Src.   
The neuronal specific cell-cell adhesion molecule L1-CAM, consists of an N-terminal 
extracellular domain (6 x immunoglobulin-like domains connected to 5 x fibronectin type 
III repeats), a transmembrane domain and a cytoplasmic domain c-terminal domain 
(CTD), which contains multiple phosphorylation sites that are thought to regulate L1-
CAM-cytoskeletal interactions (Crossin and Krushel, 2000). To date, three sites on the 
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cytoplasmic CTD of L1-CAM have been implicated in L1-CAM cytoskeletal interactions 
and C-Src is thought to be involved in the regulation of these interactions, either directly 
or indirectly (Nagaraj and Hortsch, 2006).  
L1-CAM is thought to interact with the actin-spectrin cytoskeleton by binding ankyrin B 
via the FIGQY motif in the cytoplasmic CTD. By generating L1-CAM-/- cerebellar neurons 
that expressed a L1-CAM-CTD truncation mutant (110 of 114 CTD amino acids deleted) 
whilst growing on a wild type L1-CAM substrate, Cheng et al., (2005) showed that L1-
CAM-CTD was unnecessary for neurite outgrowth. This agrees with findings by (Gil et 
al., 2003), who demonstrated that L1-CAM/ankyrin binding renders L1-CAM stationary 
in the membrane, preventing L1-CAM mediated neurite outgrowth. Thus when the 
ankyrin binding motif is absent, L1-CAM can stimulate neurite outgrowth. However, 
contradictory evidence published by (Nishimura et al., 2003) suggests L1-CAM/ankyrin 
interactions stimulate neurite initiation. Nevertheless, tyrosine phosphorylation of the 
FIGQY motif prevents L1-CAM binding to ankyrin, although it is not thought that this motif 
is directly phosphorylated by SFKs under basal conditions (Whittard et al., 2006a). 
Despite this, epidermal growth factor (EGF), neural growth factor (NGF) and fibroblast 
growth factor (FGF) receptors and the MAP kinase pathway have been implicated in 
FIGQY phosphorylation pathways, and often involve Src kinase. 
In cerebellar neurons, neurite branching but not neurite outgrowth is mediated by L1-
CAM interaction with cytoskeletal component ezrin-moesin-radixin (ERM). Both a 
juxtamembrane ERM binding motif and the RSLE endocytosis motif were demonstrated 
to be required for the regulation of neurite branching (Cheng et al., 2005). The tyrosine 
(Tyr-1176) that precedes the RSLE region is phosphorylated by C-Src (demonstrated in 
vivo), and prevents clathrin-mediated endocytosis of L1-CAM by prohibiting AP-2 binding 
to the L1-CTD (Schaefer et al., 2002). Phosphorylation of Tyr-1176 by Src may also be 
a means of perturbing L1-CAM/ERM interactions. 
A further occasion, whereby C-Src has been implicated in the regulation of neurite 
outgrowth is in relation to p190rhoGAP, which promotes neurite extension by 
downregulating the activity of RhoA. The study demonstrated that both C-Src and Fyn 
are the primary kinases in both the developing and mature brain that phosphorylate 
p190rhoGAP and C-Src-mediated phosphorylation of p190rhoGAP is known to promote 
the inactivation of RhoA (Brouns et al., 2001). However, this study did not directly link 
Src to the effects of p190rhoGAP on axon outgrowth and guidance. 
1.3.1.2 The Role of C-Src in the Adult Brain 
In the adult nervous system, C-Src regulates synaptic transmission and plasticity. 
Synaptic transmission facilitates the relay of information between neurons. This form of 
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communication is dependent upon the release of chemical messengers 
(neurotransmitters) from the pre-synapse, which bind to post-synaptic ion-channel 
receptors. Neurotransmitters can have an excitatory (e.g. glutamate) or inhibitory effect 
(γ-aminobutyric acid; GABA), resulting in the depolarisation or hyperpolarisation of the 
post-synaptic membrane respectively. Synaptic plasticity is defined by the ability of 
synapses to strengthen or weaken. This can manifest for example, as an increase or 
decrease in the amount of neurotransmitter released at the pre-synapse (short-term 
plasticity) or the number of receptors present at the post-synapse (a factor in long-term 
plasticity).    
Short-term synaptic plasticity, which may last between tens of milliseconds to minutes, 
can manifest as synaptic depression, facilitation or augmentation/posttetanic potentiation 
(PTP). During short-term depression and facilitation, the deliverance of two stimuli in 
close succession gives rise to a response to the second, which is either smaller 
(depression) or greater (facilitation) than the first. Whereas, synaptic augmentation or 
PTP occurs in response to sustained presynaptic activation and can occur for up to 
several minutes (Regehr, 2012). Such mechanisms of short-term synaptic plasticity 
regulate the mobilisation of neurotransmitter from the pre-synapse into the synaptic cleft, 
resulting in a reduction (depression; (Betz, 1970)) or increase (facilitation and 
augmentation; (Katz and Miledi, 1968, Magleby and Zengel, 1975)) in their release. For 
example, facilitation takes place, when pre-synaptic calcium levels become elevated due 
to the arrival of two closely spaced action potentials at the pre-synapse. Since pre-
synaptic calcium levels regulate membrane-vesicle fusion, more neurotransmitter is 
released after the second action potential, which strengthens the synapse (Katz and 
Miledi, 1968). On the other hand, depression occurs when the pool of readily releasable 
vesicles has become depleted. Therefore, synaptic strength declines until 
neurotransmitter levels are restored by the reserve pool of vesicles (Betz, 1970). 
The most commonly studied types of long-term synaptic plasticity, are long-term 
potentiation (LTP) and long-term depression (LTD). These forms of plasticity are largely 
regulated at the postsynapse via the modulation of glutamate receptors (Traynelis et al., 
2010). The activation of ionotropic NMDA receptors (NMDARs) in the postsynapse is 
often required for triggering both LTP and LTD. However, in order to relieve the Mg2+ 
channel blockade of glutamate bound NMDARs, sustained membrane depolarisation 
must be achieved through either high frequency stimulation (LTP) or prolonged low 
frequency stimulation (LTD) at the post-synapse (Malenka, 1994). Once activated, the 
second messenger Ca2+ enters through the channel, activating either protein kinases 
(e.g. CAMKII) in LTP or protein phosphatases (e.g. calcineurin) in LTD (Soderling and 
Derkach, 2000, Mulkey et al., 1993). The resulting, complex downstream signalling 
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cascades regulate events that either serve to strengthen (LTP) or weaken (LTD) at the 
synapse. For example, one of the main pathways through which synaptic strength is 
determined, is through the regulation of AMPA receptor (AMPAR) trafficking to the 
postsynaptic membrane (Malinow and Malenka, 2002). AMPARs are a further class of 
ionotropic receptor that are activated upon glutamate binding, resulting in Na+ influx and 
membrane depolarisation. During LTP or LTD, AMPARs are inserted into the membrane 
(Shi et al., 1999) or removed by endocytosis (Carroll et al., 1999), respectively.  
In addition to the involvement of ionotropic receptors in the regulation of long-term 
synaptic plasticity, a second class of receptor, termed the metabotropic receptors, also 
contribute to its maintenance (Mukherjee and Manahan-Vaughan, 2013). Metabotropic 
receptors differ from ionotropic receptors in that they do not contain an ion channel pore 
(for example many are G-protein-coupled receptors (GPCRs)), however, they are still 
activated upon neurotransmitter (e.g. glutamate) binding. This class of receptor is 
indirectly linked with ion channel function at the post-synapse through the regulation of 
downstream intracellular signalling pathways. Therefore, the mode of action of 
metabotropic receptors on synaptic activity is slower in comparison to ionotropic 
receptors (Mukherjee and Manahan-Vaughan, 2013). During long-term synaptic 
plasticity, multiple types of glutamate metabotropic receptors (e.g. mGluR1 and 
mGluR5), have been implicated in the regulation of ion channel activity, including 
NMDARs (e.g. Trepanier et al., 2013), AMPARs (e.g. Kelly et al., 2009) and SK channels 
(e.g. Tigaret et al., 2016).  
At the post-synapse, C-Src regulates ion channel signalling. In particularly, ionotropic 
glutamate NMDARs and AMPARs, voltage-gated potassium and calcium channels, 
GABAA receptors and nicotinic acetylcholine receptors can all be regulated by C-Src 
(Wang and Salter, 1994, Fadool et al., 1997, Cataldi et al., 1996, Moss et al., 1995, Wang 
et al., 2004). The regulation of NMDARs by Src is probably the most widely studied, 
given the high profile role of NMDARs in learning, memory and synaptic development, 
which is due to their modulation of excitatory synaptic transmission and plasticity (Sanz-
Clemente et al., 2013).                                                                                                                                                                                                                                                                                                                                     
NMDARs are heterotetrameric complexes, which consist of two NR1 subunits and two 
NR2 (NR2A-D) or NR3 (NR3A-B) subunits. Differential phosphorylation of the NR2 
subunits mediated by SFKs plays a key role in their modulation (Salter and Kalia, 2004).  
Over the past couple of decades, the role of C-Src in the regulation of NMDARs has 
been characterised in terms its biochemical, molecular and physiological roles. Src 
regulation of NMDARs stimulates long term potentiation in CA1 hippocampal neurons 
(Yang et al., 2012) and could potentially be a therapeutic target for the treatment of 
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inflammatory and neuropathic pain, schizophrenia and the damaging effects of ischemia 
and reperfusion (Liu et al., 2008, Trepanier et al., 2013).  
Protein tyrosine kinases enhance NMDAR currents in hippocampal and spinal dorsal 
horn neurons and it has been demonstrated that NR2A and NR2B subunits are tyrosine 
phosphorylated via Western blot analysis of immunoprecipitated NR2A and NR2B from 
isolated rat cortical synaptic membranes (Lau and Huganir, 1995, Wang and Salter, 
1994). Furthermore, electrophysiological experiments on human embryonic kidney cells 
(HEK-293) expressing NMDARs containing NR1 and NR2A-D subunits confirmed the 
activating effects of Src on NR2A containing channels, and demonstrated the necessity 
of the CTD for Src-mediated effects (Kohr and Seeburg, 1996). Biochemical 
characterisation of the NR2A subunit phosphorylation by V-Src, when co-expressed 
alongside the NR1 subunit in HEK-293 cells, defined the regions where NR2A was 
phosphorylated, using CTD truncation mutants of NR2A. This enabled the identification 
of specific tyrosine mutants that reduced NR2A phosphorylation. Three individual 
tyrosines, Tyr-1292, Tyr-1325, and Tyr-1387, were identified as V-Src targets (Yang and 
Leonard, 2001). Thus extensive evidence exists implicating Src in NMDAR regulation.  
In addition, there is an increasing amount of research placing Src regulation of NMDARs 
in the context of signalling pathways. For example, Lu et al. (1999) demonstrated that 
the enhancement of NMDAR currents mediated indirectly by GPCR ligand binding (i.e. 
muscarine and lysophosphatidic acid) and the subsequent activation of PKC, was 
prevented upon the inhibition of Src.  These results indicated that Src acts downstream 
of the muscarinic and lysophosphatidic acid GPCRs and PKC, to positively regulate 
NMDAR activity (Lu et al., 1999). It is speculated that PKC may activate Src indirectly, 
by modifying the tyrosine kinases CAKβ/PYK2, which in turn phosphorylate and activate 
Src, although this is yet to be confirmed.   
More recently, differential roles of Src and Fyn kinases in LTP and LTD, acting through 
different signalling pathways has been shown. In CA1 hippocampal neurons, Src 
phosphorylation of NR2A in NR1/NR2A NMDARs enhances channel activity and 
stimulates LTP. However, Fyn kinase phosphorylates NR2B in NR1A/NR2B NMDARs, 
increasing channel activity and enhancing LTD (Yang et al., 2012). This differential 
stimulation of either LTP or LTD by either NR2A or NR2B containing channels 
respectively, is thought to be a consequence of the differences between the resultant 
Ca2+ currents that flow through the channels (Erreger et al., 2005). NR1/NR2A channels 
activate and deactivate more quickly than NR1/NR2B channels, resulting in a 
considerable, yet transient influx of Ca2+ ions. Whereas, NR1/NR2A ion channels open 
and close more slowly, enabling a much greater volume of Ca2+ entry (Erreger et al., 
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2005). In the same study, roles for different GPCRs, namely the pituitary adenylate 
cyclase activating peptide 1 receptor and dopamine 1 receptor, in the selective activation 
of Src and Fyn kinases respectively, are also defined (Yang et al., 2012, Macdonald et 
al., 2005). 
Not only do these findings clearly implicate GPCRs and PKC as key players in Src 
regulation of NMDARs, they also indicate an important role for Src in the regulation of 
synaptic plasticity in the hippocampus, supporting its importance for learning and 
memory.   
A further mode of NMDAR regulation by Src has been reported, whereby activation of 
group 1 (mGluR1 and mGluR5) and 2 (mGluR2/3) metabotropic glutamate receptors 
enhance NMDAR currents via Src activation (Heidinger et al., 2002, Benquet et al., 2002, 
Yang et al., 2012, Trepanier et al., 2013). Ca2+ calmodulin dependent activation of Src, 
Fyn and Pyk2 kinases triggered by mGluR1 activity led to increased NR2A and NR2B 
phosphorylation and enhanced NMDAR currents in cortical neurons (Heidinger et al., 
2002). Benquet et al. reported similar findings in relation to mGluR1 but also realised 
that activation of mGluR5 stimulates a GPCR-dependent mechanism, which acts via the 
PKC signalling pathway to increase Src activity and enhance NMDAR currents in CA1 
neurons (Benquet et al., 2002). Furthermore and also in CA1 neurons, inhibition of the 
protein kinase A (PKA) post-mGluR2 activation stimulates Src and thus increases 
subtype specific NR1/NR2A receptor currents (Trepanier et al., 2013).  
In addition to these regulatory mechanisms, activation of C-Src via receptor tyrosine 
kinase, cytokine receptor and integrin pathways can also influence NMDAR function. It 
is thought that these pathways converge at the point of C-Src activation to effect changes 
in NMDAR regulation that ultimately controls synaptic transmission and plasticity (Salter 
and Kalia, 2004).  
A role for C-Src has also been described at the pre-synapse. Synaptosomes (isolated 
nerve terminals) derived from the hippocampi of rats that were subject to spacial maze 
learning contained increased levels and activity of C-Src. In addition to this, interactions 
with proteins including synapsin1 and synaptophysin were promoted (Zhao et al., 2000). 
These proteins along with dynamin1, are known to interact with C-Src on presynaptic 
vesicles, which is thought to regulate mechanisms involved in synaptic vesicle 
endocytosis (synaptophysin/dynamin1) and recycling (synapsin1) (Barnekow et al., 
1990, Foster-Barber and Bishop, 1998, Evans and Cousin, 2005, Messa et al., 2010). 
Therefore, in conjunction with regulating synaptic transmission and plasticity at the post-
synapse, C-Src also appears to have an important role in maintaining synaptic 
transmission at the pre-synapse.   
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1.4 SFKs in Health and Disease 
Given that C-Src is expressed ubiquitously and has been implicated in multiple cellular 
fundamental processes, it was widely anticipated that Src-/- mice would not be viable or 
at the very least display serious pathological defects. However, studies revealed that the 
C-Src knockout mouse was viable and the only abnormality that was detected was in 
relation to bone re-modelling, since the mice developed osteoporosis (Soriano et al., 
1991). Interestingly, no neurological impairments were detected, which was surprising 
since C-Src is highly expressed in the brain. It was thought that the reason that so few 
abnormalities were observed in C-Src-/- mice, was a result of the functional redundancy 
occurring between the kinases. This theory was supported by the fact that double 
knockout mice of both C-Src and Fyn or C-Src and Yes are not viable, which suggested 
that the kinases regulate overlapping functions that are essential for life (Stein et al., 
1994).  
In addition to osteoporosis, the dysregulation of C-Src has since been linked to multiple 
disease pathologies, associated with its regulation of the NMDA receptor (discussed in 
Section 1.3.1.2) and has also been linked to glutamate induced neurodegeneration (Liu 
et al., 2008, Trepanier et al., 2013, Khanna et al., 2007). C-Src is also inextricably linked 
to many types of cancer, including breast (Picon-Ruiz et al., 2016), colon (Xiao et al., 
2016), skin (Choi et al., 2015), lung (Karachaliou et al., 2016) and ovarian (Sun et al., 
2016). This is unsurprising, given that C-Src’s major cellular roles include promoting cell 
proliferation, motility, invasion and survival. When constitutively activated, C-Src, like its 
viral counterpart V-Src, possesses the ability to transform cells, which is one of the 
reasons why C-Src activity is so tightly regulated (Cartwright et al., 1987). In cancer, the 
aberrant upregulation of C-Src activity is not typically related to genetic mutations in the 
kinase, although this has been observed in some cases. Instead, it is thought that kinase 
activity is promoted by increased protein levels or in response to cellular stimuli, such as 
its recruitment to EGFRs (Ishizawar and Parsons, 2004). Currently, there are multiple 
therapeutic C-Src inhibitors in development, which are reviewed by (Kim et al., 2009).  
1.5 Neuronal Src Kinases 
In 1985, Brugge and colleagues first observed that neurons expressed a variant of Src 
that was biochemically distinct from C-Src. They demonstrated that Src expressed in 
neurons had a higher specific activity in comparison to the Src expressed in astrocyte 
cultures, and saw that the neuronal variant displayed a shift in electrophoretic mobility 
with respect to C-Src (Brugge et al., 1985). It was later revealed that two neuronal splice 
variants of C-Src exist, named N1- and N2-Src, which contain a 6 and 17 amino acid 
residue insert in their SH3 domains respectively (Figure 1.5; (Martinez et al., 1987, Pyper 
and Bolen, 1990, Pyper and Bolen, 1989).  
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N1-Src and N2-Src are splice variants derived from C-Src, which differ only by short 
inserts in their SH3 domains. Whilst N1-Src contains a 6 amino acid insert, N2-Src 
contains a 17 amino acid insert, which includes the first 5 amino acids of the N1-Src 
insert. The sequences of the amino acid inserts are indicated above. 
  
Figure 1.5: Schematic Diagram Illustrating the Mini-exon Inserts in the SH3 Domains of 
Neuronal Src Kinases. 
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Both kinases demonstrated increased catalytic activity in comparison to C-Src, although 
N2-Src appeared to have higher constitutive activity with respect N1-Src (Brugge et al., 
1985, Levy and Brugge, 1989, Keenan et al., 2015). This is thought to be a consequence 
of the placement of the N-Src inserts in the n-Src loop of their SH3 domains. The 
importance of the n-Src loop in the autoregulation of V-Src kinase activity, was 
demonstrated, when mutation of the n-Src loop resulted in increased kinase activity 
(Brábek et al., 2002). Since both N1- and N2-Src demonstrated a reduced affinity for an 
SH3:kinase linker peptide in vitro, it is proposed that the observed increased kinase 
activity may be caused by disrupted intramolecular interactions between the SH3 domain 
and kinase linker, which are crucial for the autoinhibitory regulation of the kinases 
(Keenan et al., 2015). This idea is supported by a further study, in which N1-Src activity 
remained high, despite the kinase being predominately phosphorylated at Tyr-527; the 
residue on the C-terminal tail that promotes autoinhibition (Levy and Brugge, 1989).   
The mRNA of N1-Src incorporates an 18 nucleotide mini-exon insert that arises due to 
a splicing event that occurs between exons 3 and 4 of the C-Src gene (Martinez et al., 
1987). The N2-Src mRNA sequence contains a 51 nucleotide insert, which is the product 
of two splicing events. In N2-Src mRNA, both the N1 and N2 mini-exon inserts are 
included and the N1 mini-exon acts as a splice acceptor for the N2 mini-exon. This results 
in a change in the final amino acid of the N1-Src insert from an Arg residue to a Ser  
residue (Pyper and Bolen, 1990). These splicing events are regulated by positive and 
negative regulatory elements in a tissue specific manner. In non-neuronal tissues, the 
splicing events described above are skipped (Levy et al., 1987, Martinez et al., 1987). 
This is thought to be regulated by the polypyrimidine tract binding protein (PTB), which 
binds to negative regulatory elements that lie upstream of the N1 exon and represses 
the N1 splicing event (Chan and Black, 1997). Since the N1 exon splicing event is 
required for the inclusion of the N2 exon, this would prevent the expression of both N1- 
and N2-Src in non-neuronal tissues. In neuronal cells, N1 exon splicing is dependent 
upon the presence of a conserved enhancer sequence downstream of the N1 exon and 
repression of N1 splicing by PTB is lifted however, the mechanisms involved require 
further investigation (Black, 1991, Modafferi and Black, 1997, Chou et al., 2000).  
The discovery that N1-Src is evolutionarily conserved in mammals, birds, reptiles and 
fish lead to the belief that N1-Src expression is required for neural processes 
characteristic of ‘higher’ organisms (Raulf et al., 1989, Yang et al., 1989). Since C-Src 
expression has been detected in the most basic of organisms such as the sponge, the 
evolution of the N1- and N2-Src genes suggests their involvement in more complex brain 
specific functions (Ottilie et al., 1992). The presence of a similar neuronal splice variant 
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of C-Src was also identified in frogs. Xenopus laevis produces a neuronal C-Src variant 
that contains a five amino acid insert instead of six. At both ends of the frog insert lie Arg 
residues that are conserved amongst other animals, whilst the remaining residues are 
divergent (Collett and Steele, 1992). This suggests that these conserved charged 
residues may be key to role of N1-Src. However, Collet and Steele (1992) did not find an 
N2-Src homologue present in frogs, indicating that their divergence from other 
vertebrates must have occurred before the evolution of the N2 mini-exon.  
1.5.1 The Spatiotemporal Expression of N1-Src 
Wiestler and Walter (1988) first described the pattern of expression of N1-Src in the 
developing mouse brain. They observed that N1-Src expression first became visible at 
embryonic day 10 (E10) and subsequently monitored the expression level of the kinase 
in the mouse forebrain, midbrain and cerebellum between E9 to postnatal day 28 (P28). 
In both the forebrain and midbrain, the level of N1-Src expression was considerably 
higher than C-Src. N1-Src expression peaked at E18 and declined thereafter, but 
remained at a higher level than C-Src in the forebrain, whereas in the cerebellum, C- and 
N1-Src expression was comparable between E14 to P28. Given that in the period 
between E14-18 an increasing number of cells become post-mitotic and differentiated, it 
is thought that N1-Src could play a role in these processes (Wiestler and Walter, 1988). 
In support of these data, Ross and colleagues demonstrated that N1-Src mRNA was 
prevalent in the rat central nervous system (CNS) between E15-19, signifying a 
prominent role for N1-Src in the developing brain (Ross et al., 1988).  
Studies indicate that N1-Src also plays an important role in the adult brain. The immuno-
staining of adult rat brain slices revealed that N1-Src is widely expressed in the mature 
brain, but is particularly enriched in the midbrain, hippocampus, cerebellum, pons, 
medulla and the cerebral cortex (Sugrue et al., 1990). A second study, which investigated 
the localisation of N1-Src mRNA by in situ hybridisation, supported these findings (Ross 
et al., 1988). N1-Src mRNA was most noticeably present in the forebrain, in the 
pyramidal layers and dentate gyrus of the hippocampus, the granule layer of the 
cerebellum and the olfactory bulb region of the brain. Interestingly, Le Beau and 
colleagues (1987) also measured heightened N1-Src activity in the majority of these 
structures in comparison to other brain regions. Since enhanced Src kinase activity can 
be linked with neuronal plasticity, it is thought that N1-Src could be a key component in 
driving this process. Notably, whilst both C- and N1-Src appeared to display high levels 
of mRNA in the cerebellum, N1-Src mRNA levels were markedly higher in the 
hippocampus, cerebral cortex as well as other regions of the forebrain (Ross et al., 
1988). Taking these data into account, and the fact that differential levels of C- and N1-
Src expression levels have been observed in the developing brain, this highlights the 
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spatial and temporal differences that exist in C- and N1-Src expression in both the 
mature and adult brain. Therefore, these data support the theory that both kinases will 
have different functions.   
In the foetal rat brain N1-Src is enriched in growth cone membrane extracts, suggesting 
a potential role for N1-Src in axonal extension and guidance (Maness et al., 1988). 
Whereas, in the adult brain, Sugrue and colleagues (1990) reported that N1-Src 
expression was present in all neuronal compartments i.e. the cell soma, axon, dendrites 
and nerve terminals, suggesting widespread roles for N1-Src within cells. Despite only 
containing a single lipid modification, N1-Src has also been placed at lipid rafts, which 
are signalling hubs rich in multiple types of cell surface receptors and cellular signalling 
components (Mukherjee et al., 2003). Moreover, the N1-Src detected in the lipid raft 
fractions of mouse brain lysates displayed increased kinase activity, suggesting that N1-
Src may play a role in signalling events directed from lipid rafts (Mukherjee et al., 2003). 
Interestingly, lipid rafts have been implicated in multiple neuronal functions including cell 
adhesion, axonal guidance and synaptic transmission, which are all processes that N1-
Src is predicted to partake in when considering the spatiotemporal expression of the 
kinase (Tsui-Pierchala et al., 2002).  
1.5.2 Physiological Functions of the Neuronal Srcs 
There are very few studies in the literature that have addressed the functional relevance 
of the two neuronal splice variants of Src. Whilst no specific neuronal roles have been 
assigned to N2-Src, only a couple of studies have investigated the effects of N1-Src 
overexpression in different subsets of neurons. Kotani and colleagues (2007) explored 
the role of N1-Src during the morphogenesis of Purkinje neurons, a class of GABAergic 
neuron present in the Purkinje layer of the cerebellum, which are characterised by their 
large dendritic arbours. In transgenic mice overexpressing N1-Src (WT) and 
constitutively active N1-Src (Y527F), the organisation of the Purkinje cell layer in their 
cerebellum was disrupted. This effect was more profound in the Y527F mice. In addition 
to this, a large proportion of Y527F cells at postnatal day 7 (P7) had polarization defects, 
since the multiple dendritic shafts characteristic of earlier stages in development, failed 
to converge into a single shaft. Investigations into the molecular basis for these 
observations revealed that these morphological defects were linked to the aberrant 
arrangement of microtubules present in the dendritic shafts of the unpolarised neurons 
(Kotani et al., 2007). This study directly linked the effects of N1-Src to altered cytoskeletal 
dynamics, which are integral to the processes governing neuronal morphogenesis.  
A second study, from Worley and colleagues (1997), compared the effects of both C- 
and N1-Src in multiple cell types from the developing Xenopus laevis retina. Whilst 
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axonal outgrowth was markedly reduced in retinal ganglion cells overexpressing the 
constitutively active mutants of both C- and N1-Src, their effects were different in ventral 
forebrain neurons. Conversely, the over expression of both WT and Y527F N1-Src in 
ventral forebrain neurons resulted in an increase in neurite outgrowth, whereas Y527F 
C-Src had the opposite effect. The effects of both C- and N1-Src Y527F on photoreceptor 
differentiation were also monitored, which was severely reduced in the presence of both 
kinases (Worley et al., 1997). These results, in conjunction with those observed by Kotani 
and colleagues, suggest a role for N1-Src during neuronal morphogenesis, which varied 
between different neuronal types. In addition to this, whilst C- and N1-Src overexpression 
appears to have similar effects on neuronal development in some cell types, they also 
appear to differ in others. This indicates that both C- and N1-Src could have different 
functions in some subclasses of neurons in the brain. 
Worley and colleagues (1997) also demonstrated that Xenopus epithelial cells 
overexpressing N1-Src projected neurite-like processes, whereas C-Src transfected 
cells were predominantly adopted a rounded and more spread morphology. Whilst these 
findings demonstrated the different roles for both kinases in a non-neuronal cell type, 
they also re-enforced the observation made by Kotani which suggested that N1-Src 
modulates cytoskeletal dynamics to direct changes in cell morphology.  
1.5.3 Neuronal Src Kinases in Neuroblastoma 
Whilst no neuronal functions or bona fide substrates of N2-Src have been reported, the 
kinase has been shown to be associated with the positive prognosis of neuroblastoma 
cancer patients at stage IV-S of the disease (Bjelfman et al., 1990, Matsunaga et al., 
1998). The childhood cancer, neuroblastoma, is derived from immature neuroblasts in 
the sympathetic nervous system that fail to differentiate and undergo uncontrolled 
proliferation. Like many others, the cancer is defined by a series of tumorigenic stages, 
which in this case range from stages I-IV, but can also manifest as stage IV-S (Evans et 
al., 1971). However, unlike the majority of other cancer types, neuroblastoma cells 
possess the ability to differentiate and mature. The degree of cellular differentiation that 
occurs within tumours, which is a determinant of the prognosis outcome, appears to be 
dependent on the age of the child and the stage of the cancer. For example, tumour cells 
in younger patients (under 12 months) tend to be more likely to terminally differentiate, 
making the cancer less aggressive. For the same reason, tumours at stage IV-S, can 
spontaneously regress and are therefore associated with a positive prognosis (Rudolph 
et al., 1997).  
Bjelfman and colleagues (1990) observed that neuronal Src was elevated in 
neuroblastoma cases, which had a positive prognosis. Further investigations revealed 
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that whilst N1-Src expression was upregulated in differentiating neuroblastoma cells, its 
sole expression in the absence of N2-Src was not a sufficient marker for positive 
prognosis. However, cells that had undergone or were undergoing terminal 
differentiation expressed high levels of N2-Src, similar to those observed in human brain 
tissue, which correlated with the spontaneous regression of the cancer (Matsunaga et 
al., 1998). Therefore, N2-Src was identified as a promising prognostic marker for 
neuroblastoma patients, as well as a potential therapeutic target in the treatment of the 
disease. Since there is little published data describing the functional role of N2-Src, it 
remains unclear whether N2-Src plays a causative role in the differentiation of 
neuroblastoma cells. Although it is tempting to speculate that the kinase may prove to 
be an important therapeutic target, since the closely related N1-Src has been implicated 
in the processes of neuronal differentiation by regulating cytoskeletal dynamics (see 
sections 1.5.1 and 1.5.2) (Kotani et al., 2007, Maness et al., 1988, Wiestler and Walter, 
1988, Worley et al., 1997). 
1.5.4 Substrates and Binding Partners of N1-Src 
The N1- and N2-Src mini-exon inserts occur in the SH3 domain of the kinases, which 
are important for substrate binding. The precise site of insertion lies in the n-Src loop, 
which forms an integral part of the ‘specificity’ pocket that typically interacts with the 
positively charged residue flanking the PXXP core of the substrate binding motif. The n-
Src loop, which in addition to the RT loop is the site of most variation in the SH3 domains 
of SFKs, has also been implicated in forming alternative interactions with binding 
partners. Therefore, it is sensible to predict that the SH3 domains of both N1- and N2-
Src would bind a different subset of substrates in comparison C-Src. In support of this 
prediction, a recent study published by the Evans lab demonstrated that both N1-Src and 
N2-Src displayed a reduced affinity for traditional class I and II C-Src SH3 binding ligands 
(discussed further in Section 3.1, (Keenan et al., 2015)). 
Whilst no N2-Src SH3 binding partners have been identified, there are a number of 
studies in the literature that have performed C- and N1-Src SH3 pull-down studies with 
candidate binding partners. The outcome of these studies, amongst others, are 
summarised in Table 1.1. The ability of both the C- and N1-Src SH3 domains to bind to 
the proteins of interest, was determined by blotting for the kinase SH3 domains in the 
pulldown assays and comparing the relative intensities of their protein bands. Several 
proteins, including ASAP1, RICH1, dynamin, SNP70 and the well-known C-Src substrate 
FAK (discussed in Section 1.3) bound to the C-Src SH3 domain but did not appear to 
interact with N1-Src. In addition to this, the N1-Src SH3 domain seemed to have a 
reduced affinity for 3BP-1, CR16, Daam1 and Sam68 in comparison to the C-Src SH3 
domain. These findings further support the theory that as a result of the N1-Src SH3 
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mini-exon insertion, the kinase has a reduced or complete lack of affinity for C-Src 
substrates.   
It is particularly interesting that the N1-Src SH3 does not appear to interact with FAK, 
since the C-Src/FAK complex is integral to many cellular signalling transduction 
pathways that regulate proliferation, motility, survival and neurite outgrowth in neurons. 
However, a study, performed by Ruest and colleagues (2001), demonstrated the N1-Src 
precipitated with FAK when both kinases were co-expressed in COS7 cells. Furthermore, 
the study suggested that N1-Src recruitment by FAK facilitated the phosphorylation of 
p130CAS. In addition to this, they demonstrated that in their model, N1-Src mediated 
phosphorylation of CAS was greater than C-Src (Ruest et al., 2001). Therefore, these 
observations suggest that the interaction of N1-Src with FAK via an alternative 
mechanism could be sufficient to recruit the kinase. Indeed, it has been documented that 
the autophosphorylation of FAK at Y397 creates a C-Src SH2 binding motif (Schaller et 
al., 1994). In this instance, it could be possible that N1-Src substrate specificity governed 
by the SH2 domain overrides that of the SH3 domain. Alternatively, N1-Src could be 
interacting indirectly with FAK via a different binding partner.   
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Table 1.1: A Summary of C- and N1-Src SH3 Binding Partners and their Relative 
Ability to Bind to each Kinase. 
 
N.D=not determined 
 
 
 
Protein Protein type 
Binds to: 
Comparison 
of C- and N1-
Src interaction 
Reference 
C-Src 
SH3 
(Y/N) 
N1-Src 
SH3 
(Y/N) 
ASAP1 Arf1 GAP Y N - 
(Brown et al., 
1998) 
3BP-1 Rac GAP  Y Y C>N1 
(Cicchetti et 
al., 1992) 
CR16 MAPK substrate Y Y C>N1 
(Weiler et al., 
1996) 
Daam1 Formin Y Y C>N1 
(Aspenstrom 
et al., 2006) 
Delphilin Formin - Y N.D 
(Miyagi et al., 
2002) 
Dynamin 
GTPase localised 
at the pre-
synaptic 
membrane 
Y N - 
(Foster-Barber 
and Bishop, 
1998) 
EVL 
Actin-associated 
protein 
Y Y N1>C 
(Lambrechts 
et al., 2000) 
FAK Kinase Y N - 
(Messina et 
al., 2003) 
HCN1 Ion channel - Y N.D 
(Santoro et al., 
1997) 
NR2A Ion channel - Y N.D 
(Groveman et 
al., 2011) 
Rich1 
Rho/Rac/cdc42 
GAP 
Y N - 
(Richnau and 
Aspenstrom, 
2001) 
Sam68 Adaptor protein Y Y C>N1 
(Finan et al., 
1996) 
SNP70 
Nuclear protein, 
co-localises with 
splicing factors 
Y N - 
(Craggs et al., 
2001) 
Synapsin 
Protein localised 
at synaptic 
vesicles 
Y N 
- 
 
(Foster-Barber 
and Bishop, 
1998) 
Tau 
Microtubule 
associated protein 
Y N - 
(Reynolds et 
al., 2008) 
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One protein in particular, Ena/Vasp like protein (EVL), was demonstrated to show 
preferable binding to the N1-Src SH3 in comparison to C-Src in vitro (Lambrechts et al., 
2000). EVL is a member of the Ena/Vasp family of proteins, which are known to play a 
role in axon guidance by regulating actin cytoskeletal dynamics, however the functional 
implications of the N1-Src SH3 domain binding to EVL require further investigation. In 
addition, the relatively poorly understood formin, Delphilin, has also been identified as a 
binding partner of the N1-Src SH3 domain in vitro (Miyagi et al., 2002). Delphilin acts as 
a scaffolding protein expressed in the neuronal post-synaptic density that binds the 
glutamate receptor GluRδ2, which plays a role in motor coordination, synapse formation 
and synaptic plasticity (Kashiwabuchi et al., 1995). Whilst the exact roles of Delphilin 
have not been defined, it is possible that it also serves to regulate cytoskeletal dynamics, 
which appears to be the main role of other members of the formin family (Wallar and 
Alberts, 2003). To date, the physiological relevance of the interaction between N1-Src 
and Delphilin has not been reported in the literature. 
N1-Src has also been shown to interact with the C-terminal domain (CTD) of the 
hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) in rat brain lysates 
(Santoro et al., 1997). HCN1 belongs to a family of four HCN channels (HCN1-4) that 
are expressed throughout the peripheral and central nervous systems, as well as in 
cardiac tissue. They are homotetrameric voltage gated pore loop channels known as 
‘pacemakers’, since they are responsible for the rhythmic excitation of neurons and 
cardiac pacemaker cells. The structure of each subunit has two main portions; the 
transmembrane core and the CTD. A hyperpolarization activated current (Ih) passes 
through the channels in response to membrane hyperpolarization and cAMP binding 
(Wahl-Schott and Biel, 2009). HCN1 channels have been implicated in multiple, diverse 
functions including learning and memory (Nolan et al., 2004, Nolan et al., 2003), balance 
controlled by the inner ear (Horwitz et al., 2011), resting potentials in neurons and the 
regulation of presynaptic neurotransmitter release (Southan et al., 2000). HCN1 is also 
thought to be involved in various disease pathologies including epilepsy (Santoro et al., 
2010) and Alzheimer’s disease (Saito et al., 2012).   
Little is known about the interaction and effects of neuronal Src on the HCN1 channel. 
Santoro et al. (1997) first discovered HCN1 by identifying the channel as a binding 
partner of the N1-Src SH3 domain, which was used as bait in a yeast two-hybrid 
experiment. Subsequently, there have been no reports of N1-Src regulation of HCN1, 
although there is literature describing a role for C-Src in the regulation of the HCN family 
of channels. Whole cell patch clamp experiments performed on HEK-293 cells 
transfected with HCN2 or HCN4 exhibited decelerated activation kinetics and in HCN4 
transfected cells, decreased whole cell conductance when treated with the C-Src 
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inhibitor, 4-5-amino-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3-4-d]pyrimidine (PP2) (Li et al., 
2008a, Zong et al., 2005). The same effects were shown in dominant negative Src 
mutants (Arinsburg et al., 2006, Zong et al., 2005), suggesting C-Src is involved in HCN 
channel regulation.  
Site-directed mutagenesis (SDM) experiments revealed that conserved Tyr-531 and Tyr-
554 phosphorylation sites (confirmed by mass spectrometry) in the CTD of HCN4 alter 
channel activation (Li et al., 2008a) and channel activation kinetics (Li et al., 2008a, 
Aktories et al., 2004) respectively. Li and colleagues (2008a) reported that Y531F 
mutants almost abolished the effects of PP2 on voltage dependent channel activation, 
whereas Tyr-554 mutants had unaltered activation kinetics in the presence of PP2. Zong 
and colleagues (2005) gained the same results in relation to Tyr-554 for both HCN2 and 
HCN4. This group however did not show that C-Src had an effect on voltage dependent 
activation of HCN channels or a role for Tyr-531. Despite these conflicting discoveries, it 
is apparent that Tyr phosphorylation by C-Src plays a role in HCN channel activation. 
In addition to N1-Src binding to the HCN1 channel, Groveman and colleagues confirmed 
that the CTD of the NR2A subunit in NMDA receptors (described in Section 1.3.1.2) can 
be phosphorylated by and bind N1-Src in vitro. They also demonstrated that NR1/NR2A 
receptor currents are enhanced in HEK-293 cells when co-expressed with N1-Src, 
indicating that similar to C-Src, N1-Src is capable of activating NMDAR currents 
(Groveman et al., 2011). However, this study did not investigate the differences, if any, 
between their phosphorylation of, or binding affinities to, the NR2A-CTD, nor did it report 
the effects of C- vs N1-Src on NMDAR currents. Furthermore, whether the kinases 
activate the channels via the same or different mechanisms in vivo remains to be 
discovered.   
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1.6 Aims 
Whilst little is known about the precise functions and substrates of N1-Src, the literature 
suggests that N1-Src is important in the developing brain, potentially regulating 
cytoskeletal dynamics during neuronal morphogenesis (Kotani et al., 2007, Worley et al., 
1997). In addition to this, N1-Src localization data and the interactions observed between 
N1-Src and several ion channels (Santoro et al., 1997, Groveman et al., 2011) indicate 
that the kinase may also play an important role in the adult brain. The primary aim of this 
project was to therefore clarify the roles of N1-Src in neuronal signalling through three 
specific approaches:  
1) Identify novel N1-Src substrates: 
Firstly, experiments were focussed on discovering novel N1-Src substrates. To identify 
whether HCN1 was an N1-Src substrate, in vitro kinase assays were performed using 
purified recombinant protein. In addition, the ability of N1-Src SH3 binding peptides, 
selected from putative N1-Src substrates, to enhance phosphorylation of an ideal Src 
substrate sequence, was investigated. 
2) Determine the function of N1-Src in developing neurons: 
With the aim of further understanding the role of N1-Src in neuronal development, the 
morphology of primary rat hippocampal neurons in N1-Src overexpression and shRNA 
knockdown studies were examined. 
3) Dissect the signalling pathways downstream of N1-Src: 
The signalling mechanisms through which N1-Src acts were also investigated, focussing 
specifically on L1-CAM and RhoA signalling pathways using a fibroblast cell model.  
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Molecular Biology Reagents 
Oligonucleotides were purchased from Integrated DNA technologies (Leuven, Belgium). 
Pfu DNA polymerase was purchased from Thermo Scientific (Waltham, MA) and Taq 
DNA polymerase was a kind gift from Dr Dani Ungar (University of York). DNA ligase 
and ligase buffer were obtained from Promega (Fitchburg, WI). All restriction enzymes 
were purchased from New England Biolabs (NEB, Ipswich, MA). Both NucleoSpin® 
Plasmid mini- and midi-prep kits were sourced from Machery-Nagel (Düren, Germany) 
and gel extraction kits were purchased from Quiagen (Venlo, Netherlands). DNA 
HyperLadder I and SYBR®Safe were obtained from BioLine (London, UK) and Life 
Technologies (Paisley, UK), respectively. XL10 Gold supercompetent E coli were from 
Stratagene (Stockport, UK). XL10 Gold ultra-competent cells were purchased from 
Agilent Technologies (Stockport, UK). BL21-DE3 cells were a kind gift from Dr Daniel 
Ungar, and both the Rosetta 2 and Rosetta GamiB cell strains were a kind gift from Dr 
Wayne Paes.  
The pLINK, pLINK-C3, pmCherry-N1, pRK7-NR2A vectors were a kind gift from Dr 
Sangeeta Chawla (University of York) (Grant et al., 1998). The pGEX-6P-1 plasmids 
encoding YA, PD1 were made in house by Dr Sarah Keenan and the P1-13 GST-fusion 
peptides by Dr Gareth Evans (University of York). The pSUPER N-Src shRNA constructs 
A and B were designed in the Evans lab and prepared by Katharina Mahal. The pcDNA3-
eGFP-RhoA constructs were gifts from Gary Bokoch (plasmid numbers #12965 (WT 
RhoA), #12968 (Q63L) and #12967 (T19N) (Subauste et al., 2000). L1-4A (pCDNA3-L1-
CAM) was a gift from Vance Lemmon (plasmid number #13268) (Cheng et al., 2005).  
2.1.2 Protein Biochemistry Reagents 
Protein ladders were purchased from BioRad, Hercules (CA). The PVDF and Immobilon 
Western enhanced chemiluminescence (ECL) solution were both obtained from Millipore 
(Watford, UK). Glutathione agarose beads were purchased from GenScript (Piscataway, 
NJ) and 3C protease was sourced from the Technology Facility in the Department of 
Biology, University of York. The RhoA pull down activation assay kit was purchased from 
Cytoskeleton Inc. (Denver, CO) and the GFP conjugated protein G beads used were a 
kind gift from Dr Paul Pryor (University of York). The recombinant PKC-zeta and MBP 
proteins were sourced from Millipore (Watford, UK) and Sigma (Dorset, UK) respectively.  
The following antibodies were purchased from: Actin B from Abcam (Cambridge), FLAG 
(M2) from Sigma (Dorset, UK), PY20 from BD Bioscience (San Diego, CA) and pY416 
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and GFP(a) were from Cell Signalling Technologies (Boston, MA). In addition, both α-
mouse and α-rabbit horseradish peroxidase (HRP) antibodies were purchased from 
Sigma (Dorset, UK). 
2.1.3 Cell Biology Reagents 
Dulbecco’s Modified Eagle Medium (DMEM) and Alexa Fluor® conjugated secondary 
antibodies were obtained from GIBCO, Invitrogen (Paisley, UK). EcoTransfect and 
Lipofectamine® transfection reagents were purchased from OZ Biosciences (Marseille, 
France) and Invitrogen (Paisley, UK). The GFP(b) antibody that was used solely for 
immunofluorescence experiments was a kind gift from Dr Paul Pryor (University of York).     
Unless otherwise stated all other chemicals and reagents were purchased from Sigma 
(Dorset, UK). 
2.2 Molecular Biology  
2.2.1 Polymerase Chain Reaction (PCR) 
The rat NR2A-CTD (C-terminal domain) was PCR amplified from the pRK7:NR2A 
construct. The PCR reaction contained 100 ng of pRK7:NR2A, 1X polymerase buffer, 
0.2 mM dNTPs, 1 µM of the forward (5' CGGAATTCAAGGACTGTAGCGATGTTGAC 3') and 
reverse (5' AGTATCGAATCTGATGTTTAACTCGAGGCG 3') primers, 0.5 U of Pfu DNA 
polymerase and distilled water (dH20) to 50 µl. To amplify the rat NR2A-CTD, the PCR 
reaction was subjected to the following conditions: an initial denaturation step of 95 ˚C 
for 5 min, 25 repeated cycles of 95 ˚C for 30 seconds (s) (denaturation), 53 ˚C for 45 s 
(primer annealing) and 72 ˚C for 1 minute (min) (extension), as well as a final extension 
step at 72 ˚C for 10 min.    
2.2.2 Agarose Gel Electrophoresis  
Agarose gels were used to visualise and quantify DNA bands. To prepare an agarose 
gel (0.7-2 %), agarose was dissolved in 60 ml of 1X TAE buffer (40 mM Tris, 20 mM 
acetic acid, and 1 mM EDTA) using a microwave oven. The molten agarose was briefly 
cooled and SYBR®Safe DNA stain was added at a 1 in 20,000 dilution (v/v). The solution 
was poured into a gel cassette and a suitable well comb was secured into the cassette 
to form wells. After setting at room temperature, the gel was immersed in 1X TAE and 
DNA samples were diluted with 5X Orange G loading buffer (0.5 % (w/v) Orange G and 
25 % glycerol (v/v) in dH2O) and loaded into the gel. The DNA was separated by 
electrophoresis by applying a potential difference of ~ 80 V across the gel for ~ 30 min. 
DNA within the gel was visualised under a blue safelight.  
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2.2.3 Restriction Digest of Deoxyribonucleic Acid (DNA) 
Restriction digests were performed using restriction endonucleases (NEB or Promega) 
and were carried out according to the manufacturers’ instructions. Typically, a double 
restriction digest reaction (30 µl) contained 100-500 ng of plasmid DNA, an appropriate 
reaction buffer (1X), 0.1 mg ml-1 of BSA, 1 µl of each restriction enzyme and dH20. The 
reactions were incubated for 1 hour (h) at 37 ˚C.  
For subcloning, a preparative digest reaction (60 µl) was performed, in which 2-6 µg DNA 
was digested by 2 µl of each restriction enzyme for 1 hour (h) at 37 ˚C. In this case, the 
whole reaction was loaded and separated by agarose gel electrophoresis. The relevant 
bands were excised and gel extracted (Section 2.2.4).   
2.2.4 Agarose Gel Extraction of DNA Fragments 
DNA bands were excised from an agarose gel under safelight, using a scalpel and DNA 
was extracted using a gel extraction kit, following the manufacturer’s instructions. A 
sample of the extracted product was separated by agarose gel electrophoresis (Section 
2.2.2), visualised and then quantified by comparing the band size to those of a known 
quantity from 5 µl of HyperLadder I.  
2.2.5 Annealing of Complimentary Oligonucleotides 
Complimentary oligonucleotides (oligos) were annealed in a 10 µl reaction containing 
3.3 µM of each oligonucleotide and 4 µl of annealing buffer (100 mM NaCl and 50 mM 
HEPES, pH 7.4). The mixture was incubated in a PCR machine at 90 °C for 4 min 
followed by a 70 °C incubation for 10 minutes. The annealed oligos were slowly cooled 
to 10 °C (e.g. step-cool to 37 °C for 15-20 min, then to 10 °C or room temperature) before 
using or moving them to refrigerated storage. 
2.2.6 Ligation of PCR Product into pJET1.2 
A CloneJET PCR cloning kit (Thermo Fisher Scientific, Loughborough, UK) was used to 
ligate 50-100 ng of gel-extracted, blunt-ended PCR products into the propagation vector 
pJET1.2 according to the manufacturer’s instructions.       
2.2.7 DNA Ligation 
To ligate restriction digested, gel-purified DNA, the insert was incubated with a gel-
purified linearised plasmid in a 10 µl reaction containing a 3:1 molar ratio of insert to 
vector (typically 100 ng of vector), 3 Units (U) of T4 DNA ligase, 1X ligation buffer and 
dH2O. The reaction was incubated at room temperature for 3 h or overnight at 4 ˚C.    
2.2.8 Bacterial Transformation 
Plasmid DNA (~100 ng) was incubated with 50 µl of XL10 Gold competent E.coli cells at 
4 ˚C for 15-30 minutes. To facilitate the uptake of plasmid DNA, the bacteria were heat 
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shocked for 45 s at 42 ˚C, and subsequently placed on ice for a further 2 min. Sterile 
Lysogeny Broth (LB, 450 µl of 1 % NaCl, 1 % Tryptone and 0.5 % yeast extract (w/v) in 
dH2O) was added to the bacteria, which were incubated at 37 ˚C with agitation. After 1 
h, the bacteria were spread onto LB agar (1 % NaCl, 1 % Tryptone, 0.5 % yeast extract 
and 2 % agar (w/v) in dH2O) plates containing the appropriate antibiotic(s) (ampicillin 100 
µg/ml, kanamycin 50 µg/ml, chloramphenicol 34 µg ml-1 or tetracycline 15 µg ml-1). The 
plates were incubated overnight at 37 ˚C and subsequently stored at 4 ˚C. Aseptic 
technique was employed throughout the transformation process. 
2.2.9 PCR Colony Screening 
PCR was used to screen individual E. coli colonies for the successful inclusion of a DNA 
insert into a plasmid vector backbone. A PCR reaction (20 µl) contained 1X GoTaq buffer 
(Promega), 1 µM dNTPs, 2 µM of the forward and reverse primers, 0.1 µl of Taq 
polymerase and dH2O. Finally, a scrape of each colony to be tested was mixed into 
separate PCR reactions using a sterile pipette tip. The PCR reaction conditions were as 
described in Section 2.2.1 however, the primer annealing temperature was changed to 
55 ˚ C and the extension time was extended to 1 min per kb of product during the repeated 
cycles. The PCR products were separated by agarose gel electrophoresis (Section 2.2.2) 
and successful clones were mini-prepped (Section 2.2.10). 
2.2.10 Preparation of Plasmid DNA from Bacterial Cultures 
Starter cultures containing 5 ml or 100 ml of selective LB medium were inoculated with 
a single colony (or a scrape from a glycerol stock) of E. coli transformed with the desired 
plasmid. The cultures were incubated overnight at 37 ˚C with agitation and then 
centrifuged at 4 ˚C, for 10 min, at 4500 g. Plasmid DNA was isolated from the bacteria 
using a Machery and Nagel NucleoSpin® Plasmid mini-prep kit (5 ml cultures) or a 
NucleoSpin® Midi-prep kit (100 ml cultures) according to the manufacturer’s instructions. 
The quantity and quality of isolated DNA were analysed using a NanoDrop 
spectrophotometer (Thermo Scientific) in the University of York Technology Facility.   
2.2.11 Sequencing of Plasmid Constructs 
The sequences of all DNA plasmid constructs produced were confirmed by the 
sequencing service in the Genomics Unit of the Technology Facility, University of York. 
Pre-mixes contained 100-200 ng of plasmid DNA and 3.2 µM of a vector-specific forward 
or reverse primer. The sequencing data were subsequently analysed using the Applied 
Biosystems Sequence Scanner software v1.0. ClustalW2 software was used to generate 
sequence alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
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2.2.12 Preparation of Glycerol Stocks for Storage of Plasmid DNA 
For long-term storage, 1 ml of a bacterial culture containing XL10 Gold E. coli, 
transformed with plasmid DNA, was mixed with 1 ml of sterile 50 % (v/v) glycerol solution 
(in dH2O) and stored at -80 ˚C in a cryovial.   
2.2.13 Cloning  
2.2.13.1 Src-pmCherry Constructs 
Preparative digests (Section 2.2.3) were performed to excise the full length open reading 
frame (ORF) of C-, N1- and N2-Src from the relevant pFLAG-Src-plamids and to linearise 
pmCherry-N1. The enzymes used were XhoI (5’) and BamHI (3’) with NEB buffer 3. The 
products were separated by agarose gel electrophoresis (Section 2.2.2) and gel 
extracted (Section 2.2.4). C-, N1- and N2-Src were ligated (Section 2.2.7) into linearised 
pmCherry-N1, transformed into XL10 Gold bacteria (Section 2.2.8) and the subsequent 
colonies were screened by colony PCR (Section 2.2.9). Successful colonies were 
mini-prepped and sequenced (Sections 2.2.10-11).     
2.2.13.2 pGEX-6P-1: hHCN1-CTD 
hHCN1-CTD was PCR amplified and cloned into the propagation vector pJET1.2 by 
Dr Sarah Keenan. Using the restriction enzymes SalI (5’) and NotI (3’) with buffer 3, 
preparative digests were performed to excise hHCN1-CTD from pJET1.2 and to linearise 
the plasmid pGEX-6P-1. Following the procedure outlined in Section 2.2.13.1 hHCN1-
CTD was sub-cloned into pGEX-6P-1 producing the construct pGEX-6P-1:hHCN1-CTD.  
2.2.13.3 pGEX-6P-1: rNR2A-CTD 
The rNR2A-CTD was PCR amplified from the vector pRK7:NR2A, which contained the 
ORF of the NR2A subunit of the NMDA receptor (NMDAR) (Section 2.2.1). The PCR 
product was gel extracted (Section 2.2.4), ligated into pJET1.2 (Section 2.2.6) and a 
preparative digest (Section 2.2.3) was performed using the enzymes XhoI (5’) and EcoRI 
(3’) with buffer 3 to excise the rNR2A-CTD insert from the plasmid. The rNR2A-CTD was 
then sub-cloned into linearised pGEX-6P-1 according to the procedure described in 
Section 2.2.13.1. 
2.2.13.4 pGEX-4T-1: CTD Constructs  
pGEX-6P-1:hHCN1-CTD and pGEX-6P-1:rNR2A-CTD were cut with SalI (5’) and NotI 
(3’) or XhoI (5’) and EcoRI (3’) respectively and the CTDs were individually sub-cloned 
into linearised pGEX-4T-1 following the procedures described in Section 2.2.13.1. 
2.2.13.5 pGEX-6P-1 Constructs Encoding GST-fusion Peptides. 
The plasmid pGEX-6P-1-‘Y’ containing the ideal Src substrate (Y) was generated by 
ligating the appropriate annealed oligos (See Table 2.1) into linearised pGEX-6P-1, 
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which was pre-cut using the enzymes BamHI (5’) and EcoRI (3’). Subsequently, the 
remaining annealed oligos corresponding to YA, PD1, PD1-P5A or P1-13 (See Table 
2.1) were ligated into the linearised pGEX-6P1-‘Y’ plasmid, which was pre-cut with the 
restriction enzymes SalI (5’) and NotI (3’). This yielded plasmid constructs that contained 
the Y sequence, followed by the sequence of one of the remaining SH3 domain binding 
motifs. Both oligo sequences were separated by a short linker sequence that was 15 bp 
in length and corresponded to the sequence of the multiple cloning site of the plasmid 
between the 5’ EcoRI and 3’ SalI restriction sites. The constructs containing YA and PD1 
were cloned by Dr Sarah Keenan (Keenan, 2012), whereas those containing peptides 
P1-13 were cloned by Dr Gareth Evans.  
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Table 2.1: The Oligonucleotide Sequences Used to Generate GST-fusion Peptide 
Substrates for C- and N1-Src 
Name Oligonucleotide Sequence 
Y 
 
FWD AATTCGGTGGCGGTGCAGAAGAGGAAATTTACGGTGAATTTGG  
REV TCGAACAAATTCACCGTAAATTTCCTCTTCTGCACCGCCACCG  
YA 
FWD TCGACTCGGTGGCGGTGTGAGCCTGGCGCGTCGTGCGCTGGCAGCTCTGGCGTAAGC  
REV GGCCGCTTACGCCAGAGCTGCCAGCGCACGACGCGCCAGGCTCACACCGCCACCGAG  
PD1 
 
FWD TCGACTCGGTGGCGGTGCGTGGCATCGCATGCCGGCGTATACCGCGAAATATCCGGC  
REV GGCCGCCGGATATTTCGCGGTATACGCCGGCATGCGATGCCAGCCACCGCCACCGAG  
PD1-
P5A 
FWD TCGACTCGGTGGCGGTGGCTGGCATCGCATGGCAGCGTATACCGCGAAATATCCGGC  
REV GGCCGCCGGATATTTCGCGGTATACGCTGCCATGCGATGCCAGCCACCGCCACCGAG  
P1 
 
FWD TCGACTCGAAACAAGACCACCTGCAAATACTGCTAGGTTACAATAAGG 
REV GGCCCCTTATTGTAACCTAGCAGTATTTGCAGGTGGTCTTGTTTCGAG 
P2 
 
FWD TCGACTCAAGGAAAAAGGACCAATATTAACACAAAGAGAAGCATAAGG 
REV GGCCCCTTATGCTTCTCTTTGTGTTAATATTGGTCCTTTTTCCTTGAG 
P3 
FWD TCGACTCATAGGAAGATGTCCAAGCGATCCTTATAAACATAGTTAAGG 
REV GGCCCCTTAACTATGTTTATAAGGATCGCTTGGACATCTTCCTATGAG 
P4 
FWD TCGACTCCAACCTAAAACACCAGTACCAGCACAAAGAGAAAGGTAAGG 
REV GGCCCCTTACCTTTCTCTTTGTGCTGGTACTGGTGTTTTAGGTTG GAG 
P5 
FWD TCGACTCCATAGGAGAACACCAAGTGAAGCAGATAGATGGTTATAAGG 
REV GGCCCCTTATAACCATCTATCTGCTTCACTTGGTGTTCTCCTATGGAG 
P6 
FWD TCGACTCTATTTAAGGCAACCATATTACGCAACAAGAGTAAATTAAGG 
REV GGCCCCTTAATTTACTCTTGTTGCGTAATATGGTTGCCTTAAATAGAG 
P7 
FWD TCGACTCAATTTAAAAGAACCATTATTAACATTTAGATTAAATTAAGG 
REV GGCCCCTTAATTTAATCTAAATGTTAATAATGGTTCTTTTAAATTGAG 
P8 
FWD TCGACTCACTCAAAAGAGTCCAGCTACAGCACCTAAACCAATGTAAGG 
REV GGCCCCTTACATTGGTTTAGGTGCTGTAGCTGGACTCTTTTGAGTGAG 
P9 
FWD TCGACTCGTAAAGAAAAATCCAGGAATAGCTGCAAAATGGTGGTAAGG 
REV GGCCCCTTACCACCATTTTGCAGCTATTCCTGGATTTTTCTTTACGAG 
P10 
FWD TCGACTCTATAGCAAAATACCATTAGATACAAGTAGATTAGCATAAGG 
REV GGCCCTTATGCTAATCTACTTGTATCTAATGGTATTTTGCTATAGAG 
P11 
FWD TCGACTCGGACCAAAGAGGCCTGGTAATACATTAAGAAAATGGTAAGG 
REV GGCCCCTTACCATTTTCTTAATGTATTACCAGGCCTCTTTGGTCCGAG 
P12 
FWD TCGACTCGCTGCAAAGATACCAGATAAAACAGAAAGATTACATTAAGG 
REV GGCCCCTTAATGTAATCTTTCTGTTTTATCTGGTATCTTTGCAGCGAG 
P13 
FWD TCGACTCGGAGCAAGAAGTCCAGCTCCAACAAGAAAAGAATTTTAAGG 
REV GGCCCCTTAAAATTCTTTTCTTGTTGGAGCTGGACTTCTTGCTCCGAG 
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2.3 Protein Biochemistry  
2.3.1 Protein Expression  
GST-fusion proteins were expressed in E. coli cells and subsequently purified. 
Depending on the protein, different E. coli strains were used for expression (see Table 
2.2). The majority of GST-fusion proteins were expressed in BL21 (DE3) E. coli, since 
they are deficient in the proteases Lon and OmpT, enhancing protein production from 
cloned genes. The Rosetta 2 E. coli strain was trialled or used for proteins whose 
corresponding gene sequences contained many rare E. coli codons, given that this stain 
contains plasmids that encode for several of the rare tRNAs. Additionally, Rosetta Gami 
B E. coli, which also express the rare tRNAs found in Rossetta 2 cells, were used for 
proteins containing disulphide bonds. This strain is also a double mutant in thioredoxin 
reductase (trxB) and glutathione reductase (gor), which creates a more oxidising 
cytoplasmic environment and enhances protein folding through stimulating the formation 
of disulphide bonds between cysteine residues. 
A single colony of E. coli cells, transformed with a pGEX construct, was used to inoculate 
a starter culture of LB (50 ml) and incubated with agitation (200 rpm), overnight at 37 ˚C 
in the presence of the appropriate antibiotics (See Table 2.2). The starter culture was 
added to 1 L of LB under antibiotic selection and placed in a shaking incubator for 3-4 h 
until OD600 = 0.6 - 1. The culture was induced with isopropyl β-D-1-thiogalactopyranoside 
(IPTG; 1 mM) for 3 h at 37 ˚C (or overnight at 18 ˚C) with constant agitation. Cultured 
bacteria were pelleted in a Sorvall Evolution centrifuge at 5000 g for 10 min and the 
supernatant was discarded and the pellets were frozen at -80 ˚C.  
2.3.2 Purification of Recombinant Proteins  
Different bacterial cell lysis methods were used, for the purification of each GST fusion 
protein, in order to optimise the final protein yield and stability. Sonication (i) was used 
for the purification of GST, the GST- P1-13 and GST-PTP1B-HisΔ80Src kinase protein 
purification, whereas French press (ii) was used for the purification of GST-hHCN1-CTD 
and GST-rNR2A-CTD. 
(i) Frozen E. coli cell pellets were thawed on ice and resuspended in phosphate 
buffered saline (PBS, 30 ml) containing lysozyme (133 µM final concentration), 
phenylmethanesulfonylfluoride (PMSF, 1 mM) and 1X protease inhibitor cocktail 
(Sigma-Aldrich). After incubating on ice for 30 min, Triton X-100 (1.5 % w/v) and 
dithiothreitol (DTT, 7 mM) were added. This solution was subjected to 6 x 1 min 
cycles of 30 s 10 kHz sonication and 30 s gentle agitation.  
(ii) Frozen E. coli cell pellets were thawed on ice and resuspended in breaking buffer 
(100 mM HEPES, 500 mM KCl, 2 mM β-Mercaptoethanol in dH2O) containing 
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PMSF (1 mM) and 1 X protease inhibitor cocktail. Cells were lysed at 4 ˚C using 
a manual French press (Thermo Scientific). 
Insoluble matter was removed from the lysate by centrifugation for 30 min at 17200 g 
and 4 ˚C. Cleared lysate was incubated with glutathione agarose (0.1-1 ml) for 1-2 h. 
Beads were washed five times with PBS, followed by one wash with 1.2 M NaCl in PBS 
and a further two washes with PBS. After each wash, the beads were centrifuged for 5 
min at 720 g at 4 ˚C. Protein was eluted from the beads by the addition of 600 µl 
glutathione elution buffer per 0.5 ml beads and incubation at room temperature for 20-
30 min with agitation. This elution process was repeated 3 times. Eluted protein was 
aliquoted and frozen at -80 ˚C following analysis by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Section 2.3.4). 
Table 2.2: Antibiotic and Growth Conditions for E.Coli Expressing Various pGEX 
Constructs 
Construct 
E-coli 
strain 
Antibiotic resistance 
Growth 
conditions 
post- IPTG 
induction 
pGEX-4T-1 
pGEX-6P-1 
pGEX-6P-1:Peptide 
constructs 
pGEX-6P-1:hHCN1-
CTD 
pGEX-4T-1:rNR2A-
CTD 
pGEX-6P-1:PTP1B-
HisΔ80C-Src/N1-Src 
BL21 Ampicillin (100 µg ml-1) 3-4 h at 37 ˚C 
with shaking 
(200 rpm) 
pGEX-6P-1:hHCN1-
CTD 
pGEX-4T-1:hHCN1-
CTD 
pGEX-4T-1:rNR2A-
CTD 
Rosetta 
2 
Ampicillin (100 µg ml-1) 
Chloramphenicol (34 µg ml-1) 
16 h at 18 ˚C 
with shaking 
(200 rpm) 
pGEX-4T-1:rNR2A-
CTD 
Rosetta 
Gami B 
Ampicillin (100 µg ml-1) 
Chloramphenicol (34 µg ml-1) 
Tetracycline (12.5 µg ml-1) 
Kanamycin (15 µg ml-1) 
16 h at 18 ˚C 
with shaking 
(200 rpm) 
 
2.3.3 Cleavage of the GST Tag from GST Fusion Proteins 
GST was cleaved from glutathione resin bound GST fusion proteins using PreScission 
protease (produced by York Technology Facility). Proteins were incubated with 50 µg 
PreScission protease for 48 h at 4 ˚C, rotating end over end.  
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2.3.4 SDS-Polyacrylamide Gel Electrophoresis (PAGE) 
Sodium dodecyl sulphate (SDS) polyacrylamide gels comprising a resolving gel (10-15 
% acrylamide, 0.05 % ammonium persulfate (APS), 0.01 % tetramethylethylenediamine 
(TEMED), 375 mM Tris, pH 8.8, and 0.1% SDS) and a stacking gel (5 % acrylamide, 
0.05 % APS, 0.01 % TEMED, 125 mM Tris pH 6.8 and 0.1 % SDS) were prepared and 
transferred into a gel electrophoresis tank (BioRad) containing 1X SDS-PAGE buffer (25 
mM Tris, 192 mM glycine, 0.1 % SDS). Protein samples were denatured at 95 ˚C for 10 
min and separated alongside 5 µl of a protein ladder at 180 V for approximately 1 h. Gels 
were either stained with Coomassie Brilliant blue stain for 30 min, followed by de-staining 
(40 % (v/v) methanol, 10 % (v/v) glacial acetic acid in dH2O) overnight to visualise protein 
bands or transferred to methanol-activated polyvinylidene fluoride (PVDF) membrane 
(Immobilon-P) for Western blot analysis. 
2.3.5 Wet Transfer 
Protein samples separated by SDS-PAGE were transferred onto PVDF by wet transfer. 
Briefly, 6 cm x 8 cm PVDF was pre-soaked for 1 min in methanol followed by distilled 
water for 1 min and then transfer buffer (25 mM Tris, 192 mM glycine, 20 % methanol). 
Two 6 cm x 8 cm sponges and sheets of filter paper were also soaked in transfer buffer. 
The SDS polyacrylamide gel and PVDF membrane were sandwiched between the filter 
papers and sponges in a transfer cassette and subjected to electrophoretic transfer at 
66 V for 1 h (or 20 V overnight). Successful transfer of proteins was confirmed by 
Ponceau staining, 
2.3.6 Western Blotting  
Transferred proteins of interest were detected using the appropriate antibodies via 
Western blotting (see Table 2.3 for antibodies and their dilution factors). The PVDF 
membrane was blocked with 3 % BSA (for phosphotyrosine antibodies) or 3 % Marvel 
skimmed milk powder in PBS, followed by incubation with the appropriate primary 
antibody (Table 2.3). Incubations were carried out for 2 h at room temperature or 
overnight at 4 ˚ C. The membrane was washed 3 x 5 min in PBS containing 0.5 % Tween-
20 and subsequently incubated with a HRP-conjugated secondary antibody solution (3 
% milk and 0.5 % Tween-20 in PBS) for 1 h. The membrane was subjected to 3 x 10 min 
washes with 0.5 % Tween-20 in PBS. All incubations were performed at room 
temperature with shaking unless specified otherwise. ECL substrate was added to the 
PVDF membrane, the membrane was blotted with 3 mm filter paper to remove excess 
liquid, wrapped in cling film and placed in a film cassette. Membranes were exposed to 
photo-sensitive film (Santa Cruz) for a relevant period of time. The film was developed, 
rinsed in water and fixed. 
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Table 2.3: Western Blotting Antibodies and Blocking Conditions 
 
Primary 
antibody 
Secondary antibody 
Antibody Block Concentration Antibody Concentration 
Actin B 
3 % milk 
in PBS 
1:10000 
α-rabbit 
HRP 
1:5000 
FLAG 
3 % milk 
in PBS 
1:1000 
α-mouse 
HRP 
1:5000 
GFP(a) 
3 % milk 
in PBS 
1:2000 
α-mouse 
HRP 
1:5000 
PY20 
3 % BSA 
in PBS 
1:1000 
α-mouse 
HRP 
1:5000 
pY416 
3 % BSA 
in PBS 
1:2000 
α-rabbit 
HRP 
1:5000 
RhoA 
5 % milk 
in PBS 
1:500 
α-mouse 
HRP 
1:5000 
 
2.3.7 In Vitro Kinase Assays with GST-hHCN1- and GST-rNR2A- Purified Proteins   
In vitro C-Src and N1-Src kinase assay reactions (25 µl) were performed using GST-
hHCN1- (5 µM) and GST-rNR2A-CTD (5 µM) substrates in reaction buffer A (Table 2.4). 
The ideal Src substrate GST-YA (10 µM) was used as the positive control and GST (10 
µM) alone as a negative control. The assays were performed in the absence or presence 
of 40 nM HisΔ80-C- or N1-Src for each substrate. Assays were performed at 30 ˚C for 1 
h. Kinase reactions that were performed with glutathione agarose-bound protein 
substrates contained approximately 10 µg of GST-tagged substrate. These reactions 
were performed with GST-hHCN1- and GST-rNR2A-CTD proteins that were expressed 
and purified from the pGEX-4T-1 plasmid constructs. Since these proteins contained a 
thrombin cleavage site in place of a PreScission protease cleavage site, residual 
PreScission protease present in HisΔ80-Src kinase stocks could not cleave the protein. 
The reactions were performed separately with reaction buffers B and C (Table 2.4) and 
were subjected to shaking (150 rpm) at 30 ˚C for 1 h. All reactions were terminated by 
the addition of 2 X Laemmli buffer (25 µl) and stored at -20 ˚C. Kinase assay protein 
samples were separated by SDS-PAGE and analysed by Western blotting (Sections 
2.3.4-6). 
2.3.8 In Vitro γ-32P ATP Kinase Assays with hHCN1- and rNR2A-CTD 
In vitro kinase assays were performed in 50 µl reactions containing 100 nM HisΔ80C- 
and N1-Src, 5 µM untagged hHCN1- or rNR2A-CTD, 10 mM MgCl2, 0.5 mM ATP, and 5 
µCi γ-32P ATP in 100mM Tris (pH 7.5). The reactions were incubated for 3 h at 30 ᵒC. 
Every 1 h, 10 µl of the reactions were removed, terminated with 2X Laemmli buffer and 
stored at -20 ᵒC. Further in vitro kinase assays (25 µl) with an increased concentration of 
hHCN1- (5.8 µM) and rNR2A-CTD (7.2 µM) were performed that also 
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Table 2.4: Kinase Buffers Used for In Vitro Kinase Assays Containing GST-hHCN1-
CTD and GST-rNR2A-CTD 
Reaction 
Buffer 
A B C 
 100 mM Tris 
0.5 mM ATP 
10 mM MgCl2 
40 nM Src 
pH 7.5 
100 mM Tris 
0.5 mM ATP 
10 mM MgCl2 
50 µg/ml BSA 
1 mM DTT 
40 nM Src 
pH 7.5 
100 mM Tris 
0.5 mM ATP 
10 mM MgCl2 
50 µg/ml BSA 
1 mM DTT 
200 µM NaVO43- 
40 nM Src 
pH 7.5 
 
 
contained 100 nM HisΔ80C- and N1-Src, 10 mM MgCl2, 0.5 mM ATP, and 2 µCi γ-32P 
ATP in 100 mM Tris (pH 7.5). The reactions were incubated at 30 ᵒC and terminated after 
3 h with 2X Laemmli buffer and stored at -20 ᵒC. For both types of kinase assays, an 
identical reaction with the positive control GST-YA was performed. Kinase assay protein 
samples were separated by SDS-PAGE (Section 2.4.4) and then the gels were 
sandwiched between two acetate sheets and exposed to X-ray film for 24-48 h.    
2.3.9  In Vitro Protein Kinase C-zeta (PKC-zeta) Kinase Assays with hHCN1- or 
rNR2A-CTD  
In vitro kinase assays (25 µl) were performed in the presence or absence of the 
constitutively active form of protein kinase C (PKC-zeta; 50 ng) with the rNR2A- or 
hHCN1-CTDs (5 µM). Reactions also contained 10 mM MgCl2, 0.5 mM ATP, and 2 µCi 
γ-32P ATP in 100 mM Tris (pH 7.5) and were incubated at 30 ᵒC for 3 h. Reactions were 
terminated with 2X Laemmli buffer and stored at -20 ᵒC. Identical reactions containing 
myelin basic protein (MBP, 5 µM) were performed and served as a positive control for 
PKC-zeta kinase activity. Kinase assay samples were analysed as described in Section 
2.3.8.    
2.3.10 In Vitro HisΔ80-N1-Src Kinase Assays with Putative GST-fusion Peptide 
Substrates  
In vitro HisΔ80-N1-Src kinase reactions (25 µl) containing PD1 (positive control; 1.7, 5 
or 15 µM), PD1-P5A (negative control; 1.7, 5 or 15 µM) and the putative N1-Src GST-
fusion peptide substrates P1-13 (5 µM) were performed using reaction buffer A, however, 
a kinase concentration of 5 nM was used (Table 2.4). The assays were incubated at 
30 ˚C for 1 h and the reactions were terminated by the addition of 2X Laemmli buffer (25 
µl) and stored at -20 ˚C. Kinase assay protein samples (5 µl) were separated by SDS-
PAGE in duplicate. One set of gels were analysed by Western blotting (Sections 2.3.4-
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6), whilst the other set were Coomassie stained and subsequently de-stained, to enable 
the comparison of GST-fusion peptide quantities between reactions.      
To facilitate the comparison of substrates GST-P1-13 with both GST-PD1 (5 µM) and 
GST-PD1-P5A (5 µM), densitometry was performed on the resulting blots and 
Coomassie stained gels from three replicates in Image J. Within a single replicate, the 
two blots (blot 1 contained samples P1-6 and blot 2 contained samples P7-13) contained 
the same quantitiy of a GST-PD1 positive control. Therefore the densitometry values 
were normalised to the density of the same GST-PD1 band across blots. In addition, to 
account for potential differences in the amount of substrate in each reaction, 
densitometry bands obtained for each phospho-protein were normalised to the 
densitometry values from the corresponding Coomassie stained protein bands. Finally, 
the values within each experiment were normalised to PD1 to account for potential 
differences in the processing of blots and Coomassie gels between biological replicates. 
Differences between the data values obtained were assessed for significance using a 
one-way ANOVA.      
2.3.11 Immunoprecipitation (IP) 
For each condition, a T75 flask of cultured COS7 cells (3 x 106 cells) was transfected 
with the appropriate plasmid constructs according following the procedure outlined in 
Section 2.4.3. The cells in each T75 flask were lysed in 1 ml of ice cold 1X 
radioimmunoprecipitation assay buffer (RIPA) buffer (20 mM Tris-HCl (pH 7.5), 270 mM 
sucrose, 1 % Triton X-100, 5 % glycerol, 10 mM sodium β-glycerophosphate, 1 mM 
ethylene glycol tetraacetic acid (EGTA), 1 mM ethylenediaminetetraacetic acid (EDTA), 
0.1 % β-mercaptoethanol, 1 mM sodium orthovanadate, 0.1 % phosphatase inhibitor, 1 
mM PMSF). Cells were scraped from the bottom of the flasks and extracted on ice for 10 
min. The cell lysates were then centrifuged for 10 min at 16,000 g at 4 ˚C to remove 
insoluble matter. Protein G agarose (20 µl aliquots) conjugated to a GFP antibody was 
pre-washed in RIPA buffer and incubated end over end, overnight at 4°C with the 
appropriate cell lysate. The following day, the beads were pelleted by centrifugation for 
5 min at 16,000 g at 4 ˚C. The supernatant was removed and the beads were transferred 
into SPIN-X columns (Corning) and washed x 3 with 500 µl of RIPA buffer. Proteins that 
were retained by the GFP resin were eluted upon the addition of 50 µl of 2X Laemmli 
buffer (Sigma-Aldrich) to the SPIN-X columns.  
2.3.12 RhoA Pull-down Activation Assay 
The RhoA pull-down activation assays were performed using a commercial kit purchased 
from Cytoskeleton Inc. according to the manufacturer’s instructions. For each condition, 
a 10 cm dish of COS7 cells (1 x 106 cells) was transfected with the appropriate plasmid 
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constructs according to the procedure outlined in Section 2.4.3. Cells were lysed in 500 
µl of the provided cell lysis buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 0.5 M NaCl, 2 % 
Igepal and 1 X protease inhibitor cocktail) and lysates were immediately clarified at 
10000 g, for 10 min at 4 ˚C.  
Clarified lysates were snap frozen and stored at -80 ˚C and the protein content of the 
lysates (~2 mg ml-1) was assessed by Bradford assay (Bradford, 1976). Thawed protein 
lysate aliquots (500 µl) were incubated separately with Rhotekin RhoA binding domain 
(RBD) beads (25 µg) at 4 ˚C, rotating end over end. As a positive and negative control, 
cell lysates containing wild type RhoA, were pre-loaded with guanosine triphosphate 
(GTP) or guanosine diphosphate (GDP), respectively. After a 1 h incubation, the 
supernatant was removed, the beads were resuspended in the provided wash buffer (25 
mM Tris pH 7.5, 30 mM MgCl2, 40 mM NaCl) and transferred into SPIN-X columns, which 
had been prewashed. The SPIN-X columns were centrifuged at 5000 g for 1 min at 4 ˚C 
to pellet the beads and remove the wash buffer. Proteins that were pulled down by the 
Rhotekin RBD beads were eluted upon the addition of 20 µl of 2X Laemmli buffer to the 
SPIN-X columns. Eluted samples were stored at -20 ˚C until use. Input (total protein 
lysate; 2 %) and eluted protein (10 µl) samples were run on separate gels and subjected 
to Western blotting (Sections 2.3.4-6).  
2.4 Cell Biology Techniques 
2.4.1 Culture of Mammalian Cell Lines  
The culture of mammalian cell lines was performed under sterile conditions in a Class 2 
biological safety cabinet. COS7 and B104 cell lines were cultured in high glucose DMEM 
containing glutamine and pyruvate. The media was supplemented with 10 % foetal 
bovine serum (FBS) and 1 % penicillin-streptomycin (PenStrep). Cells were maintained 
in a 37 ˚C incubator with 5 % CO2.  
2.4.1.1 Revival of Cell Stocks 
Cells were removed from storage at -80 ˚C and thawed for 2 min in a 37 ˚C water bath. 
Cells were then placed in a T25 flask containing 5 ml of media pre-warmed to 37 ˚C. The 
media was replaced the following day. 
2.4.1.2 Passage of Mammalian Cell Lines 
Adherent cells were washed with PBS and incubated with 1X trypsin-EDTA (Invitrogen) 
for 2-5 min at 37 ˚C. The trypsin was inhibited with culture medium containing 10 % FBS 
and 1 % PenStrep. Cells were collected from the bottom of the flask and centrifuged at 
130 g, for 5 min at room temperature. After centrifugation, the cells were resuspended in 
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culture medium and 1/5th of the suspension was replaced into a new flask containing pre-
warmed media.        
2.4.1.3 Cell Storage 
For long term storage, cells resuspended after passage were added in equal proportion 
to freezing media (90% FBS, 10 % DMSO) and stored, in cryovials, at -80 ˚C.  
2.4.1.4 Plating Cells 
Passaged cells were counted using a haemocytometer and 2 x 104 or 1 x 105 cells were 
plated into single wells of a 24 or 6 well plate, respectively. For immunocytochemistry 
experiments, cells were plated on 13 mm coverslips in a 24 well plate.  
2.4.2 L1-CAM Process Outgrowth Assay 
The wells of 8 well chamber slides were pre-coated with L1-CAM protein dissolved in 
PBS (40 µl; 50 µg/ml) or PBS alone (40 µl; control). 1 x 10-5 COS7 cells were plated in 
each well and subsequently transfected and processed for immunofluorescence. The 
plastic eight well chamber was removed from the slides using a tool provided by the 
manufacturer.    
2.4.3 Cell Line Transfections using EcoTransfect Reagent 
Mammalian cell lines were transfected with plasmid constructs using EcoTransfect 
according to the manufacturer’s instructions. Briefly, DMEM containing plasmid DNA was 
incubated with DMEM containing EcoTransfect (at a ratio of 1µg DNA: 2 µl EcoTransfect) 
for 20 min at room temperature. The transfection solution was applied dropwise to plated 
or flasks of cells and incubated for 48 h at 37 ˚C with 5 % CO2. Cells were either fixed 
and stained or lysed for use in an immunoprecipitation assay (Section 2.3.11) or for 
Western blot analysis (Section 2.3.4-6).  
2.4.4 Preparation of Rat Hippocampal Neurons 
Rat hippocampi were dissected from euthanised new born (postnatal day 0, P0) Wistar 
rats by Dr Sangeeta Chawla. Dr Chawla’s protocol for the preparation of hippocampal 
neurons from new born rats has been approved by the Biology Ethics Committee. The 
subsequent dissociation of cells was carried out by either myself, Dr Chawla or 
Christopher Ugbode according to a pre-published procedure (Belfield et al., 2006). 
Briefly, dissected hippocampi were incubated at 37 ˚C with papain enzyme solution for 
a total of 40 min, with additional fresh enzyme solution being added after 20 min. The 
hippocampi were washed x 3 with pre-warmed dissociation media containing kynurenic 
acid and magnesium chloride/sulphate. After washing, the hippocampi were incubated 
with 2 ml of trypsin inhibitor for 5 min at 37 ˚C. This procedure was repeated x 3 and 
followed by 3 washes with warmed growth medium. The hippocampi were dissociated 
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by trituration in growth medium and diluted in OPTI+ solution to give an equivalent 
concentration of one hippocampus per 2 ml of media. The cells were plated on coverslips 
that were pre-coated in poly-D-lysine (PDL; coverslips were incubated at RT with 15 µg 
ml-1 PDL for 1-2 h end over end and air dried under sterile conditions). Cells were plated 
at a density of 2.5 - 5 x 105 cells per well of a 24 well plate. 
2.4.4.1 Transfection of Rat Hippocampal Neurons 
P1 primary rat hippocampal neurons were transfected, 24 h after plating, with various 
DNA constructs using Lipofectamine® reagent in accordance with the manufacturer’s 
instructions. Briefly, for a single well of a 24 well plate, midi-prepped DNA and 2.5 µl 
Lipofectamine® reagent were each added to 200 µl Neurobasal media (Gibco, Life 
technologies) in separate tubes (for shRNA experiments the ratio was 0.1 µg ShRNA: 2 
ul Lipofectamine® and for mCherry constructs the ratio was 0.25 µg DNA to 2 ul of 
Lipofectamine®). The contents of both tubes were mixed and incubated at room 
temperature for 20 min. The growth medium from the hippocampal neurons was 
removed, and replaced with DNA/ Lipofectamine® solution. After a ~5 h incubation 
period at 37 ˚C with 5 % CO2, the DNA/Lipofectamine® solution was aspirated from the 
cells and the previously removed growth medium was reapplied. Cells were cultured for 
a further 48 h (P3), fixed, stained and mounted onto slides (Section 2.4.5.1). For some 
experiments (Section 4.2.7), neurons were cultured until P7 before cells were fixed. 
2.4.5 Immunocytochemistry 
2.4.5.1 Cell Fixation and Staining 
Cells were washed x 3 with PBS and fixed in a paraformaldehyde (PFA) solution (4 % 
PFA and 4 % sucrose in PBS, pH to 7.4) at room temperature. After 20 min, cells were 
washed x 3 with PBS. To permeabilise the cells, 0.1 % Triton X-100 dissolved in PBS, 
was applied for 30 min at room temperature. Cells were subsequently stained with an 
appropriate primary antibody at the required dilution for 2 h at room temperature (Table 
2.5). After washing the cells x 3 with PBS, cells were incubated in the dark with an Alexa 
Fluor® secondary antibody raised in the correct species, at a dilution of 1:500 for 1 h 
(Table 2.5). After a further 3 washes in PBS and once in water, the coverslips were air 
dried and mounted onto slides in Mowiol mounting medium (10 % Mowiol, 25 % glycerol 
in 0.1 M Tris pH 8.5) containing 1 µg ml-1 DAPI (4',6-diamidino-2-phenylindole) stain and 
stored at 4 ˚C prior to processing by microscopy. 
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Table 2.5: Primary and Secondary Antibodies Used in Immunocytochemistry 
Primary Antibody 
Secondary 
antibody 
Name Concentration Name Concentration 
GFP(b) 1:1000 α-rabbit Alexa Fluor®488 1:500 
FLAG 1:1000 α-mouse Alexa Fluor®594 1:500 
L1-CAM 1:1000 α-mouse Alexa Fluor® 488 1:500 
 
2.5 Cell Imaging  
2.5.1 Image Capture Using a Fluorescence Microscope 
Fluorescence images were captured using a Nikon TE200 epifluorescence inverted 
microscope with a RoleraXR CCD (QImaging) camera controlled by SimplePCI Software 
(Hamamatsu). Images of COS7 cells or hippocampal neurons were acquired using a 
40X or 20X objective lens.   
2.5.2 Coverslip Tiling Using the Zeiss Slidescanner 
Fluorescence images of whole coverslips containing transfected hippocampal neurons 
were acquired with a 20X objective lens, using a Zeiss AxioScan.Z1 slide scanner. 
Images were processed using the Zeiss image software analysis programme Zen Blue.  
2.6 Analysis of Cell Morphology Data 
2.6.1 Morphological Analysis Using NeuronJ 
Image analysis of both COS7 and neuronal cells was performed using ImageJ. To 
compile tiled images of the same neuron where required, the stitching plugin for ImageJ 
was used (Preibisch et al., 2009). Neurite morphology data was extracted from images 
using the NeuronJ plugin, which allows the semi-automatic tracing of neurites, which 
were subsequently categorised into neurites/processes, primary branches, secondary 
branches and tertiary branches. The NeuronJ programme calculated the lengths of 
individual neurites/processes and branches, which were subsequently compiled in 
Microsoft Excel (Meijering et al., 2004). In a similar fashion, NeuronJ was used to trace 
and measure neurite-like extensions projected by COS7 cells under different cellular 
conditions.     
To measure additional morphological parameters of COS7 cells, the perimeter of 
individual cells was manually traced in ImageJ and subsequently used to calculate the 
area (μm2) and circularity of the cells. Circularity (4π(area/perimeter2)) was used to 
describe the ‘roundness’ of the cells measured, whereby a value of 1 describes a perfect 
circle and a value of 0 represents an elongated oblong shape (Schneider et al., 2012). 
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2.6.2 Statistical Analysis of Cell Data 
Statistical analysis was performed on data combined from experiments containing at 
least three biological replicates. Statistical tests were not performed when the experiment 
comprised fewer than three biological replicates.  
Data are presented as mean ± SEM. SigmaStat v12.5 software was used to perform all 
statistical analyses. Normal distribution was determined using a Shapiro-Wilk test. For 
normally distributed data, paired or unpaired Student’s two-tailed t-test was used to 
compare two samples. Multiple comparisons on non-parametric data were made using 
Kruskal-Wallis tests (or one-way ANOVA on ranks) on the total number of cells from 
three biological replicates (unless stated otherwise). Where the outcome of the Kruskal-
Wallis test was significant, a Dunn-Bonferroni post-hoc test was used for the pairwise 
comparison between the fixed variables. For experiments containing two factors, 
statistical significance was assessed using a two-way ANOVA on the total number of 
cells from three biological replicates (unless stated otherwise). A post-hoc Tukey test 
was used to facilitate the pairwise comparison between the fixed variables where 
necessary. Results were considered significant when P < 0.05 (*). 
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Chapter 3. Discovery of Novel N1-Src Substrates 
3.1 Introduction 
The lack of tools available that enable the discrimination between C- and N1-Src kinases, 
such as N1-Src specific activators, inhibitors, antibodies and knock-out mice, has 
hampered the discovery of N1-Src substrates. It is therefore unsurprising that few bona 
fide N1-Src substrates have been identified since N1-Src’s discovery by Levy and 
colleagues in 1987. For this reason, it is anticipated that the phosphorylation of some 
neuronal substrates that have previously been assigned to C-Src activity, are in fact 
attributable to N1-Src. 
Given that N1-Src differs from C-Src by only a short insert in the SH3 domain, the area 
of the protein that co-ordinates substrate docking, it is highly likely that C- and N1-Src 
have different substrates. This was alluded to by Keenan et al., (2015), who 
demonstrated that in relation to C-Src, both N1- and N2-Src had a low affinity for ideal 
Src substrates that were linked to the canonical C-Src SH3 binding motifs (Classes I and 
II). They also showed that in vitro phosphorylation of synaptophysin, a well-established 
substrate of C-Src in the brain, was greatly reduced when incubated with N1- and N2-
Src compared to C-Src (Keenan et al., 2015). Taken together, this evidence suggested 
that N1-Src has a reduced affinity for C-Src substrates and therefore may have different 
substrates to C-Src in neurons. 
Of the few substrates known to be phosphorylated by N1-Src in vitro, the C-terminal 
domain (CTD) of the NMDA receptor (NMDAR) subunit, NR2A, has also been shown to 
be phosphorylated by V-Src and regulated by C-Src (Yang and Leonard, 2001, Yu et al., 
1997, Groveman et al., 2011). However, phosphorylation of the NR2A-CTD by C- and 
N1-Src has not been compared and since ion channel CTD phosphorylation often occurs 
at multiple residues and by more than one kinase, it is possible that C- and N1-Src might 
phosphorylate the NR2A subunit at different sites. Whilst it has been shown that V-Src 
phosphorylates the NR2A-CTD at three individual tyrosine residues, the specific 
residues phosphorylated by N1-Src remain unknown. In addition, whilst Groveman et al., 
(2011) showed that NR1-1A/NR2A receptor currents were enhanced in HEK-293 cells 
when co-expressed with N1-Src, the differential effects of C- and N1-Src were not 
investigated.  
Amongst other proteins (see Section 1.5.4), a second type of neuronal ion channel, 
hyperpolarisation-activated cyclic nucleotide-gated 1 (HCN1), has been shown to 
interact with N1-Src, however phosphorylation of the protein by N1-Src has not been 
demonstrated (Santoro et al., 1997). It was anticipated that HCN1 could be an N1-Src 
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substrate, since other HCN channels have been shown to be regulated and 
phosphorylated by C-Src (Li et al., 2008a, Arinsburg et al., 2006, Zong et al., 2005). For 
example, the direct phosphorylation of recombinant GST-HCN2-CTD was demonstrated 
in an in vitro kinase assay with C-Src (Rolli-Derkinderen et al., 2005).        
Given that very few N1-Src substrates have been identified and recent studies suggest 
that N1-Src has a lower affinity for traditional C-Src substrates, further studies carried 
out in the Evans lab sought to identify an N1-Src SH3 binding consensus motif that would 
ultimately lead to the discovery of novel N1-Src substrates (Keenan, 2012). A consensus 
motif for N1-Src SH3 substrate binding was established after performing a phage display 
experiment, in which a library of short peptides, consisting of 12 amino acids each, were 
screened for preferential binding to the N1-Src SH3 domain. Notably, the N1-Src SH3 
binding consensus motif deviated from the traditional proline rich PXXP motifs that bind 
the C-Src SH3 and instead, had preferential affinity for a PXXT/A sequence, that was 
flanked either side with a positive residue.  
A follow-up bioinformatics study was performed with the aim of identifying putative N1-
Src substrates. Proteins that contained the newly identified N1-Src SH3 binding motif, 
which were also predicted to be phosphorylated by a Src family kinase (SFK), were 
pinpointed as potential N1-Src substrates. Interestingly, after grouping the potential 
substrates into functional clusters, this revealed that a large proportion of the substrates 
identified were involved in processes that are crucial to neuronal development, including 
cell adhesion molecule signalling, Ras/Rho protein signalling and cytoskeletal 
rearrangement. This aligned with reports in the literature that N1-Src is involved in 
neuronal development (Kotani et al., 2007, Wiestler and Walter, 1988, Worley et al., 
1997).   
Whilst progress is being made, a huge gap remains in the literature with respect to our 
understanding of bona fide N1-Src substrates. This must be addressed in order to dissect 
the function of N1-Src. Given that N1-Src has been shown to be highly expressed in the 
developing brain (Wiestler and Walter, 1988) and the fact that there is evidence 
implicating N1-Src in ion-channel regulation (Groveman et al., 2011), it appears that N1-
Src could be an integral signalling component of neuronal processes taking place in both 
the developing and adult brain.  
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3.1.1 Aims  
The principal aim of this chapter was to identify novel N1-Src substrates. It was 
hypothesised that N1-Src phosphorylates the HCN1-CTD, ultimately regulating the ion 
channel’s activity. It was also predicted that both the HCN1- and NR2A-CTDs would be 
phosphorylated by C- and N1-Src to different extents, potentially at different tyrosine 
residues. Therefore, in vitro kinase assays were performed with both the GST tagged 
human (h) HCN1-CTD and rat (r) NR2A-CTDs.  
In addition to this, a second approach was adopted, with the aim of validating predicted 
N1-Src substrates that were identified in the bioinformatics study described in Section 
3.1 and which had known roles in the developing and adult brain. Peptides that were 
derived from putative N1-Src substrates and were predicted to bind the N1-Src SH3 
domain, were linked with the ideal Src substrate motif (YGEF) that is phosphorylated by 
the kinase domain, and screened for enhanced phosphorylation by N1-Src.   
  
 
 
73 
 
3.2 Results 
3.2.1 The Purification of Recombinant Src kinases 
Recombinant C- and N1-Src kinases were expressed and purified for in vitro kinase 
assays (see Section 2.3.1-2), with the aim of discovering novel N1-Src substrates. 
Multiple studies have found that the bacterial expression of Src is problematic, delivering 
highly degraded protein, poor yields and protein aggregation resulting in the formation of 
inclusion bodies (Saya et al., 1993, Osusky et al., 1995). These poor results have been 
attributed to Src kinase activity, given that the bacterial expression of an inactive mutant 
of Src eradicated these problems (Wang et al., 2001a). Wang et al., (2006) devised a 
strategy to overcome the effects of Src kinase activity on the quality of protein expression 
in bacteria. This was accomplished by fusing Src to a phosphatase catalytic domain 
(PTP1B), which is thought to counteract the aberrant phosphorylation caused by the 
kinases (Wang et al., 2006b). A similar approach has been successfully adopted by the 
Evans lab to express both C-Src and the neuronal Src kinases (Keenan et al., 2015).  
C- and N1-Src kinases are routinely recombinantly expressed minus the first 80 residues 
(Δ80), since these residues are not required for kinase activity in vitro (Keenan et al., 
2015). The Δ80C- and N1-Src were expressed with a GST tag, tyrosine phosphatase 
catalytic domain (PTP1B) and HIS tag fused to the N-termini of the proteins (Figure 
3.1A). The GST tag and PTP1B were cleaved from the Srcs, after the proteins had been 
isolated from the bacterial lysates, to yield His-Δ80C- and N1-Src (~55 kDa) 
(Figure 3.1B). To achieve this, protein bound glutathione resin, was treated with 
PreScission protease (a fusion protein of human rhinovirus 3C protease and GST). 
Figure 3.1B shows an example of the cleavage reactions and the purified cleaved protein 
for His-Δ80C- and N1-Src.  
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(A) Schematic diagram of recombinant Src kinases lacking the first 80 N-terminal 
residues (Δ80). The proteins were N-terminally tagged with GST, the phosphatase 
PTP1B and six histidine residues (HIS), to facilitate the expression and purification of the 
proteins. The PTP1B and HIS tag were separated by a PreScission protease site 
(LEVLFQ/GP) to allow for the release of GST-PTP1B from HIS-Δ80-Src. (B) Left panel 
– Coomassie stained, 12.5 % SDS polyacrylamide gel showing preparations of GST-
PTP1B-cleaved HisΔ80C- and N1-Src. Proteins were isolated from 1 L cultures of BL21 
E. coli cells, purified using glutathione resin and subsequently cleaved from their GST-
PTP1B tag with PreScission protease. The lanes correspond the whole cleavage 
reaction (CR) and purified cleaved protein (CP) for each kinase. Right panel – 
Coomassie stained, 12.5 % SDS polyacrylamide gel showing 1 μg of purified C- and N1-
Src kinases based on pre-determined protein concentrations.   
 
 
 
 
 
 
 
 
Figure 3.1: Purification of Recombinant C- and N1-Src Kinases 
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3.2.2 The Expression and Purification of GST-hHCN1- and GST-rNR2A-CTD  
Santoro et al., (1997) found that the CTD of HCN1 binds to the N1-Src SH3 domain. 
Since there is also evidence in the literature for C-Src phosphorylation of HCN channel 
CTDs (Zong et al., 2005), in vitro kinase assays were performed to determine whether 
the human HCN1-CTD (hHCN1-CTD) is an N1-Src substrate. Given that phosphorylation 
of the NR2A-CTD by C- and N1-Src has previously been documented (Groveman et al., 
2011), this was used as a positive control for the assay, with a view to performing further 
studies to pinpoint the phosphorylated residues. Therefore, firstly, GST-hHCN1- (80.5 
kDa) and GST-rNR2A-CTD (69.2 kDa) proteins were expressed and purified for use in 
in vitro kinase assays with recombinant His-Δ80C- and N1-Src kinases (Figure 3.2).  
The sequence encoding hHCN1-CTD was cloned into pGEX-6P1 and the induction of 
recombinant GST-hHCN1-CTD was achieved in BL21 E.Coli upon IPTG induction for 
3 h at 37 °C. Figure 3.2A (left panel) shows the protein recovered from the elution of 
GST-hHCN1-CTD from glutathione resin. The elution appeared successful, since there 
was a purified protein band in the region of 80.5 kDa, the molecular weight (MW) of the 
recombinant protein. However, the estimated concentration of intact GST-hHCN1-CTD 
protein was low (approximately 200 µg ml-1).  
With the aim of improving the protein yield and reducing the degradation of the protein, 
hHCN1-CTD was A) expressed in Rosetta 2 E. coli cells and B) induced at a lower 
temperature (18 °C) and over a longer period of time (overnight). Rosetta 2 cells differ 
from the BL21 strain because they contain plasmids that encode tRNAs for codons that 
are rare in E. coli, but which are often present in eukaryotic genes. Analysis of the 
hHCN1-CTD DNA sequence revealed that 72 of the 521 codons are low usage codons 
in E. coli, 17 of which are prolines; residues important for SH3 domain substrate 
interactions. In addition, a reduction in the rate of protein synthesis by expressing the 
protein overnight and at a reduced temperature, can often increase the yield of soluble 
mammalian proteins. Reducing the growth temperature also reduces the rate of 
proteolytic cleavage, which should ultimately improve the protein yield.  
An improved yield of full length GST-hHCN1-CTD was achieved using Rosetta 2 cells 
and a reduced induction temperature, since the estimated concentration of eluted protein 
was approximately 300-400 µg ml-1 (Figure 3.2 (middle panel). In addition to the increase 
in GST-hHCN1-CTD, there also appeared to be an increase in contaminants and/or 
break down products of GST-hHCN1-CTD (Figure 3.2A middle panel – right lane) 
compared to protein purified from BL21 cells (Figure 3.2A left panel – right lane). 
Centrifugal protein concentrators with a molecular weight cut off of 30 kDa were used 
with the intention of increasing protein concentration, and removing the lower molecular 
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weight degradation products, however little improvement in protein concentration was 
achieved and it was found that a large proportion of protein was retained in the filtrate 
(data not shown).   
In order to try to improve protein yield further, the method of cell lysis was modified. In 
place of sonication, a French press was used. After GST-hHCN1-CTD was expressed 
and bound to glutathione resin, the resulting protein appeared to contain a smaller 
proportion of lower molecular weight bands (Figure 3.2A, right panel – right lane), 
indicating that the French press lysis method resulted in reduced degradation of GST-
hHCN1-CTD, however the protein yield remained unchanged. This protein was carried 
forward for use as a candidate substrate for His-Δ80N1-Src in in vitro kinase assays.  
GST-rNR2A-CTD was expressed in a variety of E. coli strains for 3 h at 37 ˚ C or overnight 
at 18 ˚C to obtain optimal levels of expression (Figure 3.2 B). Cells were lysed using a 
French press and lysates were incubated with glutathione resin; after extensive washing 
of the beads, the protein was eluted. Figure 3.2 B (left panel) indicated that greater 
amounts of expressed protein were obtained using the following combination of 
conditions: BL21 cells induced for 3 h at 37 ˚C and overnight at 18 ˚C, Rosetta 2 cells 
induced for 3 h at 37 ˚ C and Rosetta Gami B cells induced overnight at 18 ˚ C. From each 
of these expression conditions, eluted protein obtained from Rosetta Gami B cells 
appeared to contain less fragmented protein (Figure 3.2B, right panel). Rosetta Gami B 
cells contain the same plasmids as Rosetta 2 cells that encode rare tRNAs in E. coli but 
also contain mutations in thioredoxin reductase and glutathione reductase genes. These 
mutated genes enhance disulphide bond formation in the cytoplasm, improving protein 
folding and stability. Similar to hHCN1-CTD, the rNR2A-CTD DNA sequence contains 
many rare codons (40/369 codons) and encodes eight cysteine residues. Thus, 
expression in Rosetta Gami B cells induced overnight at 18 ˚C was the method of 
expression selected for GST-rNR2A-CTD.  
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(A) Left panel - Coomassie stained, 12.5 or 10 % SDS-PAGE gels showing glutathione 
resin-purified GST-hHCN1-CTD (80.5 kDa) from sonicated BL21 (left gel) and Rosetta 2 
(middle gel) E. Coli cells that had been cultured at 37 °C for 3 h or 18 °C overnight post-
IPTG induction, respectively. Lanes correspond to 1 µg BSA and 10 µl eluate (E1) 
containing GST-hHCN1-CTD. Right panel - GST-hHCN1-CTD expressed in and 
isolated from Rosetta 2 E. coli cells that had been incubated at 18 °C overnight and 
subjected to the French press lysis method. Lanes correspond to uninduced (UI) and 
IPTG-induced (I) bacterial protein samples and 5 µl of glutathione resin bound GST-
hHCN1-CTD (5 µl beads). (B) Coomassie stained, 10 % SDS-PAGE gels showing: Left 
panel- Samples (2 µl) of uninduced (UI) and induced (I) BL21, Rosetta 2 and Rosetta 
Gami B cells expressing GST-rNR2A-CTD (69.2 kDa) cultured at 37 ˚C for 3 h or 18 ˚C 
overnight post-IPTG induction, Right panel- GST-rNR2A-CTD isolated from cell types 
induced under conditions described for left panel and purified using glutathione resin. 
Protein was eluted using glutathione elution buffer. Lanes were loaded with 10 µl of each 
eluate containing GST-rNR2A-CTD. 
  
Figure 3.2: Optimisation of GST-hHCN1- and GST-rNR2A-CTD Expression and 
Purification 
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3.2.3 The In Vitro Phosphorylation of GST-hHCN1-CTD and GST-rNR2A-CTD 
Could not be Detected via Western Blotting 
To determine whether HisΔ80C- or N1-Src kinase phosphorylates GST-hHCN1-CTD, an 
in vitro kinase assay was performed using the recombinantly expressed proteins 
described in Sections 3.1.1 and 3.1.2. A GST tagged peptide (GST-YA, 31.5 kDa) 
containing the ideal Src substrate peptide sequence AEEEIYGEF, was used as a 
positive control for C- and N1-Src activity (Keenan et al., 2015). GST-rNR2A-CTD was 
used as a second positive control, given that both C- and N1-Src have been shown to 
phosphorylate this protein, which is also the CTD of an ion channel expressed in the 
brain. To confirm that the GST tag was not phosphorylated, GST was incubated with 
both kinases.   
GST, GST-YA, GST-rNR2A-CTD and GST-hHCN1-CTD (5 µM) were incubated in 
individual kinase reactions with ATP (0.5 µM) and MgCl2 (10 mM) in 100 mM Tris (pH 
7.5), and in the presence or absence of HisΔ80C- or N1- Src. The composition of this 
buffer has been adopted by the Evans lab in previous studies (Keenan et al., 2015) 
(Section 2.3.8, Table 2.4). Figures 3.3 A and B, show that the purified recombinant Src 
kinases (described in Section 3.2.1) were active in the phosphorylation reactions as 
tyrosine phosphorylation of the positive control GST-YA (31.5 kDa) was evident. It was 
apparent that in Figure 3.3 A, HisΔ80C-Src phosphorylation of GST-YA, was greater 
than that of HisΔ80N1-Src. Phosphorylation of GST-YA was shown to be specific as the 
purified kinases did not phosphorylate GST, which does not contain any known Src 
phosphorylation sites and served as a negative control. Unfortunately, tyrosine 
phosphorylation of GST-rNR2A-CTD and GST-hHCN1-CTD by HisΔ80C- or N1 Src was 
not detected by this method. The blots presented in Figure 3.3 represent short exposures 
(< 1 min), however longer exposures of up to 30 min did not show a PY20 signal for 
GST-rNR2A-CTD, GST-hHCN1-CTD or GST either (data not shown).  
With the aim of optimizing the assay, the phosphorylation reaction buffer described by 
Keenan et al., (2015) was adapted to incorporate elements of that used by Zong et al., 
(2005), who demonstrated the in vitro phosphorylation of GST-HCN2-CTD by C-Src. In 
the reactions performed by Zong and colleagues, GST-HCN2-CTD was phosphorylated 
whilst still bound to glutathione resin. In addition to ATP (0.35 mM) and MgCl2 (10 mM), 
their reaction buffer also contained the reducing agent DTT (1 mM) and the phosphatase 
inhibitor, pervanadate (200 µM). Despite incorporating these changes into the kinase 
reactions (Figure 3.3 B), phosphorylation of neither the hHCN1-CTD nor the rNR2A-CTD 
were detected when incubated with HisΔ80C- or N1-Src. The blots shown in Figures 3.3   
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GST, GST-YA and rNR2A-CTD (5 µM; A) and hHCN1-CTD (5 µM; B) were incubated 
with C-, N1-Src or no kinase (control) at 30 °C for 3 h with ATP (0.5 mM), MgCl2 (10 
mM) in Tris pH7.5 (100 mM). The reactions (25 µl) were terminated with 2X Laemmli 
buffer. Samples were separated by SDS-PAGE, transferred onto PVDF and analysed by 
Western blotting using the primary antibody PY20 and anti-mouse HRP secondary 
antibody. The blots presented in (A) and (B) represent the results obtained using the 
different combinations of conditions described in (C).   
  
Figure 3.3: Attempted Detection of GST-hHCN1-CTD and GST-rNR2A-CTD 
Phosphorylation by C- and N1-Src. 
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A and B were indicative of the results obtained across several experiments with different 
conditions (summarised in Figure 3.3 C). 
3.2.4 Expression and Purification of Untagged hHCN1- and rNR2A-CTD. 
In Section 3.2.2, GST-hHCN1- and GST-rNR2A-CTD were expressed and purified, 
however protein yield was low due to high levels of protein degradation and poor elution 
from the glutathione resin. In order to determine whether the strong interaction between 
GST and glutathione resin was restricting the yield of recombinant proteins, the GST tag 
was cleaved from the N-terminus of both proteins. Proteins expressed from the pGEX-
6P-1 vector have a PreScission protease cleavage site (LEVLFQ/GP) separating the 
GST tag and the protein of interest (Figure 3.4A). To this end, PreScission protease was 
added to the glutathione resin-bound GST-hHCN1-CTD and GST-rNR2A-CTD and the 
GST tag was subsequently cleaved from each protein.  
Figures 3.4 B and C show the expression and purification steps taken in the preparation 
of rNR2A- and hHCN1-CTD. GST-hHCN1-CTD migrated to the correct size with a 
molecular weight of approximately 80.5 kDa. Upon cleavage of the protein with 
PreScission protease, the cleaved protein migrated to a level that corresponded with the 
predicted molecular weight of 54.1 kDa. The GST-rNR2A-CTD protein band also 
migrated to the correct molecular weight, in the region of 69.2 kDa, however, upon 
cleavage of the GST tag (26.4 kDa), the band observed was approximately 10 kDa 
higher than the expected size of the cleaved protein (42.8 kDa). In addition to this, the 
untagged rNR2A-CTD appeared as a doublet band. The protein concentrations of both 
rNR2A-CTD and hHCN1-CTD were estimated to be approximately 400 µg µl-1, which 
was equivalent to 9.5 and 7.7 µM, respectively. Whilst there was little improvement in 
yield, it was evident from the Coomassie staining of both rNR2A- and hHCN1-CTD, that 
the preparations contained fewer contaminants than the preparations of the GST-tagged 
equivalents (Figure 3.2). Therefore, these protein preparations containing untagged 
protein, were carried forward for use in the γ-32P ATP kinase assays.  
3.2.5 hHCN1-CTD and rNR2A-CTD Phosphorylation was not Detected by 
Autoradiography.  
Whilst phosphorylation of the GST-YA positive control was detected in previous kinase 
assays (Figures 3.3 A and B), indicating that the method used (Section 2.3.1-3) to purify 
C- and N1-Src resulted in active kinases, phosphorylation of the second positive control, 
rNR2A-CTD, was not observed by Western blotting (Figures 3.3 A and B). Since 
phosphorylation of rNR2A-CTD by N1-Src has previously been observed by Groveman  
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(A) Schematic diagram of GST-rNR2A/hHCN1-CTDs (69.2 kDa/80.5 kDa) showing the 
presence of a PreScission protease cleavage site (LEVLFQ/GP) separating the GST tag 
(26.4 kDa) from the protein of interest. 10 % SDS polyacrylamide gels show preparations 
of GST-cleaved hHCN1-CTD (54.1 kDa) (B) and rNR2A-CTD (42.8 kDa) (C). The GST-
hHCN1-CTD and GST-rNR2A-CTD were isolated from 2 L cultures of Rosetta 2 or 
Rossetta Gami B E. coli cells respectively, bound to glutathione resin and subsequently 
cleaved from their GST tag with PreScission protease. The lanes correspond to 
Uninduced (UI) and IPTG induced (I) E. coli lysates, 2.5 μl glutathione resin bound with 
rNR2A- or hHCN1-CTD and 5 μl of eluate containing cleaved protein (CP). 
 
 
 
 
  
Figure 3.4: Recombinant Expression and Cleavage of GST-hHCN1- and GST-
rNR2A-CTD. 
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et al., (2011) using ELISA, and phosphorylation by C-Src is documented in the literature 
(Yang and Leonard, 2001), further measures were taken to improve the assay. With the 
aim of increasing the sensitivity of phosphorylation detection, HisΔ80C- and N1-Src 
kinase assays were performed using γ-32P ATP across a 3 h time course. It was 
anticipated that improving the purity of the proteins (Figure 3.4), together with increasing 
the sensitivity of the assay would optimise the observed output of the reaction. 
Phosphorylation of the positive control GST-YA was detected in both time courses 
(Figures 3.5 A and B, upper panels), indicated by a band that corresponded with the 
molecular weight of the protein (31.5 kDa). However, phosphorylation of both hHCN1-
CTD and rNR2A-CTD by either C- or N1-Src was not detected (Figures 3.5 A and B, 
upper panels). The Coomassie stained SDS-PAGE gels for both experiments (Figures 
3.5A and B, lower panels), indicated that equal amounts of protein (rNR2A-CTD and 
hHCN1-CTD) were present in the reaction contents removed at each time interval. 
However, it appeared that there was breakdown of the GST-YA positive control, since a 
large band at approximately 25 kDa (most likely GST) was observed. Yet despite this, 
phosphorylation of GST-YA was still detected.   
A further kinase assay was performed (Figure 3.6), in which the largest amount of protein 
substrate achievable was added to a larger total reaction volume. This resulted in the 
maximum amount of protein being loaded onto the protein gel. The prepared reactions 
contained 5.8 µM hHCN1-CTD and 7.2 µM rNR2A-CTD, resulting in the loading of 
approximately 4.5 µg of protein on to the protein gel for analysis. This was almost double 
the quantity of protein (approximately 2-2.5 µg) that was analysed in the time course 
shown in Figure 3.5. GST-YA, rNR2A-CTD and hHCN1-CTD were incubated separately 
in the presence or absence (negative control) of C- or N1-Src with γ-32P ATP. Whilst 
phosphorylation by both C- and N1-Src of the GST-YA positive control was detected by 
the autoradiograph (Mr=~31.5 kDa), neither the rNR2A-CTD nor hHCN1-CTD were 
phosphorylated (Figure 3.6, upper panel). The Coomassie stained gels confirmed that 
equal quantities of each protein were added to the kinase reactions (Figure 3.6, lower 
panel).     
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5 µM rNR2A-CTD (A) and hHCN1-CTD (B) were incubated with C- or N1-Src at 30 °C 
for 3 h with γ-32P ATP. At different time intervals, 10 μl of the reaction was removed and 
terminated with 2X Laemmli buffer. Phosphorylation of GST-YA by C- and N1-Src was 
used as a positive control. Samples were subjected to SDS-PAGE and gels were 
exposed to X-ray film for 24 h and developed using an X-ray processor (upper panels). 
Gels were also stained with Coomassie to visualise all prominent protein bands (lower 
panels). 
 
 
 
 
 
 
 
 
Figure 3.5: Neither rNR2A-CTD nor hHCN1-CTD Phosphorylation by C- or N1- Src 
were Detected by Autoradiography. 
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GST-YA (5 μM), rNR2A-CTD (7.2 μM) and hHCN1-CTD (5.8 μM) were incubated with 
no kinase, C- or N1-Src at 30 °C for 3 h with γ-32P ATP. Reactions (25 µl) were terminated 
by addition of 2X Laemmli buffer. Samples (30 μl) were subject to SDS-PAGE and the 
gel was stained with Coomassie to visualise protein bands (lower panel). The gel was 
exposed to X-ray film for 24 h and developed using an X-ray processor (upper panel). 
 
 
 
 
 
  
Figure 3.6: Increasing the Reaction Content of rNR2A-CTD and hHCN1-CTD did 
not Result in Detectable Phosphorylation by C- or N1- Src by Autoradiography. 
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3.2.6 Phosphorylation of the rNR2A- and hHCN1-CTD by PKC was not Detected 
by Autoradiography.  
Since the detectable phosphorylation of the rNR2A-CTD by C- or N1-Src was not 
achieved, despite utilising published method modifications, a kinase assay using a third 
enzyme that was known to phosphorylate the rNR2A-CTD and thought to phosphorylate 
the hHCN1-CTD was performed (Leonard and Hell, 1997, Reetz and Strauss, 2013). 
Phosphorylation of GST-YA by purified C- and N1-Src suggested that both kinases were 
active and that it was more likely an issue with the protein substrates. The aim of this 
experiment was to determine whether this was the case by using an alternative kinase, 
namely Protein Kinase C (PKC), a serine/threonine kinase known to phosphorylate 
rNR2A-CTD on at least 3 residues (Figure 3.7A) (Chen and Roche, 2007). In addition to 
this, it is also thought that PKC phosphorylates the HCN1-CTD, since PKC is a known 
modulator of HCN1 channel activity and PKC activation corresponds with increased 
serine phosphorylation of the protein (Reetz and Strauss, 2013, Williams et al., 2015). 
Myelin basic protein (MBP), a well-known substrate of PKC, was used as a positive 
control for the experiment, in the event that rNR2A-CTD and hHCN1-CTD were not 
phosphorylated.     
MBP obtained from Sigma, rNR2A-CTD and hHCN1-CTD (5 µM), were incubated 
separately in the presence or absence of PKC-zeta and γ-32P ATP for 3 h (Figure 3.7B). 
Phosphorylation of the positive control, MBP, was detected, indicated by a band that 
corresponded with the molecular weight of the protein (18.4 kDa) and the Coomassie 
stained protein band (Figures 3.7 B). However, phosphorylation of rNR2A-CTD by PKC-
zeta was not detected (Figures 3.7 B, upper panel). In addition to this, whilst the full 
length hHCN1-CTD did not appear to be phosphorylated, there was a faint band at 
approximately 28 kDa that corresponded to a protein contaminant that originated from 
the hHCN1-CTD protein preparation. The Coomassie stained SDS-PAGE gel (Figure 3.7 
B, lower panels) indicated that equal amounts of protein (MBP, rNR2A-CTD and hHCN1-
CTD) were present in the reaction, which were incubated in the presence or absence of 
PKC-zeta. Given that the rNR2A-CTD positive control was not phosphorylated and the 
results obtained in the C- and N1-Src kinase assays, no firm conclusions could be drawn 
from these data with regards to the ability of C- or N1-Src to phosphorylate hHCN1-CTD 
or rNR2A-CTD.      
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(A) Schematic diagram showing residues 1047-1464 of NR2A i.e. the 418 residue NR2A-
CTD. Three serine (S) residues (S1291, S1312 and S1416) phosphorylated within 
NR2A-CTD by PKC are labelled. (B) MBP (5 µM), rNR2A-CTD and hHCN1-CTD were 
incubated separately with PKC-zeta and γ-32P ATP at 30 °C for 3 h. Reactions (25 µl) 
were terminated by addition of 2X Laemmli buffer and the samples (30 μl) were subjected 
to SDS-PAGE. The 10 % gel was stained with Coomassie to visualise protein bands 
(lower panel) and was exposed to X-ray film for 24 h (upper panel). 
 
  
Figure 3.7: Neither Full Length rNR2A-CTD nor hHCN1-CTD were Phosphorylated 
by PKC-Zeta when Incubated with γ-32P ATP for 3 h. 
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3.2.7 Prospective N1-Src Substrates Identified Through a Peptide Substrate 
Screen. 
Given that the phosphorylation of rNR2A- and hHCN1-CTD was not observed in vitro, a 
different approach, utilising prospective substrates from the bioinformatics screen 
(described in Section 3.1) was adopted. The aim of this was to identify novel, putative 
N1-Src substrates, that contained the N1-Src SH3 binding consensus sequence 
described in Section 3.1. In the second half of this chapter, a phosphorylation screen of 
peptides whose sequences were selected from prospective substrates of interest and 
contained the N1-Src consensus motif, was performed.  
The phosphorylation of the prospective peptide substrates was compared with the 
phosphorylation of PD1, a positive control peptide that contained the N1-Src SH3 binding 
motif, as well as PD1-P5A, the negative control for PD1, in which a critical residue 
necessary for N1-Src SH3 binding is mutated to alanine (Figure 3.8). Like the ideal Src 
substrate peptide YA each of the peptides (PD1 and PD1-P5A) were expressed as GST 
fusions (Figure 3.8). The peptides comprised the ideal Src substrate (AEEEIYGEF), 
which contained a tyrosine (Y) residue that is phosphorylated by Src, followed by a short 
linker, and finally the SH3 domain binding motif (Figure 3.8). The latter sequence 
containing the SH3 binding motif varied between the prospective peptide substrates 
selected, but most adhered exactly to the established N1-Src consensus motif 
+XPXXT/AX+ (where + is a positively charged amino acid residue and X can be any 
residue, see Figure 3.8).  
Given that the phosphorylation of the prospective N1-Src peptide substrates was to be 
compared to the level of PD1 and PD1-P5A phosphorylation, firstly, the concentrations 
at which PD1 and PD1-P5A phosphorylation differed were established. Since both PD1 
and PD1-P5A contain the ideal Src substrate sequence, both GST-fusion peptides are 
phosphorylated regardless of the presence of the N1-Src SH3 binding motif, which was 
mutated in PD1-P5A. Therefore, it was necessary to determine a protein concentration 
at which PD1 phosphorylation by N1-Src exceeded PD1-P5A phosphorylation.  
Previous studies in the Evans lab have directly compared the phosphorylation of PD1 by 
N1-Src to that of YA; the GST-fusion peptide that encodes the ideal Src substrate linked 
to a mutated C-Src SH3 binding motif, which is similar to PD1-P5A. The Km for PD1 
phosphorylation was significantly lower than that of GST-YA, and it appeared that the 
greatest differences in phosphorylation occurred between the substrate concentrations 
of 1-25 µM. PD1-P5A was also shown to be phosphorylated poorly by N1-Src at a 
concentration of 8.3 µM compared to PD1, which was similar to GST-YA (Keenan, 2012). 
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The GST- fusion peptides created contained the ideal Src substrate, AEEEIYGEF (Y), 
which contains a tyrosine residue (purple) that can be phosphorylated by Src kinase 
domains. In PD1, Y was linked to the proposed consensus motif for optimal N1-Src SH3 
binding. The control for PD1 (PD1-P5A), contained a mutation in the fifth proline residue 
(underlined) of the PD1 consensus motif, which abolishes substrate docking to the N1-
Src SH3 domain. In the putative peptide substrates, Y was linked to peptides derived 
from prospective N1-Src substrates that contained the N1-Src SH3 consensus motif, and 
were predicted to be phosphorylated by Src. Residues critical to the consensus SH3 
binding motif are depicted in bold, positively charged residues are highlighted in red.   
 
 
 
 
 
 
 
 
 
  
Figure 3.8: GST-Fusion Peptide Substrates Contained the Proposed N1-Src SH3   
Binding Consensus Sequence Linked to the ‘Ideal Src Substrate’. 
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In this study, the in vitro phosphorylation of PD1-P5A and PD1 were compared at three 
different concentrations to confirm at which concentration the greatest difference in 
phosphorylation occurred. PD1 and PD1-P5A were incubated separately with N1-Src 
kinase and ATP at final concentrations of 1.7, 5 and 15 µM. A Coomassie stained SDS-
PAGE gel confirmed equal protein loading between the PD1 and PD1-P5A reactions 
(Figure 3.9). Western blot data of the same reactions indicated that neither PD1-P5A nor 
PD1 were phosphorylated at a concentration of 1.7 µM however, PD1 phosphorylation 
exceeded PD1-P5A phosphorylation at concentrations of 5 and 15 µM. The difference in 
phosphorylation levels between PD1-P5A and PD1 was greatest at 5 µM, therefore this 
concentration was carried forward for use in the peptide substrate screen. 
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A Western blot (W.B) and the corresponding Coomassie stained 15 % gel representing 
samples (5 µl) from N1-Src kinase assay reactions containing PD1-P5A and PD1. The 
substrates (1.7, 5 and 15 µM) were incubated in separate reactions with N1-Src (5 nM), 
ATP (0.5 mM) and MgCl2 (10 mM) in Tris pH 7.5 (100 mM) for 1.5 h at 30 °C. Reactions 
were terminated with 2 X Laemmli buffer. Tyrosine phosphorylation of the GST-fusion 
peptides was detected by Western blotting, using the primary antibody α-PY20 and α-
mouse HRP secondary. 
 
 
  
Figure 3.9: Differential Phosphorylation of PD1-P5A and PD1 was Observed at a 
Substrate Concentration of 5 µM. 
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Interesting putative N1-Src substrates that fitted the criteria of containing an N1-Src SH3 
domain binding motif, as well as being predicted to be tyrosine phosphorylated by Src, 
were selected for use in the peptide substrate screen (Table 3.1). Since N1-Src is highly 
expressed in the developing brain and has been implicated to play a role in neuronal 
development, differentiation and cytoskeletal dynamics (Kotani et al., 2007, Worley et 
al., 1997, Maness et al., 1988), the majority of the prospective substrates selected for 
analysis in the screen were linked to these processes.  
RACGAP1, ARHGAP1, KALRN, TRIO and ARHGAP5 are a mixture of Rho family 
GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) 
that regulate actin cytoskeletal dynamics, many of which play a role in neuronal 
development. Proteins such as ANK2 and RAF1, are linked to the L1-CAM and MAP 
kinase signalling pathways respectively, which regulate axon outgrowth, whereas NUMB 
regulates cell differentiation through inhibition of NOTCH signalling. Previous work in the 
Evans lab has established a link between L1-CAM mediated neurite outgrowth and N1-
Src; this will be discussed further in Chapter 4. Other selected targets such as M4K-1, 
SYNJ1 and AKAP2 and PTPN6 were identified as interesting potential N1-Src substrates 
that are involved in various signalling processes in the brain or in the latter case, in the 
regulation of Src itself. Finally, whilst the NMDAR subunit NR2A does not have a 
consensus motif that conforms exactly with the optimal N1-Src SH3 binding sequence, 
it has been shown to be phosphorylated by N1-Src (Groveman et al., 2011). It would 
therefore be interesting to determine whether the selected peptide enhances 
phosphorylation of the ideal Src substrate.  
Complimentary oligonucleotides that encoded the prospective N1-Src SH3 domain 
binding peptides were annealed and sub-cloned into pGEX-4T-1 by Dr Gareth Evans. 
Successful clones encoding the GST-fusion peptides P1-P13 (see Table 3.1) were 
transformed into BL21 E. coli cells. The proteins were expressed (Figure 3.10A) and 
batch purified using glutathione resin (Section 2.3.2). The concentrations of each protein 
were determined by Nanodrop and confirmed by the observation of equal loading of 1 ug 
of each protein on a Coomassie stained gel. Many of the GST-fusion peptides expressed 
(~31 kDa), including PD1 and PD1-P5A, appeared as doublet bands on the gel (Figure 
3.10B). These GST-fusion peptides were carried forward for use in in vitro N1-Src kinase 
assays.     
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Table 3.1: Prospective N1-Src Substrate Candidates that were Selected for the In 
Vitro Kinase Assay Screen. 
Residues representing the N1-Src SH3 domain binding motif are shown in bold, with 
positively charged residues highlighted in red. Each peptide (P) was given a number 
between 1 and 13. *The consensus motif in the NR2A peptide selected, did not adhere 
exactly to the proposed N1-Src SH3 binding sequence. 
  
Peptide 
Protein of 
origin 
Peptide 
Sequence 
Role 
P1 M4K-1 ETRPPANTARLQ 
Plays a role in cerebral ischemia, 
linked with Src (Li et al., 2008b). 
P2 ANK2 KEKGPILTQREA 
Links L1-CAM to the actin 
cytoskeleton during axon outgrowth 
(Whittard et al., 2006b). 
P3 NR2A IGRCPSDPYKHS* 
NMDA receptor subunit, reportedly 
phosphorylated by C- and N1-Src 
(Groveman et al., 2011, Lau and 
Huganir, 1995). 
P4 RAF1 QPKTPVPAQRER 
MAPKKK, plays a role in neuronal 
differentiation and axon outgrowth 
(Markus et al., 2002). 
P5 NUMB HRRTPSEADRWL 
Part of the notch signalling pathway, 
regulates in cell differentiation 
(Wakamatsu et al., 1999). 
P6 PTPN6 YLRQPYYATRVN 
Phosphatase involved in Src 
regulation and regulated by Src itself 
(Poole and Jones, 2005). 
P7 RACGAP1 NLKEPLLTFRLN 
Rac GAP, cell differentiation 
(Kitamura et al., 2001). 
P8 ARHGAP1 TQKSPATAPKPM 
Rho GAP, cytoskeletal remodelling 
(Clay and Halloran, 2013). 
P9 AKAP2 VKKNPGIAAKWW 
PKA anchoring protein that is 
enriched in the cerebellum 
(Wang et al., 2001b). 
P10 KALRN YSKIPLDTSRLA 
Rho GEF, dendritic morphogenesis.  
(Yan et al., 2014, Xie et al., 2010). 
P11 TRIO GPKRPGNTLRKW 
Rho GEF, neuronal development 
(Bateman and Van Vactor, 2001). 
P12 ARHGAP5 AAKIPDKTERLH 
Rho GAP, a known C-Src substrate 
important in the developing brain 
(Brouns et al., 2001). 
P13 SYNJ1 GARSPAPTRKEF 
Synaptic vesicle endocytosis  
(Slepnev and De Camilli, 2000). 
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Coomassie stained, 15 % SDS polyacrylamide gel showing (A) samples (2 µl) of 
uninduced (UI) and induced (I) BL21 E. coli cells expressing peptides P1-13 that were 
cultured at 37 ˚C for 3 h after IPTG induction. (B) Samples (1µg) of eluted GST-fusion 
peptides that were isolated from 0.3 L cultures of IPTG-induced BL21 E. coli cells and 
purified using glutathione resin. The proteins were eluted using glutathione elution buffer, 
and the concentrations were determined using a Nanodrop spectrophotometer.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Expression and Purification of GST-Fusion Peptides P1-P13. 
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The GST-fusion proteins PD1, PD1-P5A and substrates P1-13 (5 µM) were incubated 
with N1-Src in a kinase reaction (described in Section 2.3.10). The samples were 
distributed across two blots, both containing the samples PD1-P5A and PD1, however 
the first blot contained samples P1-7 and the second represented samples P8-13. A 
second set of identical protein gels were Coomassie stained, to control for the protein 
contents of the reactions.  
The Western blots presented in Figure 3.11A demonstrate the variability in 
phosphorylation of the GST-fusion peptides between three experimental relicates of the 
substrate phosphorylation screen. Whilst PD1 phosphorylation was obviously greater 
than PD1-P5A phosphorylation for two out of three experimental replicates, there 
appeared to be a large degree of variabilty between the differences in phosphorylation 
on blots within each experiment. In addition, in the case of replicate 2, the bands for PD1 
and PD1-P5A were very similar on the blot containing samples P1-7, but this was not 
reflected by the bands for the same samples present on the second blot. Upon first 
inspection, replicates 2 and 3 did not appear to produce results that were consistent with 
the first, or each other. However these observations did not take into account possible 
fluctutations in the protein contents of the reactions evidenced by the Coomasie stained 
protein gels (Figure 3.11A; lower panels) or the differences that would inevitably arise 
from the processing of different blot exposures.   
Figure 3.11B represents data that were obtained after performing densitometry on 
phosphorylated substrate bands (~31 kDa) present on the developed blots (Figure 
3.11A), using ImageJ. Since the blots produced within each replicate both contained 
bands for the PD1 positive control, to facilitate the comparison of substrate 
phosphorylation between blots, the densitometry values of one blot were adjusted 
according to the the scale factor obtained from dividing the lowest PD1 densitometry 
value by the highest. In addition, to account for potential differences in the amount 
substrate added per reaction, the densitometry bands obtained for each phosphorylated 
protein were divided by the densitometry values from the corresponding Coomassie 
stained GST-fusion peptide bands. Finally, to account for potential differences in the 
processing of blots and Coomassie gels between biological replicates, the values within 
each experiment were normalised to PD1. Differences between the data values obtained 
were assessed for significance using a one-way ANOVA.   
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(A) Western blots and their corresponding Coomassie stained gels (15 %) representing 
samples (5 µl) from N1-Src kinase assay reactions containing the GST-fusion peptide 
substrates PD1-P5A, PD1 and P1-13 (N=3). GST-fusion peptides (5 µM) were incubated 
with N1-Src (5 nM), ATP (0.5 mM) and MgCl2 (10 mM) in Tris pH 7.5 (100 mM) for 1.5 h 
at 30 °C. Reactions were terminated by the addition of 2X Laemmli buffer. Tyrosine 
phosphorylation of the substrates was detected by Western blotting using the primary 
antibody α-PY20 and α-mouse HRP secondary. (B) In ImageJ, substrate 
phosphorylation was quantified after performing densitometry blots obtained from 3 
independent experiments. Within individual replicates, densitometry values were 
adjusted to account for different PD1 values between blots and the quantity of substrate 
added to each reaction. The resulting values obtained for each experiment were 
normalised to the values for PD1. Statistical significance was assessed using a one-way 
ANOVA. 
  
Figure 3.11: Assessment of the Tyrosine Phosphorylation of Putative N1-Src GST-
Fusion Peptide Substrates by Western Blotting 
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Densitometry analysis (Figure 3.11B) revealed that whilst the peptide substrates P1-13 
appeared to be phosphorylated by N1-Src at comparable or greater levels than PD1, no 
significant differences between the phosphorylation levels of P1-P13, PD1 or PD1-P5A 
were observed. However, the error bars, particularly for substrates P1-7, re-affirmed 
previous observations regarding the reproducibility of the results between replicates. In 
order for candidate N1-Src substrates to be identified in the future, this assay must be 
optimised, to reduce the degree of variability between replicates.   
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3.3 Discussion 
3.3.1 A Lack of In Vitro Phosphorylation of rNR2A-CTD and hHCN1-CTD by C- 
and N1-Src. 
The primary aim of this chapter was to determine whether the human HCN1-CTD was 
phosphorylated by N1-Src and to identify the critical residues required for this process. 
The second aim was to compare C- and N1-Src phosphorylation of the rNR2A-CTD, with 
a view to pinpointing the phosphorylated residues using mass spectrometry and site 
directed mutagenesis.  
However, after performing in vitro kinase assays with both the hHCN1- and rNR2A-
CTDs, phosphorylation of both of these proteins could not be detected by either Western 
blotting or autoradiography. This was particularly surprising in the case of the rNR2A-
CTD, which was a positive control for the experiment. In addition, phosphorylation of the 
rNR2A-CTD by PKC-zeta was not observed, despite this modification being reported 
previously (Gardoni et al., 2001a, Leonard and Hell, 1997). This suggested that there 
was a technical problem with the assay used. There are multiple aspects of the 
experiments performed that could have affected the outcome, which will be discussed 
below.   
Firstly, there is a possibility that there was a problem with the recombinant hHCN1- and 
rNR2A-CTD proteins, which could have contributed to the negative result of the kinase 
assays. However, measures were taken to ensure that the recombinant proteins used 
were comparable to those produced in similar studies. Prior to the expression of the 
proteins, the nucleotide sequence of both the hHCN1-CTD and the rNR2A-CTD were 
cloned into pGEX-6P-1 (or 4T-1, depending on the method used) and the construct 
sequences were verified. This provided confidence that the proteins expressed were the 
correct proteins, which had no mutations that could affect protein folding or function. In 
addition to this, mass spectrometry was used to confirm the identity of the proteins. The 
masses of the Coomassie stained GST-tagged proteins corresponded to the expected 
masses of GST-hHCN1- and GST-rNR2A-CTD, which were 80.5 and 69.2 kDa 
respectively. Whilst the coomassie stained GST-cleaved hHCN1-CTD band appeared at 
the correct mass, that of rNR2A ran slightly higher than expected. However, attempts to 
identify the exact mass of the protein were unsuccessful due to technical issues. Despite 
this, it is not uncommon for proteins to run at a slightly different mass than expected, and 
since the GST-rNR2A-CTD appeared to be the correct molecular weight, and a 
Coomassie stained GST band (26.4 kDa) was observed in the GST-rNR2A-CTD 
cleavage reaction (data not shown), it was unlikely that this was a cause for concern.  
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Notably, the recombinant GST-fusion proteins expressed both contained a ladder of 
contaminants that were visible on a Coomassie stained gel and were likely a result of 
protein degradation. It was thought that this could have been due to the fact that 
mammalian proteins were being expressed in a bacterial system, in which some 
mammalian codons are rarely used and therefore the correct tRNAs are lacking. As a 
result, protein translation can be affected. This was primarily tackled by expressing the 
proteins in E. coli strains containing plasmids that encoded tRNAs for some of the codons 
that are rarely used in bacterial protein translation. However, this did not eradicate 
protein truncation/degradation. In future, codon optimisation of the nucleotide sequences 
could be performed to replace rare codons with those that are commonplace in bacteria 
with the aim of improving protein translation, however double stranded DNA synthesis is 
costly, and might not resolve the problem of degradation.  
Altering the bacterial lysis method from sonication to using a French press appeared to 
have a mild effect on GST-hHCN1-CTD degradation, yet the greatest effects were 
observed when the proteins were cleaved from their GST tags. Whilst this did not totally 
diminish protein degradation, it appeared to be largely reduced. Despite this, improving 
the purity of the protein expressed had no effect on the outcome of the phosphorylation 
reactions performed.  
Whilst there was a possibility that the degradation products had inhibited the kinase 
reactions, studies in the literature, in which GST-HCN-CTDs have been shown to be 
phosphorylated, have used recombinant proteins that had a similar pattern of breakdown 
products. For example, recombinant HCN2- and HCN4-CTDs were shown to be 
phosphorylated by in vitro C-Src and PKA respectively and suffered a comparable 
degree of protein degradation (Zong et al., 2005, Liao et al., 2010). In addition, (Santoro 
et al., 2004) successfully showed an interaction between the HCN1-CTD and Trip8b, 
irrespective of the degradation products in the protein preparation. In all of these studies, 
the purification of GST-HCN-CTDs was performed using glutathione resin, the method 
that was adopted in this study. Furthermore, whilst the in vitro phosphorylation of the 
NR2A-CTD by C-Src was not shown using recombinant proteins, a smaller portion of the 
GST-NR2A-CTD (residues 1244-1464) including degradation products, was shown to be 
phosphorylated by α-CAMKII (Gardoni et al., 2001a, Gardoni et al., 2001b). The results 
from these studies suggested that the presence of protein degradation products affected 
neither protein phosphorylation nor protein-protein interactions.  
The activity of the recombinant Src kinases used in these experiments was confirmed by 
the successful phosphorylation of the ideal Src substrate (GST-YA). The recombinant 
kinases, which are routinely used in the Evans lab for in vitro kinase assays, have also 
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been shown to phosphorylate synaptophysin (C-, N1- and N2-Src) and the N-terminal 
domains of Mint1, 2 and 3 (C-Src only) (Keenan et al., 2015, Dunning et al., 2016). In 
addition to this, the kinase activity of PKC-zeta was demonstrated by phosphorylating 
the positive control, MBP. Thus, there is considerable evidence suggesting the kinases 
used, were capable of phosphorylating both hHCN1- and rNR2A-CTDs.  
The composition of the kinase assays used in this study, including the buffer used 
(100 Mm Tris pH 7.5) and concentration of the co-factors ATP (0.5 mM) and MgCl2 
(10 mM), had been used in previous studies in the Evans lab (Keenan et al., 2015). 
These conditions were also similar to those used by (Zong et al., 2005) in the 
phosphorylation of the HCN2-CTD by C-Src, however, the reactions also included 
1 mM DTT and 200 µM pervanadate, the latter of which is a phosphatase inhibitor. In 
addition, the kinase reactions were performed using GST-HCN2-CTD that remained 
bound to glutathione resin (beads). However, incorporation of these changes into the 
experiments performed had no effect on the outcome of the GST-rNR2A- and GST-
hHCN1-CTD phosphorylation assays. Increasing the sensitivity of the assay by 
incubating the substrates with γ-32P ATP also had no effect on the result. One possibility 
could be that the buffer in which the reactions were performed, negatively affected the 
reaction outcome. To test this, different buffers that are also commonly used for kinases 
assays, such as HEPES, MOPS or MES, could be trialled.  
Two different methods were used to detect protein phosphorylation in the studies in this 
chapter. In the first instance, protein phosphorylation was detected via Western Blotting, 
using a phospho-tyrosine specific primary antibody. This method was adopted since it 
provides a relatively simple and safe way of achieving selectivity and sensitivity. 
However, even though the phosphorylation of the YA positive control was achieved, 
phosphorylation of both the hHCN1- and rNR2A-CTDs was not detected using this 
technique. Therefore, with the aim of increasing the sensitivity of the phosphorylation 
detection method, a 32P kinase assay was designed. Using this method, phosphorylated 
proteins were radiolabelled with 32P and protein phosphorylation was directly detected 
using autoradiography. Therefore, the detection of protein phosphorylation did not rely 
upon a multi-step method involving different antibody incubations, unlike Western 
Blotting. This eradicated potential issues that may arise with Western Blotting, such as 
poor specificity of the phospho-tyrosine primary antibody, which may differ from protein 
to protein. However, after performing 32P kinase assays with both hHCN1- and rNR2A-
CTD, their phosphorylation was undetected by autoradiography. In addition to this, the 
phosphorylation of the YA positive control did not exceed and was in some cases lower 
than the signal that was generated via the Western Blotting of similar control samples. 
This suggested that this technique did not provide superior sensitivity in the detection of 
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protein phosphorylation. This could have been because the incorporation of radiolabelled 
phosphate into the substrate was too low, which could be addressed by increasing the 
concentration of radiolabelled ATP in the reaction. In addition to this, the sensitivity of 
the autoradiography detection method could be enhanced by using a phosphorescent 
intensifying screen. The β-particles emitted by 32P can sometimes pass through X-Ray 
film without activating the silver halide crystals inside the film, which is required for 
detection. When a phosphorescent intensifying screen is irradiated by one of these 
particles, it releases light which in turn activates the crystals in the film, enhancing the 
sensitivity of the assay.  
Other methods that have been used in the phosphorylation of the NR2- and HCN-CTDs 
include ELISA and the immunoprecipitation of the full length ion channel subunits from 
heterologous or primary neuronal cells that were either co-expressing a kinase, or 
incubated with a kinase post-extraction. In studies by Yang and Leonard (2001), 
phosphorylated NR2A was immunoprecipitated from HEK293 cells that co-expressed V-
Src with both the NR2A and NR1 subunits of the NMDAR or NR2A alone. In addition, 
phosphorylation of the NR2A subunit by PKC has been demonstrated with NMDARs that 
were solubilised from rat brains and subsequently incubated with PKC in vitro (Leonard 
and Hell, 1997). Multiple other studies involving the phosphorylation of the NR2-CTDs 
have also used similar approaches with multiple kinases (Lau and Huganir, 1995, 
Nakazawa et al., 2001). Groveman et al., (2011), used an alternative method to 
demonstrate the tyrosine phosphorylation of the NR2A-CTD by N1-Src. An ELISA-based 
assay was used, whereby N1-Src was incubated with Mg2+, Mn2+ and ATP in NR2A-CTD 
coated wells. Phosphorylation of the protein was detected using a HRP-conjugated 
phosphotyrosine antibody and was shown to increase steadily over a period of 1 h. There 
is a possibility that this observation could have been a false positive, however, given the 
precedence for Src phosphorylation of the NR2A subunit and the fact that N1-Src was 
also shown to bind to the NR2A-CTD, this is unlikely.   
To conclude, the experiments performed in this chapter were unable to report a definitive 
outcome with regard to whether the hHCN1-CTD is a substrate of N1-Src. Despite the 
fact that hHCN1-CTD was not reported, the lack of phosphorylation of the rNR2A-CTD, 
which has been shown to be phosphorylated by both C- and N1-Src, meant that firm 
conclusions could not be derived. Whilst it seems unlikely that the substrate degradation 
products, kinase activity or reaction buffer contents were the root cause of the problem 
given the evidence presented from the literature, it is possible that there was an issue 
regarding the correct folding of the protein substrates. 
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To determine whether the proteins are folded correctly, a technique called circular 
dichroism (CD) could be used to derive information regarding the secondary structures 
of both the hHCN1- and rNR2A-CTDs. The basis of the technique is dependent upon the 
differential absorption of left and right circularly polarised light by chromophores that 
possess intrinsic chirality. The CD spectra for peptide bond absorption in the proteins of 
interest, can provide information regarding the proportion of α-helices, β-pleated sheets 
and β-turns, which make up the secondary structures of the proteins.    
In addition to the use of CD, a functional assay could be used to ensure that the proteins 
are correctly folded. For example, the cyclic nucleotide binding domain in the HCN1-
CTD, is known to bind cyclic adenosine monophosphate (cAMP), which facilitates the 
voltage-dependent activation of the HCN1 channel (Biel, 2009). A binding assay with the 
recombinantly expressed hHCN1-CTD and cAMP- conjugated resin could be performed 
to establish whether the hHCN1-CTD is folded properly. Similarly, the NR2A-CTD has 
multiple known binding partners, including members of the PSD-95/SAP-97 family, which 
bind via there PDZ domains to the C-terminal tail of the NR2A-CTD (Niethammer et al., 
1996). Such interactions could be exploited in a pull-down assay, to determine whether 
the recombinantly expressed rNR2A-CTD is functional and folded correctly. 
Moving forward from these studies, there are multiple avenues that could be explored in 
order to try to further optimise the kinase assays, with the aim of achieving rNR2A-CTD 
phosphorylation by C-, N1-Src and PKC, such as codon optimizing the DNA sequence 
of the substrates or trialling multiple reaction buffers. However, after taking into account 
the financial and time costs, it might be more productive to perform these 
phosphorylation studies by overexpressing the CTDs or full length channel subunits with 
C- or N1-Src in heterologous cells, and subsequently immunoprecipitating the tyrosine 
phosphorylated substrates.  
3.3.2 The Design of an In Vitro Kinase Assay Peptide Substrate Screen to Identify 
Putative Novel N1-Src Peptides. 
In the second part of this chapter, the aim was to design an in vitro kinase assay screen 
to test the ability of peptides selected from putative N1-Src substrates, which contained 
the N1-Src SH3 binding motif, to enhance the phosphorylation of the ideal Src substrate. 
Interesting N1-Src substrate candidates that were identified in a bioinformatics study, 
were selected based on the fact that they were linked to processes in which N1-Src is 
predicted to play a role (e.g. the regulation of cytoskeletal dynamics during neuronal 
development; Table 3.1).  
The GST-fusion peptides PD1-P5A, PD1 and P1-13 were successfully expressed and 
purified (Figure 5.10). Although, many of the purified GST-fusion peptides appeared as 
 
 
102 
 
doublet or in some cases triplet bands on coomassie stained proteins gels. There are 
several reasons that may have contributed to this observation. For example, contaminant 
protease activity or poor protein stability may have led to the breakdown of the proteins.   
To facilitate the comparison of the phosphorylation of the different GST-fusion peptides 
P1-P13 with respect to the positive (PD1) and negative (PD1-P5A) controls, a 
concentration at which the phosphorylation of PD1 exceeded that of PD1-P5A was 
determined (µM) and carried forward for use in the N1-Src substrate screen (Figure 3.9). 
This result was in accordance with a previous result in the Evans lab whereby PD1-P5A 
was shown to be phosphorylated poorly by N1-Src at a concentration of 8.3 µM when 
compared to PD1. Therefore, an N1-Src substrate screen that compared the 
phosphorylation of P1-13, to that of both PD1 and PD1-P5A was performed at the 
selected concentration, to identify potential N1-Src substrates based on the ability of their 
corresponding predicted N1-Src SH3 binding motif peptides to enhance the 
phosphorylation of the ideal Src substrate.  
The outcome of the experiments performed were inconclusive due to the variability that 
occurred within and between expreimental replicates (Figures 3.11A and B). 
Phosphorylation of the positive control PD1 was notably greater than PD1-P5A 
phosphorylation for two out of three experimental replicates, however there was a 
noticable degree of variabilty between the differences in phosphorylation on blots within 
each experiment. Within replicate two, the bands for PD1 and PD1-P5A were very similar 
on the blot containing samples P1-7 but this was not the case in the second blot ( P1-8), 
since PD1 phosphorylation exceeded that of PD1-P5A. The densitometry analysis 
(Figure 3.11B) that compared the phosphorylation of P1-13 to PD1 and PD1-P5A 
revealed that the degree of error between the experimental replicates was large, 
particularly for samples P1-7 and no statistically significant differences were observed.   
The degree of variabilty observed, could have been linked to human error or due to 
issues that occurred during Western blotting, such as uneven transfer. Performing the in 
vitro kinase assays with γ-32P ATP would prevent any error caused by an uneven 
transfer, since autoradiography could be used to detect peptide phosphorylation.  
Alternatively, in place of using GST-fusion peptides, the phosphorylation of synthesised 
peptides lacking the GST tag could be compared in an in vitro kinase assay with γ-32P 
ATP. In this assay, the capture of positively charged phosphopeptides that are pre-
treated with phosphoric acid are captured by negatively charged phosphocellulose 
paper, which can subsequently be subjected to Cerenkov counting. This method was 
published by Hastie et al (2006) and is also commonly used to determine the kinetics of 
protein kinase reactions. If this assay can be appropriately optimised, for promising 
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substrate candidates, the kinetics of peptide phosphorylation could be compared to those 
for PD1 phosphorylation to determine whether the substrates are worth pursuing in 
further studies. 
It should also be noted that the use of phospho-specific antibodies makes the 
quantification of phosphorylated protein more difficult. This is because it is unlikely that 
all phosphorylated substrates will be labelled by the antibody and blotting must take 
place within the linear dynamic range of detection to ensure optimal quantification. These 
issues could be overcome using radioactive labelling, since a Cerenkov counter could 
be used to detect and quantify every radio-labelled protein within the samples.  
3.3.3 Alternative Methods for Discovering Novel N1-Src Substrates. 
Once optimised, the peptide screen described in this chapter could provide valuable 
information regarding the discovery of novel N1-Src substrates, however the technique 
presented is relatively low throughput. An alternative in vitro approach that has been 
published by the Schweitzer and Snyder laboratories, would involve the use of a protein 
microarray to screen hundreds of proteins simultaneously for phosphorylation by the 
kinase of interest (i.e. N1-Src; (Meng et al., 2008, Mok et al., 2009)). This would involve 
incubating immobilised functional proteins in solution with recombinant active N1-Src 
kinase and radiolabelled ATP, which could be subsequently analysed by 
autoradiography to reveal novel substrates. The main drawback of this method, aside 
from expense, is that identified targets would then need to be validated in vivo. 
An additional method, that is more frequently used to identify protein kinase substrates, 
is called phosphoproteomics (see Roux and Thibault, 2013 for a comprehensive review 
of methods). Phosphoproteomics generally requires two major steps: 1) the enrichment 
of phospho-proteins or -peptides from cellular extracts, which are 2) analysed using 
tandem-mass spectrometry (MS/MS). The data obtained from the MS/MS is used to 
identify the phosphorylated proteins (i.e. kinase substrates) from large peptide 
databases. The advantages of this method, are that it can be used to identify substrates 
from cultured cells and tissue samples, therefore the substrates that are identified are 
more likely to be physiologically relevant. However, in order to produce optimal results, 
large amounts of material are required and low abundance phospho-sites are often 
undetected. In addition to this, phosphoproteomics does not distinguish between 
proteins that are phosphorylated directly or indirectly by the kinase.  
Kevin Shokat’s laboratory developed a novel technique for identifying direct kinase 
substrates using a protein engineering based method (e.g. Blethrow et al., 2008, 
Ubersax et al., 2003). The technique involves mutating a residue in the ATP-binding 
pocket of the kinase of interest, in a manner that favours the binding of a radio-labelled 
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ATP analogue ([γ-32P]-N6-cyclopentyl-ATP), without compromising catalytic activity. The 
resultant kinase is then incubated with cellular lysates, in the presence of the ATP 
analogue, which results in the radiolabelling of target substrates that can subsequently 
be identified by MS (Blethrow et al., 2008, Ubersax et al., 2003). This approach has been 
used to successfully engineer mutants of both V-Src (Shah et al., 1997) and Fyn (Liu et 
al., 1998). It could therefore likely likely be adopted for N1-Src, since V-Src, Fyn and N1-
Src kinases share a conserved catalytic kinase domain. The main disadvantage of this 
method relates to the physiological relevance of the substrates identified, although this 
could be confirmed in vivo once the initial experiment has been completed. 
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Chapter 4. The Role of N1-Src in Neuronal Development 
4.1 Introduction 
Many of the putative N1-Src substrates that were screened in Chapter 3 had previously 
been implicated in neuronal morphogenesis. Whilst further method development will be 
required to validate the putative N1-Src substrates from Chapter 3, limited studies in the 
literature have also linked N1-Src with neuronal development (Wiestler and Walter, 1988, 
Kotani et al., 2007, Worley et al., 1997). Chapter 4 will therefore focus on determining 
the functional effects of N1-Src during neuronal morphogenesis.  
4.1.1 N1-Src and Neuronal Development. 
Both the existing literature concerning N1-Src (discussed in Section 1.5.1-2) and 
previous work in the Evans lab link N1-Src function to neuronal development. N1-Src 
expression is elevated above C-Src levels in mouse brain lysates during early 
development, from embryonic day nine onwards (Wiestler and Walter, 1988) and 
conflicting studies have shown that overexpression of N1-Src alters the morphology of 
several types of neurons after plating (Worley et al., 1997, Kotani et al., 2007). Kotani et 
al., (2007) found that in transgenic mice overexpressing constitutively active N1-Src, 
aberrant dendritic morphology occurred in Purkinje neurons and this was less apparent 
in mice overexpressing the non-mutated (less active) N1-Src. In contrast, Worley et al., 
(1997) discovered that in Xenopus ventral forebrain neurons, N1-Src overexpression 
increased the length of the longest neurite. However, the same study showed that retinal 
ganglion cells were unaffected by N1-Src overexpression, yet constitutively active N1-
Src stunted axonal outgrowth.  
Studies in the Evans lab, which utilised a novel putative peptide inhibitor of N1-Src found 
that axon number, length and the number of branches per axon decreased in cerebellar 
granule neurons (CGNs), whereas total neurite length, number of branches per axon and 
average branch length were reduced in hippocampal neurons (Keenan, 2012). Taken 
together these findings suggest that N1-Src may play different roles in different subsets 
of neurons.   
4.1.2 The Role of N1-Src in L1-CAM Mediated Neurite Outgrowth. 
A role for Src in L1-CAM-mediated neurite outgrowth was previously described by Ignelzi 
and colleagues using Src-/- mice, which did not discriminate between specific isoforms. 
A possible role for N1-Src in axonal outgrowth in relation to L1CAM signalling was 
demonstrated in the Evans lab. Cerebellar granule neurons cultured on L1-CAM had 
reduced axonogenesis and reduced axon length in the presence of a selective N1-Src 
inhibitor (Keenan, 2012). Also, 6 potential N1-Src targets have been identified, using 
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bioinformatics (described in Section 3.1.) that are involved in L1CAM signalling, including 
ankyrin B, which anchors L1CAM to the cytoskeleton, modulating L1CAM dependent 
cytoskeletal remodelling (Keenan, 2012). 
4.1.3 Using Rodent Model Systems for Studying the Effects of N1-Src on 
Neuronal Morphology. 
The N1-Src 18 bp mini-exon is conserved in rodents (Martinez et al., 1987, Cartwright et 
al., 1987), thus mouse and rat models provide useful mammalian tools for investigating 
the functions of neuronal Src. The primary cell culture of multiple types of neurons 
derived from juvenile rodent brain tissue has been well documented and is widely used 
experimentally (e.g. (Costa et al., 2016, Smothers et al., 2016, Winkle et al., 2016). In 
this study, hippocampal neurons were used to dissect the role of N1-Src during neuronal 
morphogenesis for two reasons. Firstly, N1-Src expression has previously been detected 
in hippocampal tissue, therefore manipulations of this experimental system are 
physiologically relevant (Sugrue et al., 1990). This also enables the endogenous 
expression of N1-Src to be targeted by RNA silencing methods. Secondly, hippocampal 
neurons develop a more complex neuronal morphology in culture, compared to some 
other commonly utilised cell types such as CGNs. Hippocampal neurons exhibit 
branched neurites; therefore, more complex information can be derived from 
morphological studies.  
When cultured in vitro, hippocampal neurons undergo a well characterised series of 
morphological changes, which ultimately result in polarised mature neurons (Figure 4.1). 
Upon plating, the neurons are spherical in shape, with a lamellipodium surrounding the 
periphery of the cell (Figure 4.1; stage 1). At stage two, the cells extend multiple short 
neurites, which undergo cycles of extension and retraction until one of the neurites 
begins to grow rapidly during stage 3. This neurite will eventually become the axon. After 
this stage, the remaining shorter neurites develop into dendrites (stage 4) and after 
approximately one week in culture, the functional polarisation of the axon and dendrites 
occurs and synapses are created (Dotti et al., 1988, Tahirovic and Bradke, 2009). In the 
majority of the neuronal experiments performed in this chapter, the cells were fixed 2 
days post transfection (DPT), approximately stage 4 of the polarisation process, 
therefore the effects of N1-Src on the early stages of neuronal morphogenesis could be 
assessed. 
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Adapted from (Baj et al., 2014) and (Tahirovic and Bradke, 2009). In culture, hippocampal neurons follow a distinct pattern of development (Dotti et al., 
1988). Upon plating, the rounded cells extend lamellipodia from the cell periphery (stage 1). After 0.5-1 days (d) in culture, several dynamic minor 
processes protrude from the cell body (stage 2), one of which, later (1-2 d) begins to rapidly elongate; this process will become the future axon (stage 
3). At stage 4, the shorter processes grow and develop into dendrites, after which the cells continue to mature and create synaptic connections with 
other neurons (stages 5-6).
Figure 4.1: The Neuronal Polarization of Rat Hippocampal Neurons in Culture (Dotti’s Classification System). 
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4.1.4 Aims 
The ability to specifically knockdown the neuronal splice variants of C-Src has not 
previously been achieved and in the literature, only overexpression studies have been 
reported, delivering conflicting results (Kotani et al., 2007 and Worley et al., 1997). 
Therefore, there are gaps in the field relating to the specific role of N1-Src. This study 
aimed to resolve this controversy by performing both the overexpression and knockdown 
of N1-Src in the same neuronal model (rat hippocampal neurons).  
Ignelzi et al. (1997) demonstrated that Src was required for L1-CAM mediated neurite 
outgrowth, however the specific isoform of Src (C-/N1-/N2-Src) involved was unclear. 
Previous work in the Evans lab suggested a link between N1-Src and L1-CAM-mediated 
neurite outgrowth in CGNs, but whether L1-CAM homophilic or heterophilic interactions 
were involved in the pathway was not investigated. Further experiments were performed 
using a fibroblast model, to determine whether N1-Src mediates process extension via 
L1-CAM homophilic or heterophilic interactions. 
4.2 Results  
4.2.1 Measuring the Morphological Parameters of Rat Hippocampal Neurons. 
In order to quantify changes in neuronal morphology, the NeuronJ plugin for the image 
analysis software ImageJ was used throughout this chapter. NeuronJ provides a semi-
automatic method for tracing neurons in captured microscope images, and facilitates the 
labelling and measurement of different neuronal features including neurites, primary, 
secondary and tertiary branches (Figure 4.2A).  
In this study, the overexpression and shRNA knockdown of N1-Src were performed in 
neurons dissociated from the hippocampi of new-born Wistar rats that were transfected 
after 1 day in vitro (DIV) and fixed and imaged after 2 DPT. Therefore, the effects of N1-
Src on the initial processes of neurite outgrowth could be analysed. At this stage in 
development (stage 4), the major process that will form the axon has begun to grow 
rapidly and outgrowth of the remaining ‘minor’ processes that will form the dendrites has 
also started. Despite this, at this stage the molecular distinction between the axon and 
dendrites can only be determined for approximately 70 % of cultured neurons (Baj et al., 
2014). For this reason, the parameters measured in these studies describe neuronal 
morphology in terms of neurites, for example total length of neurites and length of longest 
neurite (Figure 4.2B). Since, the mechanisms governing neurite branching are different 
to those for neurite outgrowth (Gallo, 2011), parameters describing the primary, 
secondary and tertiary branching of neurites were also measured (Figure 4.2B).  
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(A) An example of a neuronal tracing drawn over a 5 DIV hippocampal neuron that was 
transfected with pSuper after 1 DIV. Tracings were drawn using the NeuronJ plugin for 
ImageJ. Different features of the neurons including neurites (green) and primary (red), 
secondary (purple) and tertiary (yellow) branches are highlighted. (B) Schematics of the 
different combinations of tracings that were used to calculate parameters, which describe 
multiple morphological features of the neurons in vitro. 
Figure 4.2: Schematic Diagram Depicting the Method of Hippocampal 
Neuronal Morphology Analysis Using NeuronJ. 
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From the raw neuronal morphology data, it was apparent that there was significant 
variation between the data values obtained for different rat hippocampal neuron 
preparations. This might be attributable to the fact that neurons from each biological 
replicate were cultured from the dissociated hippocampi of individual rat litters that 
descended from different parents. Therefore, it is feasible that natural variation between 
rat litters was responsible for the differences observed between cultures. Alternatively, 
there is a possibility that a variation in the conditions, in which the experiments were 
performed is accountable for the results observed, given that each biological replicate 
was completed independently on different days.  
Figure 4.3 gives an example of control data, where neurons were transfected with the 
empty vector pSuper-CFP and the average total length of neurites per cell was 
measured. In this example, there was a significant difference in mean total neurite length 
occurring between replicates 1-3 and replicate 4 (Figure 4.3A). This is reflected in the 
frequency distribution plot, where there is a shift towards shorter total neurite lengths for 
replicate 4 (Figure 4.3B). To account for these inherent differences between cultures, the 
values for each treatment were normalised to the average control value for each 
parameter.  
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Rat hippocampal neurons (1DIV) were transfected with pSuper-CFP (control) for 48 h 
and processed for immunofluorescence. Using a Zeiss slide scanner, images of four 
whole coverslips were captured per condition from which 30 images of individual neurons 
were randomly selected. In ImageJ, the NeuronJ plugin was used to trace and measure 
neurites. The mean values (A) and frequency distribution (B) of the total length of 
neurites are presented. 
  
Figure 4.3: The Length of Rat Hippocampal Neurons Varied Between 
Cultures. 
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4.2.2 N1-Src Overexpression in Hippocampal Neurons Leads to Aberrant 
Neuronal Morphology.  
Previous studies characterising N1-Src overexpression in vivo have produced conflicting 
results with regards to the function of N1-Src (Section 4.1.1). In addition to this, 
overexpression of N1-Src in Xenopus epithelial cells (Worley et al., 1997) as well as the 
monkey fibroblast cell line COS7 (Keenan, 2012, Lewis, 2014) leads to the formation of 
neurite-like processes, suggesting N1-Src facilitates process extension. To begin 
characterising the role of N1-Src in the neuronal morphogenesis of rat hippocampal 
neurons, N1-Src-mCherry was overexpressed. N1-Src and C-Src overexpression were 
compared to determine the functional differences, if any, between the kinases. 
To analyse the neuronal morphology of the pmCherry, C- or N1-Src-mCherry transfected 
cells (Figure 4.4), neurites were traced and measured in NeuronJ (as described in 
Section 4.2.1) and the average number of neurites, total length of neurites and length of 
longest neurite per cell were analysed for three biological replicates (Figure 4.5).  
Hippocampal neurons overexpressing N1-Src displayed aberrant neuronal morphology 
when compared to control and C-Src overexpressing neurons, with the majority of 
neurons appearing smaller and underdeveloped (Figure 4.4). In contrast, neurons 
overexpressing C-Src were similar to control neurons, if not larger. These findings were 
supported by the quantification of neurite lengths (Figure 4.5). The mean number of 
neurites was significantly reduced in N1-Src overexpressing neurons compared control 
cells (p=0.032 *, Figure 4.5A). In addition, there was a marked significant decrease in 
the mean total length of neurites (p= <0.001 ***, Figure 4.5C) and the length of the 
longest neurite (p= <0.001 ***, Figure 4.5E) in N1- Src overexpressing neurons 
compared to control cells. These data were also depicted in frequency plots, which 
clearly showed that the distribution of values for mean total neurite length and length of 
longest neurite particularly, were shifted towards lower values (left) for N1-Src 
expressing cells (Figure 4.5 B, D and F.)   
In comparison to control cells, C-Src overexpression resulted in elevated values for all 
the parameters measured, however these differences were not significant (Figure 4.5 
A,C and E). These results were reflected in the frequency plots, where C-Src curves 
were slightly shifted to the right (Figure 4.5 B, D and F). However, the decrease in 
average number of neurites, total length of neurites and length of longest neurite in N1-
Src overexpressing cells compared to C-Src were highly significant (p <0.001 *** for all 
parameters), indicating that C- and N1-Src have hugely different effects when 
overexpressed in hippocampal neurons.  
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Representative images from an N = 3 experiment, displaying the effects of the 
overexpression of C-Src- and N1-Src-mCherry on cell morphology in comparison to the 
empty vector control (pmCherry). 1 DIV rat hippocampal neurons were transfected for 
48 h and processed for immunofluorescence. Using a fluorescence microscope, 25-30 
images were captured per condition across 3 coverslips. The Stitching plugin for ImageJ 
was used to overlay multiple images taken of the same neuron. The expression of 
mCherry and mCherry-Src kinases are displayed in green. N=3, scale bar = 50 µm. 
  
Figure 4.4: Overexpression of N1-Src-mCherry in Hippocampal Neurons Resulted 
in Aberrant Neuronal Morphology. 
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1 DIV rat hippocampal neurons were transfected with empty pmCherry (control), C-Src-
mCherry or N1-Src-mCherry for 48 h and processed for immunofluorescence. Using a 
fluorescence microscope, 26-30 images were captured per condition across 3 
coverslips. In ImageJ, the NeuronJ plugin was used to trace and measure neurites. The 
mean values and frequency distribution were assessed for the following parameters: the 
number of neurites (A, B), total length of neurites (C, D), and length of longest neurite 
(E, F). C-Src and N1-Src data were normalised to the mean value of the control for each 
replicate. The experiment was performed 3 times and statistical significance of the 
pooled data (n=84-88) was assessed in SPSS (*p<0.05, ***p<0.001). Control n=88, C-
Src n=87, N1-Src n=84. 
Figure 4.5: N1-Src-mCherry Overexpression in Hippocampal Neurons Resulted in 
Aberrant Neurite Outgrowth. 
 
 
116 
 
4.2.3 N1-Src Overexpression Affects the Development of Cultured Rat 
Hippocampal Neurons. 
After analysing the morphology of the neurons overexpressing mCherry, C-Src- and N1-
Src-mCherry, there were apparent differences in the developmental stages of the 
transfected neurons between conditions. Therefore, using Dotti’s classification system, 
depicted in Figure 4.1, the developmental stages of the neurons were determined. The 
percentage of cells at stages 1, 2 or 3 and above was calculated for each condition and 
the statistical significance between the values obtained for each developmental stage 
was determined using a one-way ANOVA, followed by a post-hoc Tukey’s test (Figure 
4.6).  
The analysis revealed that 100 % of the control and C-Src-mCherry expressing cells 
were at stage 3 or above. This meant that the cells had at least reached the stage at 
which the rapid elongation of one of the ‘minor neurites’ (the future axon) had begun. 
However, in N1-Src-mCherry transfected cells, there was a significant decrease (35 %) 
in the number of cells at stage 3 or above in comparison to Control and C-Src-mCherry 
transfected cells which corresponded to a significant increase (31 %) in the percentage 
of cells that were at stage 2 (minor processes only). These data implied that the 
overexpression of N1-Src in hippocampal neurons had a marked effect on 
developmental progression.  
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1 DIV rat hippocampal neurons were transfected for 48 h with pmcherry (Control), p-C-
Src-mcherry (C-Src) and p-N1-Src-mcherry (N1-Src), fixed and processed for 
immunofluorescence. Using a fluorescence microscope, 25-30 images were captured 
per condition across 3 coverslips. The Stitching plugin for ImageJ was used to overlay 
multiple images taken of the same neuron. The developmental stage of the neurons was 
determined using Dotti’s classification system (Dotti et al., 1988). N=3, n=25-30, 
**p=<0.01, ***p=<0.001. 
  
Figure 4.6: The Overexpression of N1-Src-mCherry Disrupted Hippocampal 
Neuron Development in Culture. 
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4.2.4 N1-Src can be Specifically Knocked Down Using shRNA. 
Whilst overexpressing the kinase is one means of gaining information about the function 
of N1-Src, manipulating the endogenous protein could provide more physiologically 
relevant information about the role of the kinase. Two common methods that would 
achieve such a result are 1.) the inhibition of kinase activity or 2.) the knock-down of 
protein expression in cells. Unfortunately, current commercial inhibitors of N1-Src are 
non-specific and target all SFKs, including C-Src (Kim et al., 2009). Therefore, it is 
impossible to assign specific functions to N1-Src using these inhibitors. For this reason, 
the approach used to manipulate endogenous levels of N1-Src concentrated upon 
achieving the specific knockdown of N1-Src kinase levels in neurons.   
In this study, two independent shRNAs, designed to specifically knock-down the 
expression of N1-Src were used (Figure 4.7). Given that N1-Src only differs from C-Src 
by an 18 base pair (or 6 amino acid) insert in the SH3 domain, the design of the shRNAs 
was limited to correspond to that area of the gene (Figure 4.7A). Since, the N2-Src SH3 
insert incorporates the first 17 base pairs as of the N1-Src SH3 insert, to ensure N1-Src 
specificity, it was important that the shRNAs not only incorporated the sequence of the 
SH3 insert, but also overlapped with the flanking sequence in Exon4 (Figure 4.7A). The 
shRNAs (designed by Dr Gareth Evans) were cloned into the pSuper-CFP vector by 
Katarina Mahal. The pSuper RNA interference (RNAi) system used, facilitates the 
production of shRNA molecules, which trigger the down-regulation of the target gene, in 
this case N1-Src.  
Given that there are no effective, commercially available antibodies to detect N1-Src, the 
specificity and efficacy of the N1-Src shRNAs A and B were tested by co-expressing 
FLAG-tagged N1-, N2- or C-Src with the individual shRNAs, in the monkey fibroblast cell 
line COS7 (Figure 4.7B). This method proved successful as each of the FLAG-tagged 
kinases could be detected by Western blot and therefore the effect of shRNA A and B 
on Flag-kinase expression levels could be assessed. The bands were subjected to 
densitometry analysis (Figure 4.7C) which illustrated the effects of shRNAs A and B on 
the expression of Flag-tagged C-, N1- and N2-Src with respect to the pSuper-CFP 
control. shRNA A predominantly affected N1-Src expression, causing a 68 % reduction 
in N1-Src protein levels. However, C- and N2-Src expression were also reduced, albeit 
to a lesser degree than N1-Src, by 16 and 35 % respectively. In contrast, shRNA B 
largely knocked down N2-Src, resulting in a 96 % reduction in protein expression. N1-
Src expression was relatively unaffected by shRNA B (reduced by 9 %), whereas there  
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(A) shRNAs A and B were designed to target N1-Src expression, however there was 
also a high degree of sequence complementarity with N2-Src. (B) COS7 cells were co-
transfected with C-, N1- or N2-Src-FLAG and empty pSuper-CFP, shRNA A or shRNA 
B. Cells were lysed in 2X Laemmli buffer after 4 h and samples were resolved by SDS-
PAGE, transferred to PVDF and analysed by Western blotting using an α-FLAG primary, 
followed by an α-mouse HRP secondary. (C) Src-FLAG bands from a data set of n=1, 
were subject to densitometry analysis using ImageJ and normalised to the densitometry 
values of the B-actin bands. 
Figure 4.7: shRNAs A and B Largely Depleted N1- and N2-Src Expression 
Respectively. 
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was a partial depletion in C-Src expression by 37 %. Together, these results suggested 
that shRNA A and B were capable of depleting the expression of multiple Src splice 
variants. However, whilst shRNA A mostly targeted N1-Src, the main target of shRNA B 
was N2-Src resulting in an almost complete knockdown.    
4.2.5 Knockdown of N1-Src with shRNA A Reduces the Length of Longest 
Neurite. 
After testing the shRNAs in COS7 cells, the shRNA constructs were transfected into 
hippocampal neurons to assess the effect of downregulating N1- and N2-Src expression 
on neuronal morphology.  
Figure 4.8 depicts representative images of control, shRNA A and shRNA B transfected 
neurons. On first inspection, pSuper-CFP-shRNA-A transfected neurons appear smaller, 
and the length of the longest neurite was shorter, in comparison to control and p-Super-
CFP-shRNA-B transfected neurons. This observation was supported by the 
morphological data gathered (Figure 4.9). In comparison to control cells, those 
expressing shRNA A exhibited a significant decrease (11.7%) in the mean number of 
neurites per cell (p=0.045 *). This result was significantly different to that obtained for 
cells expressing shRNA B, in which there was a significant increase in the number of 
neurites (15.8%, (p=<0.001 ***), compared to control cells (Figure 4.9A). The 
corresponding representative frequency plot (Figure 4.9B) supported these findings. In 
addition, whilst shRNA B had little effect on the mean total length of neurites per cell 
(Figure 4.9C) and mean length of longest neurite (Figure 4.9E), in cells containing 
shRNA A there was a significant decrease in both parameters, by 21 % and 28 % 
respectively, in comparison to control cells (p=<0.001 ***). In the frequency plots, the 
overall distribution of values was shifted to the left of the control and shRNA B curves 
(Figure 4.9 D and F).   
Taken together, these results suggested that the down-regulation of N1-Src expression 
by shRNA A negatively affected neurite outgrowth, in particular, the length of longest 
neurite and number of neurites produced. Whereas the effects of shRNA B differed, 
resulting in an increased mean number of neurites per cell.  
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Figure 4.8: Representative Images of the Morphological Effects of shRNAs A and 
B in Hippocampal Neurons. 
Rat hippocampal neurons were transfected at 1DIV with pSuper-CFP, shRNA A or 
shRNA B and fixed after 48 h.The cells were processed for immunofluorescence. Using 
a Zeiss slidescanner, images of four whole coverslips were captured per condition from 
which 30 images of individual neurons were randomly selected. Representative images 
are shown from N=3. Scale bar = 50 µm. 
  
 
 
122 
 
 
Rat hippocampal neurons (1DIV) were transfected with pSuper-CFP (control), pSuper-
CFP-shRNA-A or p-Super-CFP-shRNA-B for 48 h and fixed in 4 % PFA. The cells were 
processed for immunofluorescence and using a Zeiss slide scanner, images of four 
coverslips were captured per condition, from which 30 images of individual neurons were 
randomly selected. In ImageJ, the NeuronJ plugin was used to trace and measure 
neurites. The mean values and frequency distribution were assessed for the following 
parameters: the number of neurites (A,B), total length of neurites (C,D), and length of 
longest neurite (E,F). shRNA A and B data were normalised to the mean value of the 
pSuper-CFP control for each replicate. The experiment was performed 3 times and 
statistical significance of the pooled data (n=90) was assessed in SPSS (*p<0.05, 
**p<0.01, ***p<0.001). 
Figure 4.9: Knockdown of N1-Src by Two Independent shRNAs (A and B) Resulted 
in Atypical Neuronal Morphology. 
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4.2.6 N2-Src shRNA B Increases Neurite Branching 
After determining the effects of a reduction of N1-Src expression on neurite outgrowth, 
the effects on neurite branching were assessed. Whilst shRNA A had no significant effect 
on the primary branching of neurites compared to control cells, a slight decrease in the 
mean number of primary branches (reduced by 6.2 %, Figure 4.10A), total length of 
primary branches (reduced by 14.9 %, Figure 4.10C) and average length of primary 
branches (reduced by 8.9 %, Figure 4.10E) was observed. This was reflected in the 
frequency plots for shRNA A, where the curves were shifted left, in comparison to the 
control curves (Figure 4.10B, D and F). In contrast, for cells transfected with shRNA B, 
there was no significant change in the mean total length of primary branches (Figure 
4.10C and D), however there was a striking and significant increase (40 %) in the mean 
number of primary branches (p=<0.001 ***, Figure 4.10A). This can be visualised further 
in the frequency plot, where the shRNA B values are shifted to the right (Figure 4.10B). 
In addition to this, there is a significant decrease in the average length of primary 
branches compared to control cells (p=0.025 *, Figure 4.10E), however this does not 
vary significantly from shRNA A transfected cells (Figure 4.10E). 
In addition to studying the growth of primary branches, the percentage of cells with 
secondary (Figure 4.11A) or tertiary (Figure 4.11B) branches was determined. The 
average percentage of cells with secondary or tertiary branches was not significantly 
altered in either shRNA A or shRNA B transfected cells in comparison to the pSuper-
CFP control. 
Overall, these data suggest that the downregulation of N1-Src by shRNA A had no effect 
on the primary branching of neurites in 2 DPT rat hippocampal neurons. However, cells 
transfected with shRNA B displayed increased primary branching of neurites, with a 
shorter average length, but the mean total length of neurites was unaffected. The 
percentage of cells with secondary and tertiary branching was unaffected in cells 
transfected with either shRNA.     
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In ImageJ, the NeuronJ plugin was used to trace and measure the primary branches of 
neurites from 2 DPT hippocampal neurons that were transfected with the pSuper 
(control) or N1-Src shRNA A or B. The mean values and frequency distribution were 
analysed respectively for the following parameters: the number of primary branches 
(A,B), total length of primary branches (C,D), and the average length of primary 
branches/cell (E,F). Across 3-4 coverslips, 30 cells per condition were analysed from 
images captured using a slide scanner. The shRNA A and B data were normalised to 
the mean value of the control for each replicate. The experiment was performed 3 times 
and statistical significance of the pooled data (n=90) was assessed in SPSS (*p<0.05, 
***p<0.005). 
Figure 4.10: N1-Src Knockdown by Two Independent shRNAs had Little Effect on 
the Primary Branching of Neurites in Hippocampal Neurons. 
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In ImageJ, the NeuronJ plugin was used to trace the secondary and tertiary branches of 
3 DIV hippocampal neurons that were transfected with pSuper-CFP (Control) or pSuper-
CFP-N1-Src-shRNA-A or -B. The average percentage of cells with secondary (A) and 
tertiary (B) branches were calculated. Across 3-4 coverslips, 30 cells per condition were 
analysed from images captured using a slide scanner. The experiment was performed 3 
times and statistical significance was assessed in SPSS using a one-way ANOVA (n.s. 
= not significant). 
 
  
Figure 4.11: N1-Src Knockdown by Two Independent shRNAs did not Affect the 
Percentage of Hippocampal Neurons with Secondary and Tertiary Branches 
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4.2.7 A Time-course of N1-Src Shrna Transfection Reveals the Length of Longest 
Neurite Further Decreases with Time. 
In Section 4.2.4, the transfection of pSuper-CFP: shRNA-A into 1 DIV rat hippocampal 
neurons, which predominantly targeted N1-Src expression, resulted in a significant 
reduction in the length of longest neurite (Figure 4.10E). To determine whether this effect 
changed with respect to time, a time course was performed comparing the effect of 
shRNA A on the length of longest neurite, with that of the pSuper-CFP control. Similar to 
previous experiments, within each biological replicate, the values for the length of longest 
neurite were normalised to the mean value measured for pSuper-CFP at 2 DPT. The 
data presented incorporated two biological repeats, therefore statistical analysis was not 
performed on the data.  
In Figure 4.12A, representative images illustrate the profound effect of shRNA A on the 
length of longest neurite with respect to time, compared to control cells. shRNA A greatly 
reduced the length of longest neurite when compared to control cells and the decrease 
between control and shRNA A transfected cells became greater over time, from 21 % to 
64 % (Figure 4.12B). In addition to this, whilst the length of longest neurite in control cells 
increased with respect to time, this was also the case for shRNA A transfected cells up 
until 4 DPT, after which the length of longest neurite decreased by 47 % (Figure 4.12B). 
These data strongly indicate that the depletion of N1-Src by shRNA A reduces the length 
of longest neurite and that this effect becomes greater with time.   
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(A) Representative images showing the effect of shRNA A over time after, in comparison 
to the empty vector control (pSuper). Rat hippocampal neurons were transfected at 1DIV 
and fixed after 2, 4 or 6 h.The cells were processed for immunofluorescence. Using a 
Zeiss slidescanner, images of four whole coverslips were captured per condition from 
which 30 images of individual neurons were randomly selected. Scale bar = 50 µm. (B) 
In ImageJ, the NeuronJ plugin was used to trace and measure the length of longest 
neurite and the mean values were plotted as a function of time for control and shRNA A 
transfected cells. All data points were normalised to the mean value of the 2 DPT control 
time point for each replicate. N=2. 
  
Figure 4.12: The Effect of N1-Src Depletion by shRNA A on the Length of Longest 
Neurite Increased with Respect to Time. 
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4.2.8 The Role of N1-Src in L1-CAM Mediated Neurite Outgrowth. 
The results from the shRNA experiments (Sections 4.2.4-6) established a potential role 
for N1-Src in neurite outgrowth. N1-Src shRNA A, the most potent of the two shRNAs, 
evoked a significant reduction in the length of longest neurite (Figure 4.9E). The 
magnitude of this effect increased with respect to time up to 6 DPT (Figure 4.12). Since 
cultured hippocampal neurons are known to develop an axon after 3-4 DIV, this 
suggested that N1-Src plays a role in axon outgrowth in developing hippocampal 
neurons. One mechanism through which N1-Src could regulate axon outgrowth is via the 
L1-CAM signalling pathway. Ignelzi et al., (1994) demonstrated that impaired neurite 
outgrowth occurred in Src-/- CGNs cultured on L1-CAM. Whilst this study did not directly 
implicate N1-Src, in the Src-/- mice, C-, N1- and N2-Src expression were abolished, 
therefore this function could be linked to the neuronal kinases, which are the predominant 
isoforms of Src in the developing brain (Wiestler and Walter, 1988). In addition to this, 
studies in the Evans lab specifically pointed to a role for N1-Src in L1-mediated neurite 
outgrowth in CGNs. These studies, however, did not address whether L1-CAM 
homophilic or heterophilic interactions were responsible for the effects observed.   
Since preliminary data from the Evans lab showed that N1-Src induces the formation of 
neurite-like processes in the fibroblast cell line COS7, this concept was used to develop 
an assay to test the effects of N1-Src within L1-CAM signalling pathways. In order to 
develop a model for N1-Src-mediated process outgrowth triggered by extracellular L1-
CAM, process outgrowth was analysed in COS7 cells overexpressing mCherry (Control) 
or N1-Src-mCherry that were plated in control or L1-CAM substrate (L1-Fc) coated wells. 
To determine whether L1-CAM homophilic interactions were necessary for this process, 
N1-Src-mCherry was co-expressed with human L1-CAM in the presence or absence of 
L1-Fc. 
The data presented (Figures 4.13 and 4.14) represent a single biological replicate. In 
order to draw firm conclusions from these data, further biological repeats must be 
performed, however, early indications of the appropriateness of this model and 
preliminary findings could be examined.  
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Representative images showing the localization of N1-Src-mCherry and L1-CAM in COS7 cells, grown in the absence or presence of L1-Fc. 
COS7 cells were cultured in control or L1-Fc coated wells for 24 hours prior to being cotransfected with combinations of pmCherry (Control, red) 
or p-N1-Src-mCherry (N1-Src, red) and pcDNA5-CFP (Control, green) or pcDNA5-L1-CAM (L1CAM, green). The amount of co-localisation 
(yellow) was assessed when images were merged. The cells were fixed 48 h post-transfection and processed for immunofluorescence using a 
rabbit anti-sera raised against CFP, a mouse anti L1-CAM antibody and the relevant AlexaFluor488 secondary antibodies. Images were captured 
(30 fields of view) using a fluorescence microscope with a 40 X objective lens. Scalebar= 20 µm, N=1.   
Figure 4.13: N1-Src-mCherry Co-localised with L1-CAM in the Perinuclear Region of COS7 Cells that were Grown in the Absence or 
Presence of L1-Fc. 
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COS7 cells that were cultured in control or L1-Fc coated wells, were co-transfected with 
combinations of pmCherry or p-N1-Src-mCherry and pcDNA5-CFP or pcDNA5-L1-CAM. 
The cells were fixed 48 h post-transfection and processed for immunofluorescence. 
Images were captured using a fluorescence microscope with a 40 X objective lens and 
the percentage of cells with processes was calculated from the cells present in 30 fields 
of view (n=97-208) (A). Of the cells that had processes (n=11-43) the number of 
processes per cell (B) and the average process per cell (μm) were measured (C). N=1. 
  
Figure 4.14: Preliminary Results Indicated that Homophilic L1-CAM Signalling did 
not Enhance Process Outgrowth in COS7 Cells. 
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Figure 4.13 shows representative images of cells transfected with the different 
combinations of conditions plated in control and L1-Fc coated wells. In cells that 
expressed N1-Src-mCherry and CFP, plated under control conditions, N1-Src 
accumulated in the perinuclear region and appeared diffuse throughout the cell. This 
distribution of N1-Src-mCherry appeared the same when cells transfected with the same 
constructs were plated on L1-Fc. In contrast, when L1-CAM was expressed in control 
cells alongside mCherry, whilst there was some perinuclear localization of the protein, 
the staining revealed the presence of multiple puncta distributed throughout the cytosol. 
A similar pattern of expression was visible in cells grown on L1-Fc substrate. Upon 
expression of both N1-Src-mCherry and L1-CAM together in either control or L1-Fc 
coated wells, both proteins appeared to co-localise in the perinuclear region, however 
there was no obvious co-localization between the L1-CAM puncta in the cytosol and N1-
Src-mCherry.   
To assess the effects of N1-Src-mCherry and L1-CAM expression on process extension 
in cells plated both in the absence or presence of L1-Fc, multiple parameters were 
quantified (Figure 4.14). These included the percentage of cells with processes (Figure 
4.14A), the average number of processes (Figure 4.14B) and the average length of 
processes (Figure 4.14C). In cells co-expressing mCherry and CFP, the percentage of 
cells extending processes was low (6.02 %) when grown in the absence of L1-Fc and 
this increase more than doubled in the presence of L1-Fc (13.94 %) (Figure 4.14A). 
There was little change in the average number and length of neurites (Figure 4.14B and 
C) in these cells. 
In contrast, co-expression of N1-Src-mCherry and CFP in control wells resulted in an 
increased proportion of cells (24.81 %) with processes (Figure 4.14A). This has been 
observed in previous studies in the Evans lab and notably in Section 5.2.1-2. This has 
contributed to the hypothesis that N1-Src plays a role in cytoskeletal re-modelling and 
process formation/extension. There was only a small increase in the percentage of cells 
with processes (4.64 %) in N1-Src-mCherry and CFP expressing cells grown on L1-Fc, 
with little change observed in the average number and length of processes.  
In addition to expressing mCherry or N1-Src-mCherry with CFP (control), these proteins 
were also co-expressed with full length L1-CAM, with the aim of further understanding 
whether N1-Src regulates process outgrowth via an L1-L1 homophilic interaction 
stimulated signalling pathway.  
In mCherry and L1-CAM expressing cells grown in control wells, there was an 11.29 % 
increase in the percentage of cells with processes compared to mCherry and CFP 
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expressing cells (Figure 4.14A). Whilst the average number of processes remained the 
same (Figure 4.14B), there was a 45 % increase in the average process length (Figure 
4.14C). This suggested that L1-CAM expression in COS7 cells may enhance process 
outgrowth. When grown in L1-Fc coated wells, there was a slight increase (5.37 %) in 
the percentage of cells with processes, in comparison to control wells (Figure 4.14A). 
There was little change in the average number of neurites (Figure 4.14B), however the 
average length of neurites was reduced by 40 % back to the levels in control cells co-
expressing mCherry and CFP (Figure 4.14C).   
The difference in the percentage of cells with processes in N1-Src-mCherry and CFP or 
L1-CAM expressing cells was virtually unchanged in control wells. However, there was 
a decrease in cells with processes from 23.64 % to 16.81 % when those cells were grown 
on L1-Fc (Figure 4.14A). Whilst there was an increase in the average number of 
processes per cell from 1.11 to 1.45 (Figure 4.14B), the average length of neurites per 
cell remained unaltered (Figure 4.14C). 
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4.3 Discussion 
The studies conducted in Chapter 4 sought to gain further insight into the functional role 
of N1-Src during neuronal morphogenesis. To address this, two main approaches were 
employed; 1) the overexpression and 2) shRNA knockdown of the kinase. These 
experiments provided evidence to support the hypothesis that N1-Src is involved in 
neurite outgrowth and could play a major role in axonal elongation. The first direct 
comparison between the roles of N1- and N2-Src during neuronal development 
demonstrated different functions for the kinases. Since previous data from the Evans lab 
suggested that N1-Src may act downstream of L1-CAM signalling to promote axon 
extension, further experiments were aimed at developing a model for L1-CAM mediated 
N1-Src signalling in the heterologous fibroblast cell line COS7. Whilst further biological 
repeats are required to draw firm conclusions from the data, preliminary results 
suggested that N1-Src did not evoke downstream signalling that enhanced the formation 
or elongation of neurite-like processes. However, the data suggested that L1-L1 
homophilic signalling may have had an inhibitory effect via N1-Src signalling.   
4.3.1 The Experimental Use of Primary Hippocampal Neurons. 
Whilst there are many advantages to using cultured hippocampal neurons 
experimentally (discussed in Section 4.1.3), there are also certain caveats. The main 
limitation to consider when using dissociated hippocampal neurons is the resulting 
heterogeneous cell populations obtained. These contain both CA1 and CA3 
glutamatergic pyramidal neurons, as well as various types of GABAergic interneurons 
(Benson et al., 1994). It is important to note that data outputs from experiments using 
these cells incorporated the results from the whole cell population, since it is difficult to 
tease apart differences between cells after 3 DIV (Figure 4.1). Despite this, pyramidal 
neurons are thought to comprise approximately 85-90 % of the total cell population, 
therefore the results obtained could be largely attributed to these types of neurons 
(Schlessinger et al., 1978, Boss et al., 1987). Since dentate granule cells develop 
postnatally, these cells were not present in the P0 hippocampal preparations used in the 
experiments described in this chapter.  
There were also significant differences in the morphological parameters of control cells 
between different biological replicates, most noticeably between replicate 4 and the other 
replicates (Figure 4.3). This is likely attributed to the occurrence of natural variation 
between different rat litters. To account for these differences, individual values for each 
parameter measured in shRNA A or shRNA B expressing cells, were normalised to the 
average value of the control (pSuper-CFP transfected cells) (Figures 4.9 and 4.10). This 
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approach to data analysis has been adopted in many other studies, most notably by 
Vance Lemmon, whose pioneering work on L1-CAM mediated neurite outgrowth is 
referenced throughout this thesis (Cheng et al., 2005, Blackmore et al., 2010).   
4.3.2 N1-Src Overexpression Resulted in Aberrant Neurite Outgrowth.  
Overexpression of N1-Src in hippocampal neurons resulted in a highly significant 
reduction in the average total length of neurites and average length of longest neurite, 
as well as a reduction in the average number of neurites per cell (Figures 4.4 and 4.5). 
This indicated that the overexpression of the kinase had a severe effect on the 
development of hippocampal neuron morphology. After 3 DIV, 100 % of mCherry and C-
Src-mCherry expressing cells were at stage three or above in the developmental 
sequence of events undertaken by hippocampal neurons in culture (described in Figure 
4.1), which meant that the neurons were polarised since one of the minor neurites had 
been selected to become the axon. However, approximately half of N1-Src expressing 
cells appeared to not have progressed past stage two (Figure 4.6). This suggested that 
N1-Src-mCherry overexpression had affected the polarization of the neurons. In these 
experiments, the neurons were transfected after 1 DIV, at which point the cells measured 
were expected to have been at the developmental stages two or three. Therefore, one 
possible explanation for the results observed could be that the overexpression of N1-
Src-mCherry prevented the progression of the neurons from stage two to stage three, 
whereas the neurons that were already at stage three at the time of transfection 
subsequently suffered stunted neurite outgrowth. To test this theory, it would be useful 
to track the development of N1-Src-mCherry overexpressing neurons in real time using 
live imaging. To understand whether N1-Src-mCherry overexpression, is either delaying 
or blocking developmental progression, a timecourse overexpressing the kinase over a 
longer period of time could be performed. 
The results of N1-Src-mCherry overexpression on neuronal development observed in 
this study (Figures 4.4-4.6) have some similarities and differences when compared to 
the two N1-Src overexpression studies that have previously been published (Kotani et 
al., 2007, Worley et al., 1997). Kotani et al., (2007) used an L7 promoter to drive the 
overexpression of constitutively active N1-Src (Y535F) in Purkinje neurons of transgenic 
mice. Whilst N1-SrcY535F had little effect in P3-P5 cells, surprisingly at P7, many of the 
Purkinje neurons appeared less polarised compared to control cells and displayed 
aberrant dendritic morphology, retaining multiple dendritic shafts and forming abnormal 
dendritic branches. These defects however, were not observed in P10 mice and 
onwards, implying that another mechanism may compensate for the effect observed 
(Kotani et al., 2007). Although the results in this chapter did not report phenotypic 
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changes relating solely to dendritic structures, the results did suggest that 
overexpression of the kinase resulted in defects in neuronal polarization. Unlike this 
study, Kotani et al., (2007) did not report any findings relating to alterations in neurite 
length, nor did they discuss an axon-related phenotype, but it is unclear whether this was 
investigated. A further study by Worley et al., (1997) found that the axonal lengths of 
Xenopus ventral forebrain neurons increased in N1-Src overexpressing cells, 
contradicting the findings in this chapter. It is important to note, however, that the number 
of neurons measured by Worley et al., (1997) was of a very small sample size (n=5) 
whereas the results shown in Figure 4.5 were generated using a larger sample size 
(n=84-88 across 3 biological replicates).  
Overexpression of C-Src-mCherry in hippocampal neurons had little effect on neuronal 
morphology compared to control cells (Figure 4.4), with no significant changes in the 
average number of neurites, total length of neurites and length of longest neurite (Figure 
4.5). However, the differences in these parameters between C- and N1-Src-mCherry 
expressing cells were highly significant, given the aberrant morphology observed in N1-
Src-mCherry cells. Although C-Src has been linked to neurite outgrowth in numerous 
studies, the lack of phenotype observed in this work could be attributed to the fact that 
C-Src has relatively low constitutive activity, especially in comparison to the N-Srcs 
(Ignelzi Jr et al., 1994, Brouns et al., 2001, Keenan et al., 2015). In the various studies 
in the literature, C-Src mediated neurite outgrowth is placed in the context of a signalling 
mechanism, therefore, it is likely that C-Src activity must be triggered by a suitable 
stimulus to evoke changes in neurite outgrowth (Ignelzi Jr et al., 1994). Since it has been 
shown that N1-Src has much higher constitutive activity than C-Src, this could explain 
the severe changes in neurite outgrowth attributable to N1-Src overexpression (Keenan 
et al., 2015). To understand further the potential differences between C- and N1-Src 
function, it could be useful to compare the effects of the overexpression of constitutively 
active C-Src with wild type or constitutively active N1-Src.   
Taken together, these results suggested that N1-Src overexpression in hippocampal 
neurons leads to aberrant neuronal development by disrupting neuronal polarization as 
well as causing stunted neurite outgrowth. N1-Src-mCherry overexpression also had a 
much greater effect on neuronal morphology than C-Src-mCherry, which could be 
attributed to the differences in constitutive activity between C- and N1-Src reported in 
other studies, or differences in substrate specificity. In addition, N1-Src overexpression 
appeared to have different effects in different cell types, which suggests that N1-Src has 
cell type specific functions. Alternatively, overexpression of the kinase could lead to the 
occurrence of non-physiological effects, caused by aberrant signalling. This is a 
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possibility given the high constitutive activity of the kinase. For this reason, shRNA 
knockdown studies (Figures 4.7-4.12) were performed to shed further light on the 
physiological roles of N1-Src and will be the subject of discussion in the sections that 
follow.  
It should be noted that in order to link the effects of the overexpression of C-, N1- and 
N2-Src directly to the catalytic activity of the kinases, the experiment should be repeated 
using kinase-null mutants as an additional control. By including this control, the possibility 
that the kinases mediate their effects through the formation of protein-protein interactions 
or other means, could be ruled out. In addition to this, a second control should be 
included to assess the protein levels of the overexpressed kinases. The performance of 
this control is necessary to show that the differences between the effects of C-Src and 
N1-/N2-Src can be specifically attributed to the individual functions of the kinases and 
are not caused by differences in their expression levels. In the overexpression study 
performed in this chapter, the transfection efficiency of the neurons used was too low to 
be able to perform an accurate quantification of the kinase expression levels. However, 
this could be overcome by using a lentiviral gene delivery system to greatly improve the 
transfection efficiency of the neurons. In order to be able to deduce firm conclusions from 
these data in the future, the experiment should be repeated using both of these controls. 
4.3.3 The Specificity of the N1-Src Targeting shRNAs.  
Two independent shRNAs were designed with the aim of specifically depleting the 
expression of N1-Src. Given that N1- and N2-Src differ from each other and C-Src via 
small mini-exon inserts in their SH3 domains (illustrated in Figure 4.7A), the scope for 
designing N1-Src specific shRNAs was limited. The difficulty of this task was reflected 
by the results obtained after testing the efficacy of the shRNAs in COS7 cells (Figures 
4.7B and C). Whilst shRNA A was largely specific to N1-Src, depleting N1-Src protein 
levels by approximately 70 %, N2-Src by 35 % and C-Src by only 15 %, shRNA B was 
largely specific to N2-Src, depleting N2-Src protein levels by approximately 95 %, C-Src 
by 37 % and N1-Src by less than 10 %. These represent data from an n=1, since the 
results from additional experimental repeats were invalid due to technical faults. 
However, the outcome of the experiment is supported by the initial shRNA efficacy 
experiments performed by Katharina Mahal, who also cloned the shRNAs (Mahal, 2010). 
The depletion of C- and N2-Src protein levels by both shRNAs is likely due to the partial 
sequence complementarity shared between the shRNAs and the mRNA’s of the kinases, 
however the fact that shRNA B depleted N2-Src protein by much greater levels was 
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surprising, since shRNA A shared greater sequence complementarity with N2-Src 
compared to shRNA B.  
Ideally the efficacy of the shRNA’s would have been tested in hippocampal neurons 
however, the fact that there are no commercially available antibodies for N1-Src and the 
neuronal transfection efficiency using Lipofectamine was poor, meant that this was not 
a feasible option. To overcome these issues, the effect of the shRNAs on the levels of 
C-, N1- and N2-Src mRNA could be assessed using reverse-transcription PCR (rt-PCR), 
although a much greater neuronal transfection efficiency would need to be achieved. 
This could be addressed by using a highly efficient lentiviral system, to deliver the siRNA 
into the hippocampal neurons. In addition, an experiment similar to the one performed in 
this chapter in COS7 cells could be performed with hippocampal neurons, using the 
lentiviral system to improve transfection efficiency. 
4.3.4 Depletion of N1-Src Expression by shRNA A Resulted in Reduced Neurite 
Outgrowth.  
Depletion of N1-Src expression by shRNA A had a significant effect on neurite outgrowth 
in cultured hippocampal neurons. The average number of neurites, total length of 
neurites and length of longest neurite were significantly reduced (Figure 4.9), whereas 
neurite branching was unaffected (Figures 4.10 and 4.11). This study was the first of its 
kind, to predominantly target the knockdown of N1-Src expression, with respect to C- 
and N2-Src and suggested that N1-Src may play a role in the formation and extension 
of neurites. The impaired outgrowth of the longest neurite mediated by shRNA A, 
worsened with respect to time (Figure 4.12) implying that N1-Src expression was vital to 
the mechanisms that governed neurite outgrowth. Since the neurons analysed were fixed 
between 2-6 DPT, and 100 % of the cells were observed to have reached stage 3 or 
above using Dotti’s classification system (Figure 4.1) of hippocampal neuron 
development, it was likely that N1-Src depletion by shRNA A particularly inhibited axonal 
outgrowth. Furthermore, the decrease in the length of longest neurite between shRNA A 
transfected cells fixed at 4 and 6 DPT, suggested that in addition to inhibiting the 
mechanisms that drive neurite extension, exposure of the cells to shRNA A for this period 
of time, could have ultimately led to neurite retraction. In order to determine the statistical 
significance of the data, a third biological repeat should be performed. 
Whilst there are no studies that directly link N1-Src knockdown to neurite outgrowth, 
(Ignelzi Jr et al., 1994) found that neurite outgrowth was impaired in CGN’s cultured from 
Src-/- mice that were grown on the neuronal cell adhesion molecule L1-CAM. The mouse 
knockout used was not specific to a single splice variant of Src, and therefore the 
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expression of C-, N1- and N2-Src kinases would have been abolished in the neurons 
used. Therefore, it is plausible that this phenotype could be at least partially assigned to 
N1-Src, which would support the findings of the shRNA A transfection. However, in the 
Ignelzi study (1994), impaired neurite outgrowth was observed in CGNs that were 
cultured on L1-CAM, whereas Src-/- cells grown on laminin, which stimulates integrin 
mediated neurite outgrowth, were not affected. This suggested that Src facilitated neurite 
outgrowth via an L1-CAM dependent pathway. 
In the studies carried out in this thesis, hippocampal neurons were grown on poly D-
lysine (PDL), a commonly used synthetic polyamino acid, which facilitated the adherence 
and growth of cells on glass. Therefore, in the absence of external extracellular matrix 
signalling cues, including cell adhesion molecules and integrins, depletion of N1-Src still 
resulted in reduced neurite outgrowth. This could suggest that N1-Src drives neurite 
outgrowth via an intrinsic mechanism that operates in the absence of external factors. 
One possible explanation for this could be the high constitutive kinase activity that N1-
Src possesses. 
Src has also been linked to the regulation of neurite outgrowth in conjunction with 
p190RhoGAP, which regulates actin cytoskeletal dynamics via the GTPase RhoA. 
Overexpression of p190RhoGAP promotes neurite outgrowth in neuroblastoma cells, 
which is similar to the effects of N1-Src overexpression in fibroblasts (Brouns et al., 2001, 
Worley et al., 1997). In addition, p190RhoGAP was also shown to be the most prominent 
tyrosine phosphorylated protein in whole mouse brain lysates, which was reduced in 
Src-/- mice and almost completely abolished in Src-/-/Fyn-/- double knock out mice (Brouns 
et al., 2001). Thus, it appears that both Src and Fyn are regulators of p190RhoGAP in 
the brain. Whilst C-Src has been shown to phosphorylate p190RhoGAP in fibroblasts, 
the possibility that N1-Src could regulate the protein has not been explored (Roof et al., 
1998). Brouns et al., (2001) also demonstrated that p190RhoGAP was localised to the 
distal tips of neurites, alongside F-actin, in hippocampal neurons (E18.5) cultured on 
PDL and interestingly, biochemical studies have also shown that N1-Src is present in 
neuronal growth cone membranes in developing rat brain. Whether C- or N1-Src directly 
phosphorylates and regulates p190RhoGAP to promote neurite outgrowth in primary 
neurons still remains to be shown 
Unpublished work in the Evans lab established an N1-Src inhibitor called PD1, through 
the development of an N1-Src specific SH3 binding motif (Keenan, 2012). N1-Src 
inhibition by PD1 in hippocampal neurons resulted in a decrease in the primary branching 
of neurites, but had no effect on the average number of neurites formed or neurite 
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lengths. However, the outcomes of the shRNA A depletion of N1-Src did not support 
these findings, and pointed towards a role for N1-Src in neurite formation and extension. 
This could be explained by the occurrence of off target effects in either the PD1 or shRNA 
studies, or may be due to the differences between the methods used. As a competitive 
inhibitor of N1-Src, PD1 elicits an acute response, whereas shRNAs act to prevent 
protein synthesis by targeting mRNA for degradation. To confirm the differences in the 
functions ascribed to N1-Src and provide greater confidence in the shRNA knockdown, 
it would be useful to perform this study with a second N1-Src specific shRNA.  
Given that there was only a partial depletion in the expression of C- (12 %) and N2-Src 
(35 %) by shRNA A, it seemed that neither of the kinases were able to functionally 
compensate for the effect of the ~ 70 % depletion of N1-Src expression up to 6 DPT. 
This suggests that the kinases have different functional roles. This is in part, supported 
by the outcome of the shRNA B transfection in which N2-Src expression was 
predominantly depleted and a different morphological phenotype was observed 
(discussed in Section 4.3.5). Since the sequence, of C-Src is fully conserved with N1- 
and N2-Src, with the exception of the n-Src loop, it would be difficult to establish the 
specific functional role of C-Src in neurons, without resorting to overexpression 
techniques, which cannot always be relied upon to determine physiological function.  
4.3.5 The Overexpression and Knockdown of N1-Src Display Similar Effects on 
Neuronal Morphology. 
Interestingly, both the overexpression of N1-Src and the knockdown of N1-Src by 
shRNA A yielded similar results, in that both experiments resulted in a reduction in 
neurite outgrowth. This observation is likely attributable to the fact that the 
overexpression of a kinase can cause aberrant signalling. There are multiple 
explanations why this might occur (reviewed by Prelich, 2012). For example, the 
overexpression of the kinase might disrupt the formation of multi-protein complexes, in 
which N1-Src is a key component. This may be due to the formation of subassemblies 
that include N1-Src bound to one or more of the other complex components, but which 
do not form the whole functional complex, leading to the loss of function of the kinase. A 
further explanation could be that the overexpression of the kinase may result in the 
aberrant phosphorylation of cellular proteins, which results in the inhibition of neurite 
outgrowth. In addition to this, it is possible that overexpressing the kinase results in the 
sequestration of signalling components into complexes with N1-Src, preventing such 
components from interacting with other proteins that are also necessary for the regulation 
of neurite outgrowth.  
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4.3.6 The Effect of shRNA B on the Primary Branching of Neurites.  
Originally shRNA B was designed to knockdown N1-Src expression, however testing of 
the shRNA in COS7 cells revealed that shRNA B was in fact extremely effective at 
knocking down N2-Src expression and partially reduced C-Src levels by 37 % (Figure 
4.7). Interestingly, the results obtained from shRNA B transfected cells were different to 
shRNA A transfected cells. shRNA B transfection resulted in a highly significant increase 
in the average number of primary branches as well as a decrease in the average length 
of primary branches, with little change in the total length of primary branches per cell 
(Figure 4.10). An increase in the average number of neurites was also observed (Figure 
4.9). These results suggested that N2-Src may play a role in the primary branching of 
neurites, serving to inhibit or regulate primary branching events, and potentially 
regulating branch extension. 
To date, there are no studies in the literature describing the function or substrates of 
N2-Src in primary neurons. However, N2-Src has been linked to a positive prognosis in 
the childhood cancer neuroblastoma, in which tumour cells spontaneously differentiate 
into benign neuronal cells (Matsunaga et al., 1998, Terui et al., 2005). Whilst there is 
precedence in the literature for a role of N2-Src in neuronal differentiation, any potential 
effects that could have altered the cell fate of the hippocampal neurons could not have 
been detected in these experiments, since the fate of the cells used had already been 
determined. In addition to this, 100 % of the cells transfected with shRNA B that were 
analysed (n=90) had successfully polarised.  
Taken together, the shRNA results presented in this chapter indicate different roles for 
N1- and N2-Src in neuronal morphogenesis. Whilst shRNA A demonstrated a partial 
knockdown of N2-Src by 35 %, given there was no correlation with the results for shRNA 
B, which primarily depleted N2-Src protein levels, it is likely that the partial knockdown 
of N2-Src was not great enough to cause a significant effect. Taking this into account, 
since N2-Src protein levels were depleted by 96 % by shRNA B, whereas C-Src and N1-
Src levels were reduced by 37 % and 9 % respectively (Figure 4.7), it is reasonable to 
assume that the effects of this shRNA could be largely attributed to the role of N2-Src. 
Therefore, this study provides the first comparative analysis of the effects of both N1- 
and N2-Src on neuronal morphogenesis, and suggests that the kinases have different 
functions. N1-Src appeared to play a role in neurite extension, whereas N2-Src regulated 
the formation of primary branches (Figure 4.10). To confirm the validity of these effects, 
a second shRNA targeting each kinase should be tested. This would discount the 
possibility that off-target effects contributed to these results.   
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Chapter 5. Dissecting the Role of N1-Src in RhoA Signalling 
5.1 Introduction 
In Chapter 4, N1-Src was implicated in the mechanisms governing neurite outgrowth and 
in particular, regulation of the average number of neurites and length of longest neurite. 
Rho GTPases are key players in directing cytoskeletal dynamics during neurite 
outgrowth (reviewed in (Stankiewicz and Linseman, 2014) and mounting evidence 
suggests that there could be a potential link between N1-Src activity and RhoA signalling.  
Firstly, bioinformatics studies in the Evans lab have identified several putative N1-Src 
substrates involved in RhoA signalling, including p190RhoGAP, ARHGAP1, TRIO and 
KALIRIN (Keenan, 2012). In addition to this, N1-Src has also been shown to interact with 
DAAM1 in vitro, which is a known effector of RhoA and has been shown to mediate the 
formation of branched protrusions in fibroblasts, in a C-Src dependent manner 
(Aspenstrom et al., 2006).  
There have also been multiple reports linking C-Src and RhoA, including a study that 
identified p190RhoGAP as the principal substrate for C-Src and Fyn in the brain (Brouns 
et al., 2001) and a separate study, which reported that C-Src can directly phosphorylate 
and regulate RhoA activity in vitro (Uezu et al., 2012). With this in mind, Chapter 5 will 
focus on investigating a potential role for N1-Src in RhoA signalling, with the aim of 
providing further insight into the role of N1-Src in neurite outgrowth. 
5.1.1 RhoA as a Regulator of Cell Morphology 
Of the many processes that Rho GTPases regulate, perhaps their role in the regulation 
of cell morphology and motility, via the control of the actin cytoskeleton, are the most 
widely studied. To date, there are 20 known Rho GTPases amongst which RhoA, Rac1 
and Cdc42 are the best characterised. The role of RhoA was first demonstrated in 
fibroblasts, where RhoA activation resulted in the formation of stress fibres (contractile 
actin-myosin filaments) and focal adhesion complexes in response to various 
extracellular stimuli (Ridley and Hall, 1992). Whilst activation of RhoA promotes cell 
contraction and rounding, inactivation of this GTPase promotes membrane protrusion. 
This is also the case in neurons, where RhoA activation stimulates neurite retraction and 
rounding of the cell body and inactivation enhances neurite outgrowth (Kozma et al., 
1997). 
5.1.2 The Molecular Mechanism and Regulation of the Small GTPase RhoA 
Rho GTPases, share a common mechanism of action and are often referred to as 
‘molecular switches’, alternating between their ‘on’ (active) and ‘off’ (inactive) states, 
enabling the tight regulation of downstream signalling pathways (Figure 5.1).  
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RhoA operates as a molecular switch, which alternates between an ‘on’ (active) or ‘off’ 
(inactive) state. When bound to GDP, RhoA is rendered inactive, whereas GTP-bound 
RhoA is active. When the RhoA is active and GDP-bound, this enables effector binding 
and facilitates downstream signalling pathways. The cycling between RhoA-GDP and 
RhoA-GTP is facilitated by GEFs, which activate the GTPase and GAPs, which inactivate 
the GTPase. The C-terminus of RhoA is prenylated, which facilitates the attachment of 
active RhoA to the plasma membrane and intracellular membrane compartments. 
RhoGDIs bind to the lipid modification on RhoA and sequesters RhoA in the cytosol, 
effectively inactivating the GTPase. 
  
Figure 5.1: Schematic Diagram Illustrating the Mechanism of RhoA Activation 
and Inactivation. 
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When active, Rho GTPases are bound to guanosine triphosphate (GTP), which 
facilitates the conformation dependent binding of effector proteins. Upon hydrolysis of 
GTP to guanosine diphosphate (GDP), the GTPase switches to its inactive, GDP bound 
state, which prevents effectors binding and effectively ‘switches off’ downstream 
signalling events.  
There are two classes of proteins, namely guanine nucleotide-exchange factors (GEFs) 
and GTPase activating proteins (GAPs), which catalyse the ‘activation’ (GTP bound) and 
‘inactivation’ (GDP bound) of Rho GTPases, respectively (Figure 5.1). GEFs act by 
catalysing the exchange of GDP for GTP, whereas GAPs induce GTPase activity that 
results in GTP hydrolysis, yielding the GDP bound form (Fritz and Pertz, 2016). 
The regulation of RhoA is an extremely complex process that involves multiple inputs. In 
the human genome, whilst there are 20 members of the Rho GTPase family, there are 
83 known activators (GEFs) and 67 known inactivators (GAPs). Therefore, a single Rho 
GTPase can be regulated by multiple GAPs and GEFs. Some GAPs and GEFs also 
exhibit a degree of promiscuity and are capable of regulating more than one Rho 
GTPase. For example, the GEF Vav2 is known to activate RhoA, Cdc42 and Rac1 (Abe 
et al., 2000). In turn, the activity of Rho GAPs and GEFs can also be modulated by post-
translational modifications (e.g. (Uezu et al., 2012).  
In addition to GAP and GEF activity, a further mode of RhoA regulation occurs via the 
interaction of RhoA with a Rho guanine dissociation inhibitor (RhoGDI; Figure 5.1). The 
C-terminus of RhoA is prenylated, which facilitates the attachment of active RhoA to the 
plasma membrane and intracellular membrane compartments. RhoGDIs bind to the lipid 
modification on RhoA, effectively forming inactive complexes that are soluble in the 
cytosol (Cherfils and Zeghouf, 2013).  
The direct regulation of RhoA by post-translational modifications has also been reported. 
RhoA can be targeted for degradation upon the ubiquitination of Lys-6 and -7 or Lys-135 
by the E3 ubiquitin ligases Smurf1 and FBXl19, respectively (Wang et al., 2006a, Wei et 
al., 2013).   
Furthermore, RhoA activity can be regulated by direct phosphorylation of the protein. 
Protein kinase A (PKA) and Protein kinase G (PKG) phosphorylate RhoA at Ser-188, 
which promotes the inactivation of RhoA by sequestering the protein into a complex with 
RhoGDI (Ellerbroek et al., 2003). This modification is also thought to protect RhoA from 
ubiquitin-mediated degradation as well as disrupt the interaction between RhoA and 
ROCK, a major effector that binds to RhoA (Rolli-Derkinderen et al., 2005). C-Src has 
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been shown to phosphorylate RhoA at Tyr-34 and -66, which is also proposed to disrupt 
effector binding and therefore downstream signalling processes (Uezu et al., 2012).  
5.1.3 Aims  
Since there is evidence to suggest that N1-Src may play a role in RhoA signalling, the 
aim of this study was to determine whether N1-Src drives cytoskeletal dynamics via a 
RhoA dependent signalling mechanism. This work was carried out using a fibroblast 
model (also used in Chapter 5), in which N1-Src overexpression has previously been 
shown to increase process formation and reduce cell area in COS7 cells (Keenan, 2012). 
The hypothesis underpinning this work is that N1-Src will serve to promote the 
inactivation or act downstream of inactivated RhoA, which will ultimately lead to 
increased process formation and outgrowth in COS7 cells. This was investigated using 
a variety of cell biology and biochemical techniques.  
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5.2 Results 
5.2.1 Dissecting the Role of N1-Src in RhoA Signalling Using RhoA Mutants.   
In this chapter, a fibroblast model was employed to address the hypothesis that N1-Src 
regulates neurite outgrowth via the inhibition of RhoA. As previously described in Chapter 
4, the overexpression of N1-Src-mCherry in COS7 cells results in the formation of 
neurite-like processes in a portion of cells, which suggests that N1-Src regulates 
conserved cytoskeletal mechanisms that direct changes in cell morphology. This 
phenotype is not commonly observed in COS7 control cells (≤10 %) and therefore 
provides a simpler model for investigating manipulations of N1-Src signalling, as subtle 
effects on neurite outgrowth in hippocampal neurons can often be difficult to detect. A 
further advantage of using the COS7 cell line for studying N1-Src signalling is that these 
cells can be cultured and transfected more easily than neurons.      
In this study, the morphology of COS7 cells overexpressing N1-Src-mCherry alongside 
wild type (WT), constitutively active (Q63L) and dominant negative (T19N) GFP-RhoA 
was analysed. RhoA Q63L is a mutant that is unable to hydrolyse GTP and is therefore 
locked in the GTP-bound active state, whereas RhoA T19N acts by sequestering 
upstream GEFs, thus preventing exchange of GDP for GTP, rendering the protein 
inactive (Figure 5.2).   
The RhoA proteins were N-terminally-tagged with GFP, therefore an empty vector GFP 
control was used as a negative control. In addition to this, the GFP and RhoA constructs 
were co-transfected with plasmids expressing C-Src-mCherry (to compare with N1-Src-
mCherry) and mCherry (a control for the Src-mCherry constructs). Multiple 
morphological parameters were measured, including the percentage of cells with 
processes (Figure 5.4A), cell area (Figure 5.6A) and the circularity of the cells (Figure 
5.6B).    
Representative images indicated that, for all three GFP-RhoA constructs (WT, Q63L and 
T19N), the proteins were largely localised in the perinuclear region of COS7 cells (Figure 
5.3). They also appeared diffuse within the cytosol with some protein concentrated within 
small puncta. In the case of GFP-RhoA-WT and -Q63L, some protein was localised at 
the plasma membrane (Figure 5.3). When co-expressed with C-Src-mCherry, GFP-
RhoA-WT, -Q63L and -T19N appeared to co-localise with C-Src-mCherry in the 
perinuclear region (Figure 5.3B). This was also the case for N1-Src-mCherry co-
expressed with GFP-RhoA-WT and -T19N, but was less apparent in GFP-RhoA-Q63L 
transfected cells, where the RhoA mutant appeared more diffuse throughout the cells 
(Figure 5.3C). Upon first inspection, the morphology of cells expressing GFP-RhoA-
Q63L was more compact and rounded. Whereas in GFP-RhoA-WT and -T19N  
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RhoA wild type (WT) is capable of cycling between inactive GDP-bound and active GTP-
bound RhoA and vice versa, which is facilitated by GEFs and GAPs. The dominant 
negative RhoA mutant (T19N) is GDP bound, since the protein sequesters Rho GEFs, 
preventing the exchange of GDP for GTP. This protein can also interfere with other Rho 
GTPase signalling pathways since some GEFs are capable of regulating more than one 
GTPase. Constitutively active RhoA is continuously locked in the GTP bound active form 
and sequesters effector proteins, triggering downstream signalling events.  
Figure 5.2: Schematic Diagram Illustrating the Dominant Negative and 
Constitutively Active RhoA Mutants. 
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Representative images of COS7 cells co-transfected with empty- (A), C-Src (B) or N1-
Src-mCherry (C) and RhoA WT, Q63L or T19N. Cells were transfected for 48 h fixed and 
processed for immunofluorescence. Images were captured of 15 fields of view per 
condition using a fluorescence microscope. N=3, scale bar= 50 µm.   
Figure 5.3: N1-Src Co-localises with RhoA WT and T19N in the Perinuclear Region 
of COS7 Cells, which is Less Apparent in RhoA Q63L Expressing Cells. 
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transfected cells, a greater number of cells appeared to project neurite-like processes, 
particularly when co-transfected with mCherry or N1-Src-mCherry (Figures 5.3 A and C).  
To assess the differential effects of the GFP-RhoA constructs on the ability of COS7 cells 
to form neurite-like processes in the presence of mCherry, C-Src- or N1-Src-mCherry, 
the percentage of cells with processes and average number of processes per cell were 
quantified (Figure 5.4). Statistical analysis revealed that the percentage of cells with 
processes for GFP, GFP-RhoA-WT, -Q63L and -T19N expressing cells, was not 
dependent upon the Src-mCherry construct that was co-expressed, despite the fact that 
N1-Src-mCherry overexpression in control (GFP) and GFP-RhoA-T19N expressing cells 
resulted in an elevation in the percentage of cells with processes with respect to the 
corresponding mCherry expressing cells (Figure 5.4A). However, statistical analysis of 
the data did indicate that the overall average of the percentage of cells with processes 
in N1-Src-mCherry expressing cells was significantly higher in comparison to mCherry 
(p=0.049 *) and C-Src-mCherry (p=<0.001 ***) expressing cells (statistics for averaged 
data not shown on graph). In addition to this, the ability of cells overexpressing GFP-
RhoA-WT and -T19N to form processes (Figure 5.4A) was significantly elevated with 
respect to GFP-RhoA-Q63L (p=0.037 * and <0.001 ***, respectively) and GFP (T19N 
only; p=0.005 **) cells (statistics for averaged data not shown on graph).   
Figure 5.4B shows data depicting the average number of processes per cell, which 
follows the same trend as the percentage of cells with processes data (Figure 5.4A). 
Statistical analysis of these data indicated that process formation in the GFP-RhoA 
construct transfected cells was dependent on the presence of the Src-mCherry construct.  
The data highlighted that in GFP-RhoA-T19N cells co-expressing mCherry, there was a 
significant increase in the average number of processes per cell in comparison to GFP 
and GFP-RhoA-Q63L transfected cells (Figure 5.4B). The phenotype of RhoA WT 
transfected cells appeared to lie somewhere between that of GFP-RhoA-Q63L and -
T19N cells. Whilst the values obtained for C-Src-mCherry did not vary widely with respect 
to mCherry transfected cells, N1-Src-mCherry promoted process formation (Figure 
5.4B).  
The increase in the average number of processes in cells co-expressing N1-Src-mCherry 
and GFP was close to significance (p=0.061) when compared to mCherry containing 
cells. In addition to this, process formation was significantly higher in N1-Src-mCherry 
and GFP-RhoA-T19N expressing cells with respect to their mCherry and C-Src-mCherry 
expressing counterparts (p>0.001 ***). Whereas in GFP-RhoA-Q63L expressing cells 
process formation was comparable across mCherry, C-Src-mCherry and N1-Src-
mCherry expressing cells.  
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The percentage of cells with processes (A) and average number of processes per cell 
(B) were determined from images of COS7 cells that were co-transfected with mCherry, 
C-Src- or N1-Src-mCherry plasmids and constructs expressing GFP, GFP-RhoA-WT, -
Q63L or -T19N. The cells were transfected for 48 h, fixed and processed for 
immunofluorescence. The analysis was performed on 30 cells per condition, from a 
maximum of 15 fields of view. The experiments were performed 3 times and statistical 
analysis of the average number of processes per cell was performed on pooled data 
(n=90) using a two-way ANOVA. (* p<0.05, ** p<0.01, *** p<0.001).   
 
Figure 5.4: The Effects N1-Src-mCherry and the GFP-RhoA Mutants on Process 
Extension in COS7 Cells. 
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Although process extension by N1-Src-mCherry and GFP-RhoA-Q63L cells was not 
significantly different from their GFP transfected counterparts, it was significantly 
reduced in comparison to GFP-RhoA-WT (p=0.001 ***) and -T19N (p<0.001 ***) 
expressing cells. This indicated that N1-Src-mCherry was unable to promote process 
formation in the presence of GFP-RhoA-Q63L.  
With the aim of further understanding the effects of N1-Src-mCherry on process 
outgrowth, a more in depth morphological analysis was performed on the conditions that 
resulted in more than 20 % of the cells producing neurite-like processes (Figure 5.5).  
When N1-Src-mCherry was co-expressed with GFP-RhoA-T19N, there was a significant 
increase in the average number of processes (Figure 5.5A) and total length of processes 
per cell (Figure 5.5B), when compared to GFP (p=0.01 ** and 0.007 **, respectively) and 
GFP-RhoA-WT (total length of processes only; p=0.022 *) cells (Figure 5.5B). However, 
there was no significant change in the length of the longest process (Figure 5.5C), 
average process length (data not shown) or the number of branches per cell (Figure 
5.5D). Furthermore, when comparing the same morphological parameters in mCherry or 
N1-Src-mCherry cells co-expressing GFP-RhoA-T19N, it was apparent that N1-Src-
mCherry activity significantly enhanced the effects of GFP-RhoA-T19N process 
outgrowth (Figure 5.5E, p=0.008 **) and branching (Figure 5.5H, p=0.02 *), which 
resulted in an increase in the total length of processes (Figure 5.5F, p= 0.009 **). Once 
again, the length of the longest process and average process length (data not shown) 
remained unaffected.   
The area of cells co-expressing WT RhoA and mCherry was comparable to GFP 
expressing cells. However, GFP-RhoA-Q63L expression triggered a significant decrease 
in cell area with respect to GFP or GFP-RhoA-WT cells (Figure 5.6A, p=0.008 ** and 
0.006 **, respectively). In addition, there was a close to significant or significant reduction 
in the area of GFP-RhoA-T19N expressing cells in comparison to control (GFP; p=0.058) 
and GFP-RhoA-WT (p=0.042 *) cells, respectively. In terms of cell area, C-Src 
expressing cells behaved similarly to mCherry expressing cells, with the exception of 
GFP-RhoA-T19N, in which the area remained unchanged in relation to GFP and GFP-
RhoA-WT cells (Figure 5.6A). Therefore, there was a significant increase in the average 
area of GFP-RhoA-T19N cells expressing C-Src-mCherry, compared to mCherry 
(p=0.006 **).  
Amongst N1-Src-mCherry transfected cells, the area of GFP, GFP-RhoA-WT and -T19N 
containing cells was comparable, however GFP-RhoA-Q63L induced a significant 
reduction in the average cell area with respect to GFP-RhoA-WT (p=0.015 *) and -T19N  
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The average number of processes, total length of processes, length of longest process 
and number of branches per cell were determined for cells that were identified as 
extending processes and that were transfected with constructs encoding either N1-Src-
mCherry and GFP (n=19), GFP-RhoA-WT (n=22) or -T19N (n=34; A-D), or GFP-RhoA-
T19N and mCherry (n=20) or N1-Src-mCherry (n=34; E-H). The analysis was performed 
on data obtained from three experiments and statistical analyses were performed on the 
pooled data (see n numbers above) (* p<0.05, ** p<0.01, *** p<0.001).    
Figure 5.5: Process and Branch Formation is Enhanced in Cells Co-expressing N1-
Src-mCherry and GFP-RhoA-T19N. 
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The average cell area (A) and circularity (B) of cells were determined in ImageJ after 
tracing the perimeter of cells that were co-transfected with mCherry, C-Src- or N1-Src-
mCherry and GFP, GFP-RhoA-WT, -Q63L or -T19N. The cells were transfected for 48 
h, fixed and processed for immunofluorescence. The analysis was performed on 30 cells 
per condition, from a maximum of 15 fields of view. The experiments were performed 3 
times and statistical analysis was performed on pooled data (n=90) using a two-way 
ANOVA. (* p<0.05, ** p<0.01, *** p<0.001).   
 
Figure 5.6: The Effects of N1-Src-mCherry and the GFP-RhoA Mutants on the 
Cell Area and Circularity of COS7 Cells. 
 
 
154 
 
(p=0.024 *) (Figure 5.6A). In cells co-expressing N1-Src-mCherry and GFP, GFP-RhoA-
WT or -Q63L, there was a significant reduction in cell area with respect to their mCherry 
expressing counterparts (p=<0.001 ***, 0.011 *, 0.026 *, respecitvely). Whereas in GFP-
RhoA-T19N expressing cells, the cell area was consistent with the corresponding 
mCherry control (Figure 5.6A). 
In comparison to C-Src-mCherry cells co-expressing GFP or GFP-RhoA-T19N, there 
was a significant decrease in the cell area of the equivalent cells expressing N1-Src-
mCherry (p=0.045 * and p=<0.001***, respectively). 
Taken together, these data indicated that in mCherry expressing cells, both GFP-RhoA-
Q63L and -T19N reduced cell area in comparison to control and GFP-RhoA-WT cells. In 
addition, the results emphasised the fact that N1-Src-mCherry overexpression with GFP 
and the RhoA constructs reduced cell area with respect to their mCherry expressing 
counterparts, with exception of GFP-RhoA-T19N cells, which remained unchanged.  
To further understand the effects of the RhoA constructs on cell morphology, in the 
presence or absence of C- and N1-Src-mCherry, the circularity of the cells was 
measured (Figure 5.6B). The data obtained indicated that the circularity of the cells 
expressing the different RhoA constructs was not dependent on the expression of the 
Src-mCherry construct. 
In general, the circularity of the cells expressing GFP, GFP-RhoA-WT, -Q63L or -T19N 
appeared similar regardless of the presence of the mCherry constructs. However, it 
should be noted that the difference in the overall mean values of circularity were 
significantly different for C-Src-mCherry expressing cells with respect to mCherry and 
N1-Src-mCherry expressing cells. This reflects the slight increase in the circularity of C-
Src-mCherry transfected cells in comparison to mCherry and N1-Src-mCherry 
transfected cells (Figure 5.6B). In addition to this, there was a statistically significant 
increase (p<0.001 ***) in the average circularity values of GFP-RhoA-Q63L expressing 
cells, with respect to the other Rho constructs (GFP, GFP-RhoA-WT and -T19N) (Figure 
5.6B). It should also be noted that the circularity of cells co-expressing GFP-RhoA-T19N 
and N1-Src-mCherry, was reduced by approximately 30 and 40 % compared to their 
corresponding cells expressing mCherry and C-Src-mCherry, respectively (Figure 5.6B).   
Overall these data suggested that whilst C-Src-mCherry expressing cells behaved 
similarly to mCherry expressing cells, N1-Src-mCherry appeared to promote process 
outgrowth and reduce cell area in GFP, GFP-RhoA-WT and -T19N cells (Figure 5.6A). 
A closer inspection of the morphology of process-extending cells provided additional 
evidence indicating that N1-Src-mCherry overexpression enhanced GFP-RhoA-T19N- 
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mediated process and branch formation. However, the Q63L RhoA mutant prevented 
N1-Src-mCherry-mediated process formation, increased cell circularity and decreased 
cell area further. 
5.2.2 Manipulating RhoA-N1-Src Signalling via the Inhibition of Rho. 
With the aim of providing further insight into the role of N1-Src in Rho signalling 
pathways, a selective inactivator of Rho isoforms A, B and C was used. Exoenzyme C3 
transferase (C3) ADP-ribosylates an asparagine residue (Asp 41) in the effector binding 
region of Rho. This modification serves to inhibit the activation of Rho proteins via GEFs 
and results in the sequestration of ADP-ribosylated Rho-GDP in the Rho-GDI complex, 
in the cytosol (Figure 5.7, (Aktories et al., 2004)). Apart from also inactivating Rho B and 
C, this differs to the dominant negative RhoA mutation (T19N) because although RhoA 
is locked into the inactive GDP-bound form, T19N also sequesters RhoA GEFs, which 
might also interfere with the activation of other Rho family GTPases. In these studies, C- 
and N1-Src-mCherry were co-expressed with C3, to assess whether the kinases 
enhanced or reduced the effects of C3 inactivation.   
Empty mCherry, C-Src- and N1-Src-mCherry constructs were co-transfected into COS7 
cells with the empty vector pLINK or the Rho inhibitor C3 (pLINK-C3) to determine the 
effect of N1- and C-Src-mCherry on process outgrowth in cells containing inactivated 
RhoA, B, C.   
Upon first inspection, cells co-transfected with pLINK and N1-Src-mCherry appeared 
smaller with many extending neurite-like processes from the cell body, whereas mCherry 
and C-Src-mCherry expressing cells were larger and more spread (Figure 5.8A). Both 
C- and N1-Src-mCherry were largely co-localised to the perinuclear regions of the cell 
(Figure 5.8A). However, when mCherry or the Src-mCherry constructs were co-
expressed with C3, a large proportion of the cells exhibited a decrease in the area of the 
cell body, which also extended one or more neurite-like processes.  
To quantify the effects of C3 on process formation in the presence of C- and N1-Src-
mCherry, firstly, the percentage of cells with processes under each condition was 
analysed (Figure 5.8B). The analysis revealed that in control cells (pLINK) expressing 
N1-Src-mCherry, the percentage of cells with processes was significantly higher (28.9 
%) than in mCherry (8.9 %; p=0.004 **) and C-Src-mCherry (7.8 %; p=0.003 **) 
expressing cells. When mCherry and C-Src-mCherry were co-expressed with C3, the 
RhoA/B/C inhibitor; there was a highly significant increase in the percentage of cells with 
processes from 8.9 % to 45.6 % (p <0.001 ***) and 7.8 % to 50 % (p <0.001 ***), 
respectively. Similarly, there was a large increase in C3 and N1-Src-mCherry expressing  
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The exoenzyme C3 transferase ADP-ribosylates RhoA at Asp-41. This modification 
inhibits Rho A, B and C by preventing the activation of Rho via GEFs and leading to the 
sequestration of ADP-ribosylated Rho-GDP in the Rho-GDI complex in the cytosol. 
(Adapted from Aktories et al., 2004). 
 
  
Figure 5.7: Schematic Diagram Illustrating the Inhibition of RhoA-C by C3. 
 
 
157 
 
 
(A) Representative images of COS7 cells co-transfected with empty-, C-Src or N1-Src-
mCherry and pLINK or pLINK-C3 (C3). Cells were transfected for 48 h, fixed and 
processed for immunofluorescence. Images were captured of 15 fields of view per 
condition using a fluorescence microscope. N=3, scale bar= 50 µm. (B) The percentage 
of cells with processes was determined from 30 cells per condition, from a maximum of 
15 fields of view. The experiments were performed 3 times and statistical analysis was 
determined using a two-way ANOVA (* p<0.05, *** p<0.001).   
  
Figure 5.8: Overexpression of N1-Src-mCherry did not Enhance C3 Mediated 
Process Formation. 
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cells compared to control cells from 28.9 % to 47.2% (p=0.003 **). However, when 
comparing the percentage of C3 expressing cells with processes between groups, i.e. 
mCherry, C-Src- and N1-Src-mCherry expressing cells, there was very little difference 
(45.6, 50, and 47.2 %, respectively). 
In addition to this, exactly the same data trends were observed when analysing the 
average number of processes per cell (data not shown).     
These data demonstrated that both N1-Src and inactive Rho were capable of individually 
promoting process formation in control cells (i.e. pLink or mCherry expressing cells 
respectively), however N1-Src-mCherry was unable to further drive process outgrowth 
in cells containing inactive Rho above the levels observed in both mCherry and C-Src-
mCherry expressing cells. 
To further understand the effects of N1-Src-mCherry in C3 expressing cells, further 
morphological analysis was performed on the conditions that resulted in greater than 20 
% of cells producing neurite-like processes (Figure 5.9). Of the cells co-expressing N1-
Src-mCherry and C3 that formed processes, the average number of processes (p=0.002 
**, Figure 5.9A), total length of processes (p=0.006 **, Figure 5.9B) and number of 
branches (p=0.005 **, Figure 5.9D) per cell were significantly elevated with respect to 
the corresponding GFP expressing cells, whereas process length remained unchanged 
(Figure 5.9C). However, when the same properties were compared amongst C3 
expressing cells containing mCherry, C-Src- or N1-Src-mCherry, there were no 
significant changes (Figures 5.9 E-H). This suggested that N1-Src-mCherry 
overexpression did not enhance the effects of C3 on process or branch formation in 
COS7 cells.  
In control (pLINK transfected) cells, there was a significant decrease in the mean area 
of cells expressing N1-Src-mCherry with respect to mCherry (p <0.001 ***) and C-Src-
mCherry (p <0.001 ***) containing cells, which were comparable (Figure 5.10A). 
Interestingly, when mCherry and C-Src-mCherry were co-expressed with C3, the area 
of the transfected cells was significantly reduced to similar levels by approximately 40 % 
(p<0.001 ***) (Figure 5.10A). Whilst the area of N1-Src-mCherry and C3 transfected cells 
decreased a further 22 % in comparison to control cells (p=0.017 *), the average cell 
area was not significantly different to cells co-expressing both C3 and mCherry or C-Src-
mCherry (Figure 5.10A).   
The trends in the differences in the circularity of the cells analysed (Figure 5.10B) were 
very similar to those observed with cell area. N1-Src-mCherry overexpression in control  
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The average number of processes, total length of processes, length of longest process 
and number of branches per cell were determined for cells that were identified as 
extending processes and that were transfected with either N1-Src-mCherry and pLINK 
(n=26) or C3 (n= 45; A-D), or C3 and mCherry (n=41), C- (n=45) or N1-Src-mCherry 
(n=45; E-H) constructs. The analysis was performed on data obtained from three  
experiments and statistical analyses were performed on the pooled data (** p<0.01).   
Figure 5.9: Process and Branch Formation, as well as the Length of Longest 
Process was Comparable in Cells Co-expressing C3 and empty-, C- or N1-Src-
mCherry. 
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The average cell area (A) and circularity (B) of cells were determined in ImageJ after 
tracing the perimeter of cells that were co-transfected with mCherry, C-Src- or N1-Src-
mCherry constructs and pLINK (control) or pLINK-C3 (C3). The cells were transfected 
for 48 h, fixed and processed for immunofluorescence. The analysis was performed on 
30 cells per condition, from a maximum of 15 fields of view. The experiments were 
performed 3 times and statistical analysis was performed on pooled data (n=90) using a 
two-way ANOVA. (* p<0.05, *** p<0.001).   
Figure 5.10: The Effects of the mCherry-Srcs and C3 Inactivation of Rho on the 
Cell Area and Circularity of COS7 Cells. 
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(pLINK) cells resulted in a significant reduction in circularity of the cells with respect to 
mCherry and C-Src-mCherry transfected cells (p<0.001 ***), indicating the shape of the 
cells expressing N1-Src-mCherry were more elongated, which is visible in Figure 5.8A. 
Notably, in C-Src-mCherry expressing cells, there was a significant increase in circularity 
with respect to mCherry expressing cells (p <0.038 *). When co-expressed with C3, the 
circularity in mCherry, C- or N1-Src-mCherry expressing cells was significantly reduced 
(p <0.001 ***) to similar levels, in comparison to control cells (Figure 5.10B). 
Taken together, these results indicated that the overexpression of N1-Src-mCherry in 
COS7 cells results in a similar, yet weaker phenotype to the inactivation of RhoA by C3. 
N1-Src-mCherry overexpression in pLINK transfected cells resulted in an increase in the 
percentage of cells with processes (Figure 5.8B) and a decrease in cell circularity (Figure 
5.10B) as well as cell area (Figure 5.10A) compared to mCherry containing cells. Cells 
overexpressing C-Src-mCherry largely resembled mCherry expressing cells with the 
exception that C-Src-mCherry containing cells had a higher circularity. Irrespective of the 
presence of C- or N1-Src-mCherry, the percentage of cells with processes (Figure 5.8), 
circularity and cell area (Figure 5.10) was comparable in C3 expressing cells. A more in 
depth analysis of the cells extending processes also revealed that C3 had the same 
effects on the average number of processes (Figure 5.9E), total length of processes 
(Figure 5.9F), length of longest process (Figure 5.9G) and number of branches per cell 
(Figure 5.9H) in mCherry, C-Src and N1-Src-mCherry containing cells. This indicated 
that N1-Src-mCherry did not enhance the effects of C3 within this experimental system. 
This result was different to that in Figure 5.4, where N1-Src-mCherry enhanced process 
outgrowth above control levels in GFP-RhoA-T19N (dominant negative) transfected 
cells. 
5.2.3 Overexpression of GFP-RhoA-WT, -Q63L and -T19N did not Affect N1-Src-
FLAG Activity in COS7 Cells. 
The effect of the overexpression of GFP-RhoA-WT, -Q63L and -T19N on the activation 
status of N1-Src- in comparison to C-Src-FLAG was explored to determine whether the 
kinase acts downstream of RhoA under basal conditions (Figure 5.11). Phosphorylation 
of the kinase on Tyr-416 (Y416) in the active site is a marker of kinase activity. The 
different GFP-RhoA constructs (including GFP) were co-expressed with either C- or N1-
Src-FLAG and kinase activity was detected via Western Blotting.   
Phosphorylation of C-Src-FLAG at Tyr-416 was elevated in the presence of GFP-RhoA-
WT in comparison to cells overexpressing GFP alone. However, the GFP-RhoA-Q63L 
and -T19N mutants did not enhance C-Src-FLAG activity over the levels observed in 
GFP and C-Src-FLAG expressing cells. It should be noted that expression of levels of 
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the different RhoA mutants varied, which may account for the reduced C-Src activity 
seen in GFP-RhoA-mutant and C-Src-FLAG expressing cells. Upon first inspection, N1-
Src-FLAG activity, in cells co-expressing N1-Src-FLAG and GFP-RhoA Q63L, appeared 
reduced compared to GFP, GFP-RhoA-WT and -T19N expressing cells. However, the 
amount of N1-Src-FLAG also appears reduced, which could account for this observation. 
Therefore, overall, N1-Src-FLAG activity did not appear to be affected by GFP-RhoA-
WT, -Q63L or -T19N. 
In figure 5.11B, the levels of Tyr-416 phosphorylation were quantified by performing 
densitometry analysis of the protein bands from three biological replicates. Since the 
protein levels of Src-FLAG and the GFP-RhoA mutants appeared to vary between 
conditions, phosphorylation of Tyr-416 was normalised to the amounts of both Src-FLAG 
and RhoA-GFP.  
In C-Src-FLAG transfected cells, the results indicated that Tyr-416 phosphorylation 
appeared slightly higher when cells were co-transfected with GFP-RhoA-WT or -Q63L in 
comparison to control cells. Whereas C-Src-FLAG and GFP-RhoA-T19N co-transfected 
cells displayed even higher levels of kinase activity with respect to control cells. However, 
statistical analysis of these data confirmed that these observations were insignificant. In 
cells co-transfected with N1-Src-FLAG and GFP, GFP-RhoA-WT or -Q63L, the level of 
Tyr-416 phosphorylation was similar between conditions.  This was slightly elevated in 
N1-Src-FLAG cells co-expressing GFP-RhoA-T19N, although this observation was not 
significant. Overall, these data indicated that the co-expression of neither C- nor N1-Src-
FLAG with the GFP-RhoA mutants resulted in significant changes to the activity of the 
kinases.  
It should also be noted that the baseline level of Tyr-416 phosphorylation in N1-Src-
FLAG transfected cells was elevated, when compared to C-Src transfected cells. 
However, the error bars on the N1-Src data points were particularly large, indicating that 
a high degree of variation occurred within the three biological replicates. In addition, there 
was no significant interaction between the C-Src- and N1-Src-FLAG data. Further 
repeats of this data set should be performed in order to determine the potential 
differences between the kinase activity of C-Src- and N1-Src-FLAG in COS7 cells.   
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COS7 cells were co-transfected with C-Src- or N1-Src-FLAG and GFP, GFP-RhoA-WT, 
-Q63L or -T19N. The cells were transfected for 48 h, lysed, separated by SDS PAGE 
and subject to Western blot analysis. Kinase activity was assessed by monitoring the 
phosphorylation of Tyr-416. The blots shown are a representative of n=3. B) Tyr-416 
phosphorylation was quantified by performing densitometry in ImageJ. Phosphorylation 
of Tyr-416 was normalised to the amounts of Src-FLAG and GFP-RhoA and statistical 
analysis of the data (n=3) was performed using a two-way ANOVA.  
  
Figure 5.11: Overexpression of GFP-RhoA-WT, -Q63L or -T19N had Little Effect on 
C- or N1-Src-FLAG Activity. 
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5.2.4 N1-Src and C-Src-FLAG Interacted with Active GFP-RhoA-WT in COS7 
Cells.  
Since N1-Src appeared to co-localise with GFP-RhoA-WT and -T19N (Figure 5.3), the 
possibility that N1-Src interacts with RhoA was investigated. An immunoprecipitation (IP) 
using α-GFP conjugated resin that bound the GFP-tagged RhoA-WT was performed to 
determine whether N1-Src-FLAG could be pulled-down with the GTPase in COS7 cells 
(Figure 5.12). Further negative controls were performed to confirm that N1-Src-FLAG did 
not interact with GFP and that GFP-RhoA-WT did not interact FLAG alone. Whilst these 
controls were verified, N1-Src-FLAG did not appear to be pulled-down by GFP-RhoA-
WT.  
As p190RhoGAP has previously been shown to interact with RhoA, as a positive control, 
the blot was probed with a p190RhoGAP specific antibody, however the protein could 
not be detected in either the input or pull-down lanes (data not shown).  
The overexpression of constitutively active C-Src has previously been linked to RhoA 
phosphorylation in mouse 3T3 cells and directly inactivates RhoA activity (Uezu et al., 
2012). However, GFP-RhoA-WT did not appear to be phosphorylated in N1-Src-FLAG 
overexpressing cells (Figure 5.12). It should also be noted that in the input lanes for the 
cell lysates containing N1-Src-FLAG, bands representing a phospho-tyrosine modified 
protein, which corresponded to the molecular weight of N1-Src, were present. However, 
this was not detected in the GFP-RhoA-WT/N1-Src-FLAG IP lane (Figure 5.12). 
Together these results suggested that N1-Src neither phosphorylates nor interacts with 
RhoA WT. However, the inclusion of a further positive control to demonstrate that GFP-
RhoA-WT interacts with known binding partners (e.g. p190rhoGAP) will be required to 
verify the latter result.    
5.2.4 C- and N1-Src-FLAG Evoked Differential Effects on the Activation of GFP-
RhoA-WT. 
Previous experiments have suggested that N1-Src-FLAG does not bind to or 
phosphorylate GFP-RhoA-WT under basal cellular conditions, however, these studies 
did not provide evidence regarding the effect of the kinase on GTPase activity. Therefore, 
to assess the effect of both C- and N1-Src-FLAG on RhoA activity, a commercial RhoA 
GTPase activation assay kit was used.  
The basis of this assay relies upon the well characterised interaction between the RhoA 
binding domain (RBD) of Rhotekin (a RhoA effector) and RhoA-GTP. The kit consists of 
a pull-down assay that can be used to indicate the levels of GTP-bound RhoA in treated  
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COS7 cells were co-transfected with Empty- or N1-Src-FLAG and GFP or GFP-RhoA-
WT constructs for 48 h. The cells were lysed in RIPA buffer and GFP or GFP-RhoA-WT 
was immunoprecipitated from cell lysates using an α-GFP resin. Input (1 %) and 
immunoprecipitation (IP) samples were separated by SDS-PAGE and subject to Western 
blot analysis. The blots shown are representative of the results obtained for n=3.   
 
  
Figure 5.12: N1-Src-FLAG neither Interacted with nor Phosphorylated GFP-RhoA-
WT. 
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cells. The advantage of using this kit is that it is designed to monitor the activation status 
of endogenous cellular RhoA, however this proved technically difficult. Whilst GTP 
loaded RhoA was easily detected (positive control), in two separate experiments, either 
trace levels or no active RhoA were detected in cell lysates containing Empty-, C-Src- or 
N1-Src-FLAG. Therefore, it was difficult to deduce any conclusions from these data 
regarding the effects of the kinases (data not shown). 
Taking this into account, the experiment was repeated in cells that were transfected with 
GFP-RhoA-WT (Figure 5.13). In addition to controls, whereby cells were loaded with 
either GDP (negative) and GTP (positive), which confirmed the GFP-tagged GTPase 
was functional, further controls, were transfected with either GFP-RhoA-Q63L (positive) 
or -T19N (negative). In the case of GFP-RhoA-T19N expressing cells, no signal 
indicating the presence of GFP-RhoA-GTP was detected, whereas a large signal was 
observed for the cells that contained GFP-RhoA-Q63L (Figure 5.13). 
The result observed for the GFP-RhoA-T19N negative control implied that the GFP tag 
had no affinity for the GST-Rhotekin RBD resin. In comparison to cells that co-expressed 
both GFP-RhoA-WT and an empty FLAG construct, C-Src-FLAG appeared to evoke an 
increase in the amount of GTP-bound GFP-RhoA-WT. This was also true for N1-Src-
FLAG expressing cells but to a lesser extent than for C-Src. The PVDF membrane 
containing the pull-down samples was probed with an α-FLAG antibody to determine 
whether the kinases co-purified with GFP-RhoA-GTP. Both C-Src- and a small amount 
N1-Src-FLAG were detected in the pull-downs.  
Taken together, these results suggested that both C- and N1-Src-FLAG activate GFP-
RhoA-WT under basal cellular conditions and interact with GFP-RhoA-GTP but this 
interaction is much weaker in N1-Src-FLAG transfected cells. In order to confirm the 
results obtained in this assay, replicate experiments must be performed. In order to 
confirm the results obtained in this assay, replicate experiments must be performed. In 
addition, a further negative control that would involve a GST-Rhotekin pulldown in the 
absence of GFP-RhoA-WT should be included, to discount the possibility that C- or N1-
Src could be binding to Rhotekin . 
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COS7 cells were co-transfected with Empty-, C-Src or N1-Src-FLAG and GFP-RhoA-
WT, -T19N (negative control) or -Q63L (positive control) construcuts for 48 h. In the first 
two lanes, cell lysates were pre-loaded with either GTP (positive control) or GDP 
(negative control). Using a RhoA GTPase kit, the cells were lysed and samples were 
incubated with GST-Rhotekin-RBD resin to pull-down active GTP-bound GFP-RhoA. 
Input (2 %) and pull-down samples were separated by SDS-PAGE and subject to 
Western blot analysis. N=1, *cells were co-transfected with an Empty FLAG vector.   
  
Figure 5.13: C- and N1-Src have Differential Effects on the Activation Status of 
GFP-RhoA. 
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5.3 Discussion 
5.3.1 Dissecting the Role of N1-Src and RhoA in the Regulation of Process 
Outgrowth in COS7 Cells. 
The studies conducted in Chapter 5 sought to determine whether N1-Src-mediated 
process outgrowth in COS7 cells is dependent upon RhoA inactivation. Using a 
combination of RhoA mutants and a RhoA inhibitor in COS7 cells, as well as biochemical 
approaches, the role of N1-Src in RhoA signalling was dissected. The outcomes of these 
experiments are discussed below. 
5.3.1.1 The Effect of N1-Src-mCherry on Cell Morphology 
When overexpressed in COS7 cells, N1-Src-mCherry promotes process formation; this 
was demonstrated in Figures 5.4 and 5.8 and has previously been shown in the Evans 
lab (Keenan, 2012). Despite the fact that there was not a statistically significant 
difference in the percentage of cells with processes between the cells co-expressing 
either of the Src-mCherry and GFP-RhoA constructs (Figure 5.4A), the overall mean 
percentage of cells with processes for N1-Src-mCherry transfected cells was significantly 
higher than that of mCherry and C-Src-mCherry expressing cells. In addition to 
increasing process formation, N1-Src-mCherry overexpression also resulted in a 
significant reduction in cell area (Figure 5.6A) and in some cases, circularity (Figure 
5.10B). This model was used, in conjunction with biochemical studies, to test the 
hypothesis that N1-Src regulates cell morphology of COS7 cells (in particular process 
formation) via the inhibition of RhoA.  
To test the effects of N1-Src on RhoA signalling (or vice versa), N1-Src-mCherry was 
overexpressed with different GFP-RhoA constructs and a RhoA inhibitor (C3). 
Overexpression of the GFP-RhoA-mutants and C3 had distinct effects on cell 
morphology themselves (Figures 5.3-6 and 5.8-10) and will be discussed in Section 
5.3.1.2-4 to follow. 
5.3.1.2 The Effect of RhoA Inactivation on Cell Morphology 
GFP-RhoA-T19N (dominant negative mutant) expression resulted in an elevation of 
process formation (Figure 5.4), a reduction in cell area (Figure 5.6A), but cell circularity 
remained unaffected (Figure 5.6B). This mimicked the effects of N1-Src-mCherry 
overexpression, suggesting that signalling resulting from GFP-RhoA inactivation (T19N) 
and via N1-Src worked towards a common goal. This was supported by the observation 
that inhibition of all three Rho proteins (A, B and C) also resulted in elevated process 
outgrowth (Figure 5.8). 
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Analysis of process formation in cells co-expressing N1-Src-mCherry and GFP-RhoA-
T19N in comparison to the corresponding mCherry or GFP expressing cells, produced 
conflicting results (Figure 5.4). The percentage of cells with processes in cells co-
expressing mCherry and GFP-RhoA-T19N or N1-Src-mCherry and GFP were very 
similar (~20-25 %). When N1-Src-mCherry and GFP-RhoA-T19N were expressed 
together the effect on the percentage of cells with processes was almost additive (~40 
%), which suggested that N1-Src-mCherry and GFP-RhoA-T19N act through separate 
pathways (Figure 5.4A).  
However, when quantifying the average number of processes per cell (Figure 5.4B), the 
effect appeared synergistic (more than additive), which would suggest that both GFP-
RhoA-T19N and N1-Src-mCherry were working together to enhance process formation 
(Figure 5.4B). However, this would be unlikely to be as a result of N1-Src-mCherry 
inhibiting the GTPase, since the T19N construct is dominant negative, thus RhoA is 
already inactivated.  
An in depth analysis of the cells that contained the construct combinations that produced 
greater than 20 % of cells with processes (Figure 5.5), revealed that whilst the average 
number of processes was significantly higher in N1-Src-mCherry and GFP-RhoA-T19N 
co-transfected cells, the effect appeared to be additive, rather than synergistic (Figure 
5.5A). This agreed with the data presented in Figure 5.4A, which suggested that N1-Src 
and RhoA act via separate pathways to drive process formation in COS7 cells. The 
presence of N1-Src-mCherry in GFP-RhoA-T19N expressing cells, had a significant 
impact on the number of branches per cell (~0.7 branches per cell), compared to GFP-
RhoA-T19N cells expressing the mCherry control (~0.2 branches per cell, Figure 5.5H). 
Comparing this result to the number of branches per cell observed for GFP and N1-Src-
mCherry expressing cells (~0.2 branches per cell, Figure 5.5D) the effect of N1-Src-
mCherry and GFP-RhoA-T19N together appeared to be synergistic. However, 
confidence in this result should be improved by increasing the sample size, since the 
error bars were very large.  
5.3.1.3 The Effect of the RhoA/B/C Inhibition on Cell Morphology 
A further experiment that was aimed at understanding the potential interplay between 
N1-Src and RhoA GDP-mediated process outgrowth, was performed using the 
RhoA/B/C inhibitor C3 (Figures 5.8-10). In this experiment, almost 50 % of cells 
transfected with pLINK-C3 produced processes regardless of the Src-mCherry status of 
the cells (Figure 5.8B). However, the percentage of cells with processes when N1-Src-
Cherry was co-expressed with pLINK-C3 did not appear to be the result of an additive 
effect of the percentages of cells with processes when mCherry and C3 or N1-Src-
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mCherry and pLINK (control) were co-expressed (Figure 5.8B). This result differed from 
the additive effect seen when N1-Src-mCherry and GFP-RhoA-T19N were co-expressed 
(Figure 5.5A), which suggested that both N1-Src and inactive RhoA work via separate 
pathways. There are multiple explanations that could explain this outcome. 
Firstly, since all of the cell parameters that were measured were comparable in C3 
expressing cells (Figure 5.8B), it is possible that within the experimental system used, 
maximal phenotypic effects were observed and therefore the effects of additional 
stimulators of process outgrowth (i.e. N1-Src) were not clearly represented. A second 
theory is that N1-Src-mCherry drives RhoB or C inactivation, which is why an additive 
effect on neurite outgrowth was not observed, since the Rho GTPases were inhibited by 
C3. Alternatively, the opposite could have occurred, whereby inactive Rho B or C 
antagonised N1-Src-mCherry mediated process formation. However, it seems unlikely 
that inactive Rho would serve to inhibit N1-Src, when they are working towards a 
common goal and this also appears to be the function of active RhoA (discussed in 
Section 5.3.1.5).   
Before a valid conclusion can be deduced from the C3 data, a dose response experiment 
using a commercial cell permeable C3 protein should be performed to ascertain the 
upper boundaries of the model, and determine the validity of the results obtained. 
Alternatively, a similar titration could be performed using a small molecule inhibitor of 
RhoA, namely Rhosin (Merck Millipore, Watford, UK)(Shang et al., 2012). 
5.3.1.4 The Effect of Constitutively Active RhoA on Cell Morphology.  
In cells overexpressing GFP-RhoA-Q63L (constitutively active mutant), process 
formation remained comparable to the GFP control (Figure 5.4), whereas cell area 
decreased (Figure 5.6A) and circularity increased (Figure 5.6B). This was in line with the 
known function of active RhoA, which promotes stress fibre formation and acto-myosin 
contractility. 
The data for the co-expression of N1-Src-mCherry with GFP-RhoA-Q63L, suggested 
that this RhoA mutation prevented N1-Src mediated process formation (Figure 5.4). In 
addition to this, ithe circularity of N1-Src-mCherry and GFP-RhoA-Q63L co-expressing 
cells (Figure 5.6B) was equivalent to the cells co-expressing GFP-RhoA-Q63L and the 
mCherry control, whereas cell area was significantly reduced (Figure 5.6A) when N1-
Src-mCherry was present versus mCherry alone. However, there was not a significant 
difference in cell area when GFP or GFP-RhoA-Q63L were co-expressed with N1-Src-
mCherry. The constitutive activation of RhoA probably inhibited N1-Src mediated 
process outgrowth via cross-talk with the N1-Src signalling pathway. Co-expression of 
N1-Src-mCherry with GFP-RhoA-Q63L did not appear to directly affect N1-Src activity, 
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however this does not discount the fact that RhoA-Q63L could disrupt a signalling 
pathway downstream of N1-Src.  
5.3.1.5 The Effect of N1-Src-on the Activation of RhoA 
Under basal conditions, in cells containing GFP-RhoA-WT, there is a mixture of GDP- 
and GTP-bound RhoA, which was evidenced by the RhoA GTPase activation assay 
(Figure 5.13). This could explain the fact that the GFP-RhoA-WT cell morphological 
phenotype lay somewhere in between that of GFP-RhoA-Q63L and-T19N when co-
expressed with the mCherry control. The opposing roles of GDP- and GTP-bound RhoA, 
the latter of which was demonstrated to be enhanced by N1-Src-FLAG expression 
(Figure 5.13), could also account for the phenotype observed in cells co-expressing 
GFP-RhoA-WT and N1-Src-mCherry, whereby neither the percentage of cells with 
processes (Figure 5.4A), nor the average number of processes per cell (Figure 5.4B) 
were altered with respect to the cells co-expressing N1-Src-mCherry and the GFP 
control. 
Finally, the RhoA GTPase activation assay revealed that in cells transfected with N1-
Src-FLAG and GFP-RhoA-WT, the kinase promoted the activation of RhoA and some 
N1-Src-FLAG was pulled down with active (GTP-bound) RhoA (Figure 5.13). Whilst this 
experiment needs to be repeated, one explanation for N1-Src serving to activate RhoA, 
could be that the kinase forms part of a negative feedback loop modelled in Figure 5.14. 
This would involve the self-regulation of N1-Src mediated process outgrowth. This type 
of regulation is not uncommon, and since COS7 cells would not ordinarily form neurite-
like processes, the existence of a negative feedback regulatory step could be feasible. 
Since small amounts of N1-Src-FLAG appeared to be pulled down with GFP-RhoA-WT-
GTP, it is possible that N1-Src could form part of a complex with RhoA-GTP, in which it 
serves to regulate the activity of a Rho GEF to facilitate RhoA activation. In order to test 
this, it would be interesting to perform mass spectrometry on the proteins that are pulled-
down in complex with RhoA, to identify candidate substrates.   
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Both GDP-bound RhoA and N1-Src promote process outgrowth in COS7 cells, whereas 
activation of RhoA results in stress fibre formation and acto-myosin contractility and 
inhibits N1-Src mediated process outgrowth. In a proposed negative feedback loop, N1-
Src mediated process outgrowth may be self-regulated by activating RhoA. 
 
 
 
 
 
Figure 5.14: Schematic of the Proposed N1-Src/RhoA Signalling Pathway 
Regulating COS7 Cell Morphology. 
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5.3.2 The Alternate Roles of C- and N1-Src in RhoA Signalling 
For the most part of this chapter, the roles of both C- and N1-Src-mCherry in RhoA 
signalling were investigated, enabling a comparison of the two kinases. In Figure 5.9B 
(C3 experiment), there was a significantly reduced proportion of cells extending 
processes amongst control cells (pLINK transfected) expressing C-Src-mCherry in 
comparison to N1-Src-mCherry.This data was also supported by the data in Figure 5.4, 
in which the overall average percentage of cells with processes in cells overexpressing 
C-Src-mCherry and the RhoA constructs, was also significantly reduced with respect to 
the corresponding N1-Src-mCherry expressing cells. In addition to this, the overall 
average value of circularity (Figure 5.10B) for C-Src-mCherry transfected cells was 
significantly higher in comparison to Empty- and N1-Src-mCherry containing cells. Since 
increased circularity is a feature of GFP-RhoA-Q63L expressing cells (Figure 5.6B), this 
observation could be in part related to the fact that C-Src-FLAG overexpression 
appeared to activate GFP-RhoA-WT in COS7 cells, under basal cellular conditions 
(Figure 5.13). 
The average area of the cells co-expressing C-Src-mCherry and GFP was similar to their 
mCherry expressing counterparts, however the cell area of N1-Src-mCherry containing 
cells was significantly reduced (Figure 5.6A). When combined, these data highlighted 
the opposing roles of C- and N1-Src in the regulation of cell morphology. Whilst C-Src-
mCherry expressing cells appeared more rounded and spread, N1-Src-mCherry 
promoted process outgrowth and shrinking of the cell body.  
In C-Src-mCherry transfected cells, process formation did not vary significantly in GFP-
RhoA-WT, -Q63L and -T19N cells in comparison to the GFP control (Figure 5.4). There 
was also no observable difference in process formation between C-Src-mCherry cells 
co-expressing either GFP-RhoA-Q63L or -T19N. In contrast, a significant difference in 
the average number of processes per cell was observed between the GFP-RhoA-Q63L 
and -T19N cells co-expressing either mCherry or N1-Src-mCherry (Figure 5.4B). 
However, the error bar for the percentage of cells with processes in C-Src-mCherry and 
GFP-RhoA-T19N co-transfected cells was particularly large (Figure 5.4A), therefore 
further repeats of this dataset would increase confidence in this outcome. Despite this 
large error bar, these data further emphasised the difference between the effects of C- 
and N1-Src-mCherry on process outgrowth in COS7 cells, whereby C-Src-mCherry had 
little effect on process formation and cells behaved similarly to mCherry control cells.    
5.3.2.1 The Differential Activation of RhoA by N1 and C-Src 
Surprisingly, preliminary data suggested that C-Src activated RhoA to a greater extent 
than N1-Src under basal cellular conditions (Figure 5.13). Whilst it seems sensible that 
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C-Src would activate RhoA more so than N1-Src, given the role of N1-Src in process 
outgrowth, the majority of the literature linking C-Src with RhoA, conclude that C-Src 
serves to inactivate RhoA (Arthur et al., 2000, Brouns et al., 2001). 
 In neurons, the inactivation of RhoA via p190RhoGAP, which has been shown to be a 
major substrate of Src in the brain, promotes axon outgrowth and fasciculation and 
formed part of the basis for the investigation in this chapter (Brouns et al., 2001). 
Moreover, in non-neuronal cells types, C-Src-mediated inactivation of RhoA via the 
stimulation of p190RhoGAP activity in response to integrin engagement, has been widely 
studied and plays a key role in the regulation of cell-matrix adhesion, cell spreading and 
migration (reviewed in Huveneers and Danen, 2009). Although it should be noted that in 
the latter studies, this mechanism was dependent on the engagement of integrins via an 
extracellular stimulus, whereas the studies in this chapter were performed under basal 
conditions.    
One possible pathway through which C-Src could promote RhoA activation is via the 
regulation of RhoGDI. RhoGDI binds inactive RhoA, prevents activation of the GTPase 
and sequesters the protein into the cytosol. Co-transfection of constitutively active C-Src 
and RhoGDI in HeLa cells revealed that the kinase phosphorylates RhoGDI under basal 
conditions (DerMardirossian et al., 2006). This was shown to largely reduce the amounts 
of RhoA, Rac1 and Cdc42 in complex with RhoGDI, resulting in an increase in membrane 
localised RhoGDI.  
Although the direct effects on Rho GTPase activation were not shown biochemically, 
diminished levels of the RhoA, Rac1 and Cdc42 in complex with RhoGDI appeared to 
increase cell spreading and membrane ruffling; functions that are associated with the 
activation of Rho GTPases.   
5.3.3 RhoA as a Binding Partner for N1-Src 
Preliminary data also suggested that both C- and N1-Src-FLAG interacted with GFP-
RhoA-GTP and that this interaction appeared proportional to the degree of RhoA 
activation (Figure 5.13). Although this interaction needs to be confirmed by repeating the 
experiment with further controls, this observation could potentially reinforce the idea that 
C-Src substrates bind poorly to and are weakly phosphorylated by N1-Src. This 
phenomenon was proposed by Keenan et al., (2015) and has also been alluded to in 
multiple other studies, whereby the N1-Src SH3 domain has been shown to bind multiple 
proteins including CR16, Synapsin and DAAM1 with reduced affinity in comparison to C-
Src (Weiler et al., 1996, Onofri et al., 1997, Aspenstrom et al., 2006). In addition to this, 
other studies have shown that some C-Src SH3 binding partners, such as SNP70, 
 
 
175 
 
ASAP1 and RICH1, are unable to bind N1-Src (Richnau and Aspenstrom, 2001, Craggs 
et al., 2001, Brown et al., 1998).  
Taking the above evidence into account, it is possible that both C- and N1-Src-FLAG 
activated GFP-RhoA-WT by modulating the same substrate. If this was the case, how 
the interaction between both C- or N1-Src with active RhoA, could relate to a potential 
mechanism involving the phosphorylation of RhoGDI is unclear, and should be the 
subject of future studies. Alternatively, N1-Src could be acting via a completely separate 
mechanism to C-Src. To address this, it would be interesting to perform mass 
spectrometry on the Src-RhoA-GTP complexes to identify and compare the potential 
binding partners and substrates of the kinases.       
5.3.4 Concluding Remarks  
The RhoA mutant data presented in this chapter suggest a potential role for N1-Src in 
process outgrowth via a signalling pathway that is independent of RhoA-GDP related 
signalling. However, in order to determine whether this observation is correct, further 
clarification of the effect of N1-Src in C3 treated cells is required. If this role is confirmed, 
the hypothesis underpinning this work, which stated that N1-Src regulates process 
outgrowth by inactivating RhoA, would be disproved. Further data suggested that N1-
Src could form part of a negative feedback loop, whereby stimulation of process 
outgrowth by N1-Src enhanced RhoA activation, which subsequently served to prevent 
N1-Src mediated process outgrowth. However, further experiments should be performed 
to confirm these proposals. Preliminary data also indicated that both N1- and C-Src 
interacted with RhoA GTP but to different extents, providing further biochemical evidence 
for the differences between C- and N1-Src.     
Whilst further repeats of some datasets are required, these results have provided new 
insights into the regulation of N1-Src mediated process outgrowth in COS7 cells. Future 
work should be directed towards investigating the role of N1-Src in other Rho GTPase 
signalling pathways, such as Rac1 and Cdc42, which have also been implicated in 
neurite outgrowth (Hoshino and Nakamura, 2003). Whilst monitoring the role of N1-Src 
in the basal signalling pathways of COS7 cells has provided a good starting point for 
studying N1-Src effects in heterologous cells, moving forwards, identifying the external 
cues that trigger downstream N1-Src signalling pathways in neurons should be a priority.    
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Chapter 6. Conclusions and Future Directions 
The work presented in this thesis provides a thorough characterisation of the cell 
functions of N1-Src during neuronal development and incorporates the first mechanistic 
insight into N1-Src signalling. In addition, progress was also made towards the 
development of an in vitro peptide phosphorylation screen for identifying putative N1-Src 
substrates, which could provide a useful tool for future studies. The specific outcomes of 
this thesis are discussed below.     
6.1 N1-Src as a Regulator of Ion Channel Signalling 
With a dearth of N1-Src substrates in the literature, HCN1, which was identified in a N1-
SH3 yeast 2-hybrid screen, appeared to be an excellent candidate for further study 
(Santoro et al., 1997). There is precedence of a role for N1-Src in ion channel signalling, 
given that N1-Src has been shown to bind and phosphorylate the NR2A subunit of the 
NMDAR (Groveman et al., 2011). In addition, the phosphorylation and regulation of 
related HCN channels (2 and 4) by C-Src has previously been demonstrated (Zong et 
al., 2005, Li et al., 2008a). With this in mind, in vitro phosphorylation assays with the 
intracellular HCN1-CTD were performed.  
Whilst the phosphorylation of the HCN1-CTD could not be detected from in vitro kinase 
assays, the fact that the NR2A-CTD positive control was not phosphorylated either, 
meant that no firm conclusions could be derived from these data. Therefore, HCN1- and 
NR2A-CTD could not be ruled out as N1-Src substrates, especially since the 
phosphorylation of NR2A has been demonstrated previously (Groveman et al., 2011).    
C-Src is not thought to regulate HCN1 channel activity, since studies in the Yu lab 
indicated that HCN1 channel currents expressed in HEK293 cells were unaffected by 
SFK inhibition, whereas HCN2 channel activation was inhibited, despite the fact that C-
Src is co-immunoprecipitated with both channels (Yu et al., 2004). The addition of N1-
Src into a similar system would be a simple way of determining the physiological effects 
of N1-Src on channel regulation, as a secondary approach. It would be interesting to 
perform immunoprecipitation assays with both C- and N1-Src, comparing both the 
binding affinities for HCN1 and the channel phosphorylation status. It is possible that the 
HCN1 channel could be a weaker substrate for C-Src than N1-Src. Sequence analysis 
of the HCN1-CTD revealed that is does not contain a N1-Src SH3 binding motif, however 
it does contain several PXXP motifs, which should be explored if the phosphorylation of 
the channel is demonstrated in cells.   
Groveman et al., (2011) demonstrated that the NR2A-CTD of the NMDAR was 
phosphorylated in vitro by N1-Src and also showed that NR1/NR2A receptor currents 
 
 
178 
 
were enhanced in HEK-293 cells when co-expressed with N1-Src. Whilst N1-Src served 
as a positive control in the experiments carried out in this thesis, the ultimate aim, if 
phosphorylation had been demonstrated, was to identify and compare the tyrosine 
residues phosphorylated by N1-Src to those of C-Src, using mass spectrometry and to 
subsequently confirm these findings using site directed mutagenesis. A peptide selected 
from the NR2A tail (RCPSDPYK) was also included in the GST-fusion peptide substrate 
screen, since it largely conformed to the N1-Src SH3 binding consensus motif that was 
previously identified in the Evans lab by Dr Sarah Keenan (Keenan, 2012). When this 
peptide screen is optimised, the results could provide evidence this region binds to N1-
Src and the mutagenesis of critical residues of the NR2A subunit could be performed to 
potentially abolish this interaction in cells.       
Both NMDARs and the HCN1 channel are vital for correct brain function. Indeed, the 
dysregulation of these channels has severe implications in health and disease. For 
example, the improper regulation of the NMDAR has been linked with neurodegenerative 
disease (Mota et al., 2014a, Mota et al., 2014b), schizophrenia (Cohen et al., 2015) and 
ischemic stroke (Knox et al., 2013). One method through which N1-Src might be 
implicated in the damaging effects of cerebral ischaemia, is through the stimulation of 
the M4K-1 pathway via NMDAR activation. Li et al., (2008b) demonstrated that the 
application of the generic SFK inhibitor PP2, resulted in the decreased activation of M4K-
1, which subsequently downregulated the MLK3/JNK3/c-jun pathway, known to mediate 
ischemic effects. This was thought to be mediated via SFK activation of the NMDAR. 
The same inhibitor was subsequently shown to protect neuronal cells against ischaemic 
mediated-cell death. This theory would align with the observation by Groveman et al., 
(2011) that N1-Src activates NMDARs, although both C-Src and Fyn are also capable of 
activating them. The indiscriminate effects of PP2 on SFKs, makes it difficult to pin-point 
the kinase involved and requires further investigation. However encouragingly, M4K-1 
was also identified as a potential N1-Src substrate that was included in the in GST-fusion 
peptide screen in Chapter 3. The potential phosphorylation of M4K-1 could provide a 
further layer of kinase regulation in response to cerebral ischemia.  
6.2 The Role of N1-Src in Neuronal Development and Cytoskeletal 
Dynamics 
In this study, the effects of N1-Src on primary rat hippocampal neuronal morphology 
were determined. The shRNA-mediated knockdown of N1-Src impaired neurite 
outgrowth, particularly with respect to the length of longest neurite. In addition, there was 
also a significant reduction in the number of neurites per cell. Together these data not 
only implicated N1-Src in axon outgrowth, but also suggest that N1-Src plays a role in 
neurite formation.  
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The striking effects of N1-Src on neuronal morphology implied that N1-Src is involved in 
the regulation of neuronal cytoskeletal dynamics. The combined effects of both actin and 
microtubule dynamics drive axon outgrowth: microtubule polymerization creates a 
pushing force originating from the axon shaft, whereas the retrograde flow of actin at the 
leading edge of the growth cone creates a pulling force. The signalling mechanisms that 
ultimately coordinate these actions are diverse and complex. A comprehensive view 
outlining these pathways is reviewed in (Lewis et al., 2013).  
For several reasons this study focused on the potential role of N1-Src in RhoA GTPase-
mediated neurite outgrowth. Many of the GST-fusion peptides that were screened in 
Chapter 3 were derived from multiple Rho GTPase GAPs or GEFs that had previously 
been demonstrated to play a role in neuronal development. For example, 
p190BRhoGAP, whose role is to inactivate RhoA, had previously been demonstrated to 
promote axonal outgrowth and guidance (Brouns et al., 2001). In addition, Src and Fyn 
has been identified as the main kinase that phosphorylates the GAP in the developing 
brain. Whilst, C-Src has been shown to phosphorylate p190RhoGAP in non-neuronal 
cells, the presence of a putative N1-Src SH3 binding motif on the GAP suggested this 
protein could also be under the regulation of N1-Src.  
Although the results of the N1-Src substrate screen were inconclusive, a complimentary 
study was performed to determine the effects of N1-Src on RhoA signalling in COS7 
cells. The data suggested that whilst the inactivation of RhoA enhanced process 
formation in COS7 cells under basal cellular conditions, N1-Src did not mediate these 
effects. Although, the constitutive activation of RhoA prevented N1-Src mediated 
process formation and surprisingly, N1-Src appeared to enhance RhoA activation, which 
I speculated could form part of a negative feedback loop.   
The overexpression of N1-Src also resulted in impaired neurite outgrowth, with a 
significant proportion of cells failing to polarise. The conflicting results obtained for the 
shRNA and overexpression studies suggested that the dysregulation of N1-Src when 
overexpressed, resulted in non-physiological effects. A previous study by Kotani and 
colleagues (2007), who overexpressed N1-Src in cerebellar Purkinje neurons, also noted 
defects in neuronal polarisation since the multiple dendritic shafts characteristic of earlier 
stages in development, failed to converge into a single shaft. They linked this to the 
aberrant arrangement of microtubules, visible by EM, present in the dendritic shafts of 
the unpolarised neurons (Kotani et al., 2007). In hippocampal neurons, microtubule 
stabilization in one of the minor neurites formed in the early stages of development 
occurs prior to axon specification and outgrowth (Witte et al., 2008). However, when 
neurons are treated with the microtubule stabilising reagent taxol, the resultant effect is 
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aberrant neuronal polarization (Conde and Caceres, 2009). Given that the 
overexpression of N1-Src has been demonstrated to negatively affect neuronal 
polarisation, investigating the role of N1-Src in the regulation of microtubule dynamics 
could provide an interesting line of inquiry. 
6.3 Different Roles of C-, N1- and N2-Src 
The work carried out in Chapters 4 and 5 highlighted the different functions of the three 
Src isoforms. Whilst the overexpression of C-Src had no effects on cultured hippocampal 
neuronal morphology, the overexpression of N1-Src resulted in aberrant neuronal 
polarization and neurite outgrowth. The second major difference observed between C- 
and N1-Src was the differential activation of RhoA, under basal cellular conditions. Whilst 
the latter result requires further conformation, the differences observed provide specific 
examples that highlight how the small structural difference in the n-Src loop of the SH3 
domain of N1-Src, is capable of altering both phenotype and signal transduction with 
respect to C-Src. In addition, the first direct comparison of the functions of N1- and N2-
Src during the neuronal morphogenesis of hippocampal neurons in vitro was performed. 
shRNA knockdown of both kinases revealed that whilst N1-Src plays a critical role in 
driving neurite outgrowth, N2-Src appears to play a role in the regulation of neurite 
branching. In conclusion, these studies have provided direct evidence, suggesting that 
all three Src isoforms regulate different cellular processes.    
6.4 Future Directions 
The N1-Src and N2-Src shRNAs characterised in this study provide a useful tool for 
dissecting the roles of N-Src in neuronal development. To take this research one step 
further, the splice variant specific shRNAs could be used to generate N1- and N2-Src 
specific knockout mice. Although firstly, the phenotypic effects of these shRNAs should 
be confirmed by testing a second set of shRNAs targeting the two splice variants. This 
technique, which has previously been demonstrated by (Tiscornia et al., 2003), would 
involve generating transgenic mice that constitutively express the shRNAs. Since both 
the N1- and N2-Src genes incorporate the N1 mini-exon insert, knocking down N1-Src 
would also result in the loss of N2-Src. Therefore, using shRNAs to constitutively 
knockdown the kinases would overcome this issue.  
The previously generated C-Src-/- mice were deficient in C-, N1- and N2-Src expression, 
making it impossible to assign any phenotypes observed to C-Src only. The literature 
indicated that no obvious neurological phenotypes arose in the absence of the kinases, 
which was thought to be in part due to the functional redundancy between Src kinases 
(Soriano et al., 1991). It’s also possible that other signalling pathways could compensate 
for the loss of Src, for example during neurite outgrowth. However, Ignelzi and 
 
 
181 
 
colleagues (1994) demonstrated that neurite outgrowth was impaired in cultured 
cerebellar granule neurons from C-Src -/- mice that were grown on L1-CAM, which has 
since been demonstrated in the Evans lab to be potentially regulated by N1-Src (Keenan, 
2012).  
The generation of an N1-Src deficient mouse would facilitate a more in depth analysis of 
the effects of N1-Src at a phenotypic level but perhaps more importantly at the molecular 
level. It would enable the analysis of multiple neuronal types in the brain and help 
produce a more comprehensive picture of the cell type-specific functions of N1-Src 
during neuronal morphogenesis. In addition, the analysis of brain tissue slices, could be 
used to determine the physiological relevance of N1-Src mediated effects, by assessing 
the native biological architecture of neuronal networks. The dissection of N1-Src 
signalling pathways with respect to external stimuli (e.g. growth factors or cell adhesion 
signalling) and downstream targets (e.g. Rho GTPases) could feasibly be carried out in 
neurons, in place of simpler models, eliminating the obstacle of poor transfection 
efficiency. 
In conclusion, this study has been instrumental in providing a platform for future lines of 
investigation into the roles of N1-Src.  The key to advancing the findings reported in this 
thesis, will involve the further integration of both phenotypic studies and those seeking 
to de-lineate the signalling transduction pathways through which N1-Src operates in 
neurons.    
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Abbreviations 
3’   Three prime 
5’   Five prime 
aa   Amino acid(s) 
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor  
APS  Ammonium persulfate 
Arg  Arginine 
ATP   Adenosine triphosphate  
BSA  Bovine serum albumin 
C   Carboxyl  
˚C   Degrees centigrade  
cDNA   Copy deoxyribonucleic acid 
CGNs  Cerebellar granule neurons 
CNS  Central nervous system 
Cos-7   African green monkey kidney fibroblasts 
CTD  C-terminal domain 
dH2O   Distilled water 
DIV  Days in vitro 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid  
dNTPs  Deoxynucleoside triphosphates 
DPT  Days post-transfection 
DRD1  Dopamine 1 receptor 
DTT   Dithiothreitol  
E  Embryonic 
ECL   Enhanced chemiluminescence 
ECM  Extracellular matrix 
E.coli   Escherichia coli  
EDTA  Ethylenediaminetetraacetic acid  
EGFR  Epidermal growth factor receptor 
EGTA  Ethylene glycol tetraacetic acid 
 
 
184 
 
ERK  Extracellular signal-regulated kinase 
EVL  Ena/Vasp-like protein 
FAK  Focal adhesion kinase 
FBS   Foetal bovine serum 
g   Grams 
g   Gravitational force 
GABA  у-aminobutyric acid 
GAP  GTPase activating protein 
GDP  Guanosine diphosphate 
GFP   Green fluorescent protein  
GPCR  G-protein coupled receptor 
GST   Glutathione-S-transferase  
GTP  Guanosine-5’-triphosphate 
HCN(1) Hyperpolarisation-activated cyclic nucleotide-gated (channel 1) 
HIS   Epitope tag consisting of histidine residues 
HRP   Horseradish peroxidase 
Ih   Hyperpolarisation activated current 
IPTG  Isopropyl-β-D-1-thiogalactopyranoside  
kbp   Kilobase pairs  
kDa   Kiladaltons  
L   Litre(s) 
L1-CAM L1-cell adehesion molecule  
LB   Lysogeny broth 
LTD  Long-term depression 
LTP  Long-term potentiation 
µg   Microgram(s)  
µg µl-1   Microgram(s) per microlitre 
µg ml-1  Microgram(s) per millilitre 
µm   Micrometre(s)  
µm2   Micrometre(s) squared  
µM   Micromolar  
M   Molar   
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mg   Milligram(s)  
mGluR Metabotropic glutamate receptors 
mg ml-1 Milligrams(s) per millilitre 
ml  Millilitre(s)  
mm  Millimetre(s) 
mM   Millimolar 
MBP  Myelin binding protein 
min   Minute(s)  
MW   Molecular weight 
N   Amino  
NEB  New England Biolabs 
ng   Nanogram(s) 
NMDAR N-methyl-D-aspartate receptor 
O.D600   Optical density measured at 600 nm 
Oligos  Oligonucleotides 
ORF(s)  Open reading frame(s)  
P  Postnatal 
PAC1  Pituitary adenylate cyclase activating peptide 1 receptor 
PBS   Phosphate buffered saline  
PCR   Polymerase chain reaction  
PDGFR Platelet derived growth factor receptor 
PDL  Poly-D-lysine 
PenStrep  Penicillin-streptomycin  
pH   -log10 concentration of hydrogen ions 
PI3K  Phosphoinositide 3-kinase 
PKC   Protein kinase C 
PKL  Paxillin kinase linker 
PMSF   Phenylmethanesulfonylfluoride  
PP2  (+-butyl)pyrazolo[3,4-d]pyrimidine 
Pro  Proline 
PTB  Polypyrimidine tract binding protein 
PTM  Post translational modification 
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PVDF   Polyvinylidene fluoride membrane 
RhoA  Ras homolog gene family member A 
RIPA  Radioimmunoprecipitation assay 
RBD  RhoA binding domain 
RNA   Ribonucleic acid  
RSV  Rous sarcoma virus 
RTK  Receptor tyrosine kinase 
RTPs  Receptor tyrosine phosphatases 
S  Seconds 
SDM  Site directed mutagenesis 
SDS   Sodium dodecyl sulphate  
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Ser  Serine 
SH2  Src homoly 2 
SH3   Src homology 3  
ShRNA Short hairpin RNA 
SFK  Src family kinase 
TAE  Tris-acetate-EDTA 
TBS   Tris buffered saline  
TBST   Tris buffered saline containing Tween-20  
TEMED  Tetramethylethylenediamine 
Thr  Threonine 
tRNA   Transfer RNA  
U   Units 
Uml-1   Units per ml 
V   Volts 
v/v   Volume per volume 
WT  Wild type 
w/v   Weight per volume  
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